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ii. Abstract 
In human melanoma cell lines, the calcium binding protein S100A2 augments 
the antiproliferative activity of interferon-alpha (IFNα) by an unknown mechanism. I 
show by microarray profiling that recombinant over-expression of S100A2 
upregulates the expression of a subset of IFNα response genes beyond the maximal 
cytokine inducible level including IFITM3, a gene with documented antiproliferative 
activity. I have chosen IFITM3 as chromosomal IFNα response reporter gene in a 
model system consisting of two human melanoma cell lines ME15 and D10 
described previously (Brem, Oraszlan-Szovik et al. 2003). In ME15 cells IFITM3 
expression is strictly IFNα dependent whilst it is constitutively expressed in the IFNα 
resistant D10 cells. It was shown that S100A2 is sufficient to restore IFNα sensitivity 
in D10 (Foser, Redwanz et al. 2006) and I show by indirect immunofluorescence 
cytoplasmic localization of S100A2, which eliminates a direct function as a 
transcriptional enhancer of IFITM3 expression and other antiproliferative genes. I 
show that treatment of ME15 melanoma cells with the demethylating agent 5-aza-
2’deoxycytidine (DAC) results in a significant increase of IFITM3 expression following 
IFNα stimulation suggesting a DNA methylation mediated mechanism. Based on 
bisulfite sequencing of the IFITM3 core promoter, I show that D10 cells exhibit 
hypomethylation and I demonstrate that S100A2 is required for kinetic and reversible 
IFNα induced CpG demethylation in ME15 cells. Since p53 signaling is not functional 
in D10 cells I propose an indirect mechanism of methylation that involves p53 
controlled signaling pathways. 
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1 
1. INTRODUCTION 
 
1.1. INTERFERON 
 
1.1.1. History of Interferon 
Interferon was discovered 50 years ago as a host-derived interference activity 
induced by heat-inactivated viral particles (Isaacs and Lindenmann 1957). The 
advent of a novel technique termed “high performance liquid chromatography” 
enabled purification of interferon from virus-infected leukocytes 20 years after its 
discovery (Rubinstein, Rubinstein et al. 1978). In the 1980s advances in technology 
provided new possibilities in research but gene cloning was a difficult task compared 
to today. A combination of peptide sequencing and differential cloning finally allowed 
isolation of the first recombinant gene encoding the human interferon-α (Maeda, 
McCandliss et al. 1980; Borden, Sen et al. 2007). Since then, several additional 
interferons have been discovered and are classified in two categories, namely type I 
and type II interferons, that signal through distinct pathways but induce similar 
responses such as immune defense or antiviral activity (Stark, Kerr et al. 1998). 
 
1.1.2. Type I And Type II Interferons 
A hallmark of interferon type I and type II activity is the induction of anti-
proliferative activity coupled to transcriptional activation of target genes. The major 
role of type I and type II interferons in the cell, as well as upon excretion into the 
extracellular lumen, is their antiviral activity. Interferons are induced upon viral 
infection but it was also noticed that interferon can be induced by bacteria and 
protozoa (Akira, Uematsu et al. 2006). Therefore interferons execute vital activities in 
the maintenance of the healthy organism. 
The type I interferons are made up of the IFNαs and IFNβs, both located on 
chromosome 9 in the human genome, in addition to IFNω, IFNε, IFNκ, IFNδ and IFNτ. 
All these interferons share structural similarities (helical cytokine family) (Decker, 
Muller et al. 2005), contain 165 to 200 amino acids and are mostly non-glycosylated 
(Borden, Sen et al. 2007). The IFNα protein family consists of 13 functional 
homologues and one pseudogene. Members of the type I interferon family are 
involved not only in viral combat but also in cell differentiation and proliferation 
control (Henco, Brosius et al. 1985). 
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The only type II interferon is IFNγ, which is located on chromosome 12 (Henco, 
Brosius et al. 1985). This interferon is produced in natural killer cells or in activated T 
cells upon viral and bacterial assault. IFNγ is conserved throughout many species 
and loss of IFNγ has been shown to provoke autoimmune disorders. The pleiotropic 
functions that IFNγ exhibits made it difficult to introduce in clinical treatments, 
nevertheless IFNγ is absolutely indispensible in the innate and adaptive immune 
responses (Miller, Maher et al. 2009). 
 Interleukin 28 and interleukin 29 have recently been recognized as a third 
class of interferons: the lambda interferons (Borden, Sen et al. 2007). In contrast to 
type I and II these interferons have introns and up to five exons (Uze and Monneron 
2007). Located on chromosome 19, the IFNλs activate similar pathways to IFNα and 
IFNβ but use a different set of receptors (Uze and Monneron 2007). IFNλ receptors 
exhibit selective expression, in contrast to the IFNα/β receptors which are 
constitutively expressed to guarantee immediate signal transduction upon viral threat. 
 
1.1.3.  Interferon-alpha Signaling 
The interferon pathway is one of the most studied signaling pathways (figure 
1). Following virus-induced expression of IFNα the cytokine is excreted and binds to 
the type I interferon receptor 1 (IFNAR1), promoting heterodimerization with the type 
I interferon receptor 2 (IFNAR2). Thereafter a tyrosine phosphorylation cascade is 
initiated inside the cell. The tyrosine kinase TYK2 associated with the IFNAR1 and 
the Janus kinase JAK1 permanently bound to the IFNAR2 reciprocally phosphorylate 
the intracellular receptor subunits and each other (Borden, Sen et al. 2007). Next, 
signal transducer and activator of transcription 1 and 2 (STAT1 and STAT2) are 
recruited to the receptors where JAK2 phosphorylates the tyrosine subunits of 
STAT1 and STAT2, which subsequently associate with another subunit, the 
interferon response factor 9 (IRF9; also named p48), to form the interferon stimulated 
gene factor 3 (ISGF3) complex. In a last step, this ISGF3 complex translocates to the 
nucleus where it stimulates gene expression classically by means of the interferon 
stimulated response element (ISRE) (Decker, Muller et al. 2005). The STAT1 are 
also able to homodimerize to form the AAF (alpha-interferon activation factor) factor 
and upon nuclear translocation they bind to the GAS element (interferon-gamma 
activated site) to induce alternative interferon gene transcription (Taniguchi and 
Takaoka 2001). 
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Figure 1 
Figure 1. Main features of the IFN-α/β signalling pathway. On the other hand, another IRF-
family member, IRF-2, is a nuclear factor that also binds to ISRE, and this factor interferes with ISGF3 
action, thereby functioning as atranscriptional attenuator. Taniguchi, T. and A. Takaoka (2001). "A 
weak signal for strong responses: interferon-alpha/beta revisited." Nat Rev Mol Cell Biol 2(5): 
378-86. (Taniguchi and Takaoka 2001) 
 
It is crucial for the cell to shutdown interferon signaling therefore the IFNα 
inducible SOCS proteins are expressed also. SOCS1 binds to the IFNR receptors 
and inhibits binding of JAKs and TYKs by sterical hindrance as well as by receptor 
dephosphorylation. Another way to close down IFNα signaling is by promotion of 
phosphorylases which act on the receptors as well as on STATs to inactivate them. 
PIAS binds to the STATs and inhibits their transciptionnal activity therefore interfering 
with the IFNα pathway also (Greenhalgh and Hilton 2001; Naka, Fujimoto et al. 2005). 
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1.1.4.  The Interferon Induced Transmembrane Protein IFITM3 
The interferon-induced transmembrane protein (IFITM3) is a small (17 kDa) 
antiproliferative protein. It belongs to a family consisting of three functional IFTIM 
proteins, 1-8U (IFITM3), 1-8D (IFITM2) and 9-27 (IFITM1) as well as one 
pseudogene (Lewin, Reid et al. 1991). IFITM3 belongs to the early response genes, 
has two ISRE elements and is inducible by IFNα in the human melanoma cell lines 
ME15 and D10 (Certa, Seiler et al. 2001; Brem, Oraszlan-Szovik et al. 2003) with 
protein expression peaking at around 6 hours post- IFNα stimulus. IFITM3 seems to 
be deregulated in cells classified as interferon resistant, therefore does not exert its 
antiproliferative properties (Deblandre, Marinx et al. 1995). Additionally, studies have 
shown that over-expression of recombinant IFITM3 leads to proliferation inhibition in 
IFNα-sensitive cell lines (Brem, Oraszlan-Szovik et al. 2003). IFITM3 is therefore 
considered a marker for interferon resistance and it has also been identified as an 
early carcinogenesis biomarker of colon tumors (Fan, Peng et al. 2008). 
 
1.1.5.  Interferon-alpha – Clinical Relevance 
Recombinant IFNα became the first protein based drug in the 1980s and even 
though treatment of hepatitis C virus (HCV) infected patients is a predominant use of 
IFNα, this cytokine is also used to treat other diseases such as schizophrenia 
(Hurlock 2001), multiple sclerosis and melanoma (Kirkwood 1998). In 1987 Spiegel 
noted that IFNα was a potent drug in hematologic malignancies, since IFNα 
normalized blood cell counts upon treatment. (Spiegel 1987). Seven years later 
Guttermann reviewed various diseases successfully treated with IFNα either alone or 
in combination with other substances such as retinoids or interleukins: hairy cell 
leukemia, chronic myelogenous leukemia, angiogenic diseases, viral diseases (HCV, 
herpes virus, hepatitis B virus, papilloma virus and HIV) and fibrosis. Gutterman 
concludes that IFNα is potent drug but that it needs further research on the 
mechanisms of action (Gutterman 1994). Furthermore type I interferons feature 
tumor suppressing activities and therefore widen their clinical application spectrum to 
various pathophysiologies (Pestka 2003). 
The pleiotropic functions of interferons validate them as a potential drug 
(figure 2) and understanding of the underlying molecular mechanism involved in the 
interferon signaling will contribute to improved possibilities in successful treatment of 
patients suffering from virus infection, cancer and other diseases. 
___________________________________________________________________ 
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 Figure 2 
Figure 2. Antitumor actions of IFNα and IFNβ. Pestka, S. (2003). "A dance between 
interferon-alpha/beta and p53 demonstrates collaborations in tumor suppression and antiviral 
activities." Cancer Cell 4(2): 85-7. (Pestka 2003) 
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1.1.6.  Interferon-alpha Resistance 
Unfortunately, features like partial responses, side effects and especially drug 
resistance currently limit therapeutic efficacy of IFNα treatment. This holds true for 
hepatitis C virus infected patients also which currently are being treated with a 
combination of a viral RNA polymerase inhibitor gold standard and pegylated 
recombinant IFNα and has improved their convalescence from 20% to 50% (Duong, 
Christen et al. 2006). Resistance to interferons can be mediated by different means. 
Chadha et al. present four resitance mechanisms affecting the interferon molecule 
inactivation of intererons either by freely circulating interferon receptor capture or by 
inhibitory proteins thet are still under investigation and interference with IFNα 
synthesis either through elevated leves of prostaglandin E2 or by cAMP 
phosphodiesterase mediated cAMP reduction which is necessary for IFNα synthesis 
(Chadha, Ambrus et al. 2004). There are though other ways to develop resistance to 
IFNα and the most evident causes are chromosome aberrations and mutations in the 
IFNα signaling pathways. Interestingly, although resistance by mutation does occur, 
it is not the most prevalent method for cells to develop resistance. More often it was 
observed that there is lack of diligence in the IFNα signaling pathway (Pansky, 
Hildebrand et al. 2000). It has been shown, that IFNα resistance can be induced in 
human melanoma cells with high doses of IFNα (Brem, Oraszlan-Szovik et al. 2003) 
and genes upregulated in resistant cell lines imply possible active mechanisms of 
IFNα resistance (Certa, Seiler et al. 2001). Additionally, microarray analysis 
comparing gene expression of the human melanoma celll lines ME15 and D10 upon 
IFNα administration revealed that the JAK/STAT pathway is delayed but not 
defective in the resistant cell line D10 proposing an alternative resistance mechanism 
involving secondary signaling pathways rather than the JAK/STAT pathway (Certa, 
Wilhelm-Seiler et al. 2003).  
Another level of signaling interference occurs in the modulation of signaling 
proteins by means of methylation or defects in the same. These modulations are 
essential in maintaining accurate IFNα signaling. Interestingly, HCV infected patients 
have been treated successfully with S-adenosylmethionine (SAM) the substrate for 
methylation (Duong, Christen et al. 2006; Li, Chen et al. 2010). 
IFNα resistance strikingly demonstrates how crucial this signaling pathway is 
when it comes to the combat of virus infections, cancer and other diseases. To this 
point a vast variety of IFNα response inhibition has been described and this fact 
underlines the crucial function of the importance of a diligent IFNα signaling. 
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1.2. EPIGENETICS 
 
1.2.1.  History of Epigenetics 
The first biologist known to propose an epigenetic model according to his 
research was Paul Kammerer in the early 1920. Kammerer supposedly showed that 
toads were able to aquire features namely the nuptial pads and propagate them to 
their offspring (Pennisi 2009). Lamarque had postulated a plastic model of 
inheritance around 1800 which was widely accepted until the early 20th century. 
Anyhow, around that time the deterministic genetic model prevailed and the 
Lamarckien model was set aside. Unfortunately the story concerning Kammerer took 
a turn when he embellished his results and as a consequence was excluded from the 
scientific community (Pennisi 2009). When Muller reported his findings of the position 
effect variegation in the 30’s the ground was set for a new direction in the biological 
concepts (Muller and Tyler 1930). One of the major contributors in the exploration of 
epigenetics is Barabara Mc Clintock. In 1951 she had observed a the chromosomal 
position-effect variegation in maize (Mc Clintock 1951) and when she introduced her 
findings on movable genetic elements (Yarmolinsky 1981) the scientific community 
started to assume that these effects observed most likely promoted genetic variability 
(Campbell 1981). During those 20 to 30 years many suggestions had been proposed 
and some puzzling effects not congruent with the deterministic genetic code were 
acknowledged as epigenetics. According to Gottschling epigenetics is defined as “a 
change in phenotype that is heritable but does not involve DNA mutation” 
(Gottschling 2007) and others as for example Feinbergs definition conforms with the 
mentioned, setting the focus on inherited features that are not transducted by the 
genetic code (Feinberg and Tycko 2004).  
 
1.2.2.  Basics of Epigenetics 
The idea that all somatic cells contain the complete genome was not proven 
and accepted until the 1970s when the famous cloning experiment with Xenopus skin 
was performed (Gurdon and Laskey 1970; Laskey and Gurdon 1970). With this 
insight it became clear that the differentiated somatic cells did not involve genetic 
mutations or loss of genes but that the genes themselves must be regulated in a 
more complex manner. X-chromosome inactivation observed a while earlier provided 
one mechanistic cellular strategy to modulate its somatic phenotype (Ohno, Kaplan 
et al. 1959) and it was clear that DNA associated proteins, e.g. histones, must be 
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8 
involved in gene expression regulation (Stedman 1950). Until 1964 it was not clear 
how histones were able to exhibit regulatory effects and Alfrey et al. introduced the 
concept of gene activation by histone acetylation (Allfrey, Faulkner et al. 1964). Along 
with the occurrence of acetylated histones there was soon also the finding of the 
according proteins, histone acetyltransferases (HATs). It took quite a while to find 
enzymes promoting deacteylation but finally these HDACs were also discovered 
(reviewed in (Losick 1998)). Furthermore histones are subject to specific histone 
methylation leading to heterochromatin recruitment and propagation of silenced DNA 
(Bannister, Zegerman et al. 2001). Additional players in the regulation of gene 
expression are the small RNAs which can be involved in proper heterochromatin 
formation and RNA interference adds another layer to epigenetic gene expression 
regulation through DNA methylation (Mathieu and Bender 2004). Many different 
modifications can be observed and DNA methylation is probably one of the most 
exciting modulations of the language of life.  
 
1.2.3. DNA Methylation 
In the 1970’s Holliday doing quite some work on DNA replication realized that 
CpG methylaltion would administer a sound explanation how DNA repair 
mechanisms are able to distinguish daughter from parental DNA strands when 
proofreading the replicated double helix (Holliday and Pugh 1975). Bird et al. 
introduced methylation sensitive restriction enzymes and were able to demonstrate 
that CpG sites were either completely methylated or demethylated thus confirming 
the model Holliday had proposed earlier (Bird and Southern 1978). Years later Bird 
discovered the first methyl binding protein MeCP1 (Bird 1993) that directly was 
involved in CpG methylation gene suppression. Later on MeCP2 was identified and 
since then a variety of DNA methylation binding proteins have been discovered 
(Wade, Jones et al. 1998). 
In mammals, DNA methylation occurs at the cytosine base followed by an 
adjactent guanosine base through covalent binding thus the termination CpG 
methylation. Statistically the CpG content of the DNA various between 4 and 6% and 
usually three courters of all CpGs are methylated (Ehrlich, Gama-Sosa et al. 1982). 
Interestingly there are sites that exhibit either lower or higher contents of CpG. Very 
often seen throughout the DNA is the suppressed CpG content of under one percent. 
Whenever a stretch of 200 bases contains more than 55% CpG base combinations it 
is considered a CpG island. In general these are encountered in the promoter 
regions of genes (McKeon, Ohkubo et al. 1982) and they have even served as 
___________________________________________________________________ 
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markers in the search for novel genes since two thirds of all genes feature these CpG 
islands. Unfortunately it is a bit more complicated to map DNA methylation patterns. 
Unwittingly, Bird et al. started an approach by using restriction enzymes particular to 
DNA unmethylated CpG sites (Bird and Southern 1978). The so obtained fragments 
were originally called “HpaII tiny fragments” but soon the preferred applied 
terminology shifted to CpG islands (Gardiner-Garden and Frommer 1987; Bird 2009). 
In contrast to the normally methylated CpG sites these island are often not 
methylated at all especially in germ cells (Bird, Taggart et al. 1985). Frommer et al. 
introduced the bisulfite conversion where every unmethylated cytotosine is 
deaminated resulting in a thymidine instead of the original cytidine. This means, that 
every cytosine that has survived the bisulfite treatment was originally methylated and 
when the strands are sequenced or hybridized to a microarray chip these methylated 
cytosines can be easily identified (Frommer, McDonald et al. 1992). 
In order to maintain sound CpG methylation cells are dependant on their 
methyltransferases. To date five different DNA methyltransferases are known two of 
which are definitely expressed and functional in humans: the de novo DNA 
methyltransferase DNMT3b and the maintenance DNA methyltransferase DNMT1 
both of which use S-adenosyl-methionine (SAM) as a substrate. It is still not quite 
clear how the de novo DNA methyltransferase recognizes the CpGs that are not 
supposed to be methylated and the effect seen in germ cells, when all CpG sites are 
completely demethylated is still puzzling the scientific community (Rougier, Bourc'his 
et al. 1998). Mutations in the DNMTs have fatal consequences, lethal in mice, lack of 
DNA methyltransferase in humans lead to a disease called ICF syndrome 
(immunodeficiency, centromeric instability, facial abnormalities) which is associated 
with reduced methylation in the pericentric regions of the chromosome (Ehrlich 2003). 
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Figure 3 
Figure 3. Modes of action of DNMT1, MBD2, MBD3, MBD4, MeCP2 and Kaiso. (A) MBD1 
binds to methylated CpGs and mediates repression (B) DNMT1 is responsible for the DNA 
methylation (C) MBD2 is a component of the Mi-2/NuRD complex and binds to methylated CpGs to 
mediate repression. (D) MBD2 and MBD3 do not coexist in the same Mi-2/NuRD like complexes. 
MBD3 does not bind methylated DNA. (E) Kaiso binds methylated CpGs through a zinc finger motif 
and mediates both sequence-specific as well as methylation-dependent suppression. (F) MBD4 
repairs mismatches and may also function as a repressor. (G) MeCP2 seems to bind the Sin3A 
repressor complex, which acts to remodel chromatin. Sansom, O. J., K. Maddison, et al. (2007). 
"Mechanisms of disease: methyl-binding domain proteins as potential therapeutic targets in 
cancer." Nat Clin Pract Oncol 4(5): 305-15. (Sansom, Maddison et al. 2007)  
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Another group of proteins involved in the methylated CpG sites and regions 
are the methyl binding proteins. Most of them exhibit a methyl binding domain hence 
their names: MBD1, MBD2, MBD3 and MBD4. As introduced earlier MeCP2 is also a 
known methyl binding protein (Bogdanovic and Veenstra 2009). MeCP1 turned out to 
be a protein complex rather than a single protein containing MBD2 along with 
different histone acetylases (Feng and Zhang 2001). Another methyl binding complex 
is termed Mi-2/NURD complex which contains MBD3 (Wade, Gegonne et al. 1999) 
and it exerts nucleosome remodeling as well as histone deacetylase activities 
(Esteller 2005). The methyl binding proteins share up to 70 % homology and they are 
crucial in maintaining accurate transcriptional regulation. There is a further protein, 
Kaiso, which itself does not contain an MBD binding site but embodies a zinc finger 
domain to bind DNA. These proteins interact with eachother and the methylated or 
nonmethylated DNA to maintain truthful transcription regulation (see figure 3) and 
disruptions of the MBDs, MECP2 and Kaiso cause fatal diseases. 
As described above mutations in proteins involved in DNA methylation 
maintenance (DNMTs) and binding (MBDs) leads to different diseases such as ICF 
syndrome and the disruption of MeCP2 is known to cause Rett syndrome (Amir, Van 
den Veyver et al. 1999). It is furthermore known that DNA methylation aberrations 
are involved in cancer development. This happens through either hypermethylation of 
tumor suppressor genes or hypomethylation of oncogenes therefore leading to 
inactivation or activation of gene expression, respectively (depicted in figure 4) 
(Sansom, Maddison et al. 2007). Interestingly, in the mouse multistage skin cancer 
progression model it has been found that the degree of tumor development 
correlates well with DNA hypomethylation (Fraga, Herranz et al. 2004). Furthermore 
DNA hypomethylation is being used as a potent marker of some cancers (Esteller, 
Corn et al. 2001). Esteller outlines different CpG methylation affected mechanisms in 
the development of cancer: Cell cycle proteins, DNA repair machinery, hormonal 
response, p53 network and cytokine signaling are all subject to DNA methylation and 
loss or aberrations of DNA methylation cause fatal derangement (Esteller 2005). A 
powerful tool in the discovery of aberrant gene expressions and X-chromosome 
silencings as well as cancer treatment is the cytosine analog 5’-aza-2’-deoxycytidine 
(DAC). This substance is incorperated into the DNA but unlike the original cytosine 
DAC is not subject to methylation but instead binds DNMTs covalently therefore also 
exhibiting DNMT inhibitory effects (Jones and Taylor 1980). 
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Figure 4 
 
Figure 4. The MBD proteins and neoplasia. Red arrows indicate that the protein has a tumor 
augmenting effect, and blue arrows indicate that the indicated protein has a protective effect against 
tumor formation. Sansom, O. J., K. Maddison, et al. (2007). "Mechanisms of disease: methyl-
binding domain proteins as potential therapeutic targets in cancer." Nat Clin Pract Oncol 4(5): 
305-15. (Sansom, Maddison et al. 2007) 
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1.2.4. DNA Methylation and Interferon Resistance 
Epigenetics is known to be involved in silencing of genes (Epstein, Smith et al. 
1978) and aberrations in DNA methylation lead to changes in the expression of tumor 
suppressor genes as well as oncogenes and therefore promote cancer development 
(Jones and Laird 1999). Senescence can be induced in the immortalized Li-Fraumeni 
syndrome cells by treatment with the DNA demethylating and DNA methyltransferase 
(DNMT) inhibitory agent DAC and interestingly IFNα treatment exhibits a similar 
effect in these cells (Fridman, Rosati et al. 2007). Additionally treatment of human 
pancreatic cancer with DAC leads to activation of the interferon signaling pathway 
(Missiaglia, Donadelli et al. 2005). In mice, suppression of endogenous IFNs 
enhances development of metastases (Reid, Minato et al. 1981) and microarray 
studies with DAC treated immortalized cells revealed expression of a significant 
number of IFN pathway genes (Kulaeva, Draghici et al. 2003). Resistance to IFNα in 
renal carcinoma as well as melanoma cells can be overcome either by means of 
DAC or DNMT1 depletion by using its antisense (Reu, Bae et al. 2006). IFNα 
resistant HCV replicant harbouring cells exhibit sensitivity to IFNα upon treatment 
with DAC (Naka, Abe et al. 2006) again implicating a strong relationship between 
IFNα and DNA methylation. Evidence is obviously arising that the mechanisms 
behind IFNα resistance also involve aberrations in the biology of Epigenetics such as 
DNA methylation. 
 
Treatment System Effect Reference 
DAC or IFNα 
Li-Fraumeni syndrome 
cells induction of senescence 
(Fridman, Rosati et 
al. 2007) 
DAC or 
DNMT1depletion 
renal carcinoma as well 
as melanoma cells 
resistance to IFNα is 
overcome 
(Reu, Bae et al. 
2006) 
DAC 
resistant HCV replicant 
harbouring cells 
resistance to IFNα is 
overcome 
(Naka, Abe et al. 
2006) 
DAC 
human pancreatic 
cancer 
activation of the interferon 
signaling pathway 
(Missiaglia, Donadelli 
et al. 2005) 
DAC immortalized cells 
enhances IFN pathway 
gene expression 
(Kulaeva, Draghici et 
al. 2003) 
suppression of 
endogenous IFNs mouse 
enhances development of 
metastases 
(Reid, Minato et al. 
1981) 
Table 1. Overcoming interferon resistance by means of DNA methylation modulation 
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1.3. BACKGROUND 
 
1.3.1. The Human Melanoma Cell Lines ME15 and D10 
The ME15 and D10 cell lines are derived from human melanomas and the 
D10 cells exhibit IFNα resistance in that proliferation does not decrease upon IFNα 
stimulus (Figure 5) (Certa, Seiler et al. 2001). Both cell lines have been thoroughly 
characterized over the past years and therefore constitute an elaborate model to 
investigate mechanisms of IFNα resistance. Interestingly the resistance seen in D10 
cells was thought to be resulting from a defect in the JAK/STAT pathway, since no 
chromosomal aberrations nor muations had been found (Pansky, Hildebrand et al. 
2000). Anyhow, coregulation of many IFNα-inducible genes in ME15 and D10 cells 
propose that IFNα resistance of the D10 cell line is caused by abnormal signaling or 
delay downstream of the IFNα response therefore not involving the JAK/ STAT 
signaling cascade (Certa, Wilhelm-Seiler et al. 2003). Certa et al. have furthermore 
identified differently regulated gene-clusters and they highlighted a set of genes one 
of which is the imprinted maternally expressed transcript H19. This gene is 
upregulated in the IFNα sensitive cell line ME15 and known to be involved in DNA 
methylation and imprinting (Brannan, Dees et al. 1990). Another gene was found to 
be upregulated solely in D10 cells namely the DSS1 and loss of the same is 
associated with DNA damage (Li, Zou et al. 2006). These findings support the notion 
that alternative mechanisms are involved in the development of IFNα resistance. 
Crosstalk between pathways have been suggested as an additional layer of 
complexity in signaling (Certa, Wilhelm-Seiler et al. 2003). Elevated levels of 
transforming growth factor beta (TGFβ) have been observed in IFNα resistant HCV 
patients (Vidigal, Germer et al. 2002) and a similar effect might be partially 
responsible for the delayed gene expression response to IFNα seen in D10 cells. In 
conclusion IFNα resistance observed in D10 cells involves secondary effects apart 
from the primary IFNα response or the JAK/STAT signaling cascade, and alternative 
signaling pathways have been proposed in transmodulation of the IFNα stimulus. 
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Figure 5 
 
Figure 5. Proliferatiion of ME15 and D10 cells. DNA synthesis was measured by 3H-
thymidine incorporation in the absence or presence IFNα. Certa, U., M. Seiler, et al. (2001). "High 
density oligonucleotide array analysis of interferon- alpha2a sensitivity and transcriptional 
response in melanoma cells." Br J Cancer 85(1): 109. (Certa, Seiler et al. 2001). 
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1.3.2. S100A2 Restores Interferon-alpha Sensitivity 
In order to investigate previously proposed pathway crosstalks in IFNα 
signaling TGFβ stimulus was combined with the IFNα treatment. Foser et al. 
demonstrated that co-stimulation with IFNα and TGFβ restores antiproliferative 
activity in the resistant human melanoma cell line D10 (Figure 7, middle) (Foser, 
Redwanz et al. 2006). Furthermore, co-stimulation induces the cooperative activation 
of 28 genes including the insulin growth factor binding protein 3, IGFBP3, and the 
small calcium binding protein, S100A2 (figure 6) (Foser, Redwanz et al. 2006). 
 
 
 
 
 
 
 
 
 
 
           
           
           Figure 6 
Figure 6. Proliferation control genes with additive induction by IFNαK134 and TGFβ. Up-
regulated transcripts are displayed in blue. Foser, S., I. Redwanz, et al. (2006). "Interferon-alpha 
and transforming growth factor-beta co-induce growth inhibition of human tumor cells." Cell 
Mol Life Sci 63(19-20): 2390. (Foser, Redwanz et al. 2006) 
 
Stable over-expression of S100A2 but not IGFBP3 in melanoma cells leads to 
a marked inhibition of cell proliferation in the presence of Ca2+ ions in response to 
IFNα stimulation (Figure 7). It has been suggested that calcium signaling as well as 
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the calcium protein S100 is involved in the interferon pathway (Naeim, Hoon et al. 
1987; Gutterman 1994). Therefore, the combined activity of the upregulated calcium 
binding protein S100A2 along with the calcium efflux induced by IFNα plots a 
plausible correlation of the TGFβ and the IFNα signaling pathways. Nevertheless, the 
issue of IFNα resistance in D10 cells persists unsolved and continuing investigations 
of possible malfunctions in the cell response to cytokines remains subject of thorough 
research. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 
Figure 7. IFNα enhances antiproliferative activity of S100A2. S100A2 protein expression 
correlates with mRNA abundance (top). Growth rates of ME15 and D10 cells stably transfected with 
S100A2 (middle). IFNα induces intracellular calcium release (bottom). Foser, S., I. Redwanz, et al. 
(2006). "Interferon-alpha and transforming growth factor-beta co-induce growth inhibition of 
human tumor cells." Cell Mol Life Sci 63(19-20): 2390. (Foser, Redwanz et al. 2006) 
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1.3.3. The Small Calcium Binding Protein S100A2 
The family of S100 type calcium binding proteins consist of as many as 21 
members with pleiotropic functions (Eckert, Broome et al. 2004). Shared feature of all 
S100 proteins is the so called EF-hand motif which binds calcium and this leads 
subsequently to dimerization and activation (Donato 2001). It is commonly known 
that calcium plays crucial roles in a wide range of different cellular functions (Berridge, 
Lipp et al. 2000). Unlike the universally expressed Ca2+ binding protein calbindin 
S100 proteins exhibit differential expression throughout various cell types and 
therefore provide cell type specific Ca2+ signaling (Zimmer, Wright Sadosky et al. 
2003). They work as modulators of signal transduction through phosphorylation or by 
acting as Ca2+ level sensors. They change their subcellular distribution, interact 
directly with transcription and even trigger Ca2+ signals themselves (Schafer and 
Heizmann 1996; Mandinova, Atar et al. 1998). S100 proteins are known to be crucial 
in stress response, epidermal wound repair and differentiation and aberrations of 
S100 expression often result in carcinogenicity (Eckert, Broome et al. 2004).  
Interestingly, S100A2 is often downregulated in melanomas or breast tumors 
(Pedrocchi, Schafer et al. 1994; Maelandsmo, Florenes et al. 1997), which is 
consistent with a putative role in cell cycle control. In ME15 cells S100A2 expression 
is induced by TGFβ and further boosted by IFNα co-stimulation, which links these 
two signaling pathways at a transcriptional level (Foser, Redwanz et al. 2006). Since 
S100A2 is known to be hypermethylated upon others in mammary cancer (Lee, 
Tomasetto et al. 1992; Wicki, Franz et al. 1997) and prostate cancer (Rehman, Cross 
et al. 2005) the implication is close to suggest a possible epigenetic link in the co-
regulating effect of TGFβ and IFNα on IFNα inducible genes. 
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1.4. AIM OF THE STUDY 
Since S100A2 in contrast to other TGFβ-inducible genes (like the insulin 
growth factor binding protein 3; IGFBP3) leads to restoration of IFNα sensitivity in 
D10 cells, I am addressing the modulatory effect of S100A2 on the gene expression 
of the IFNα-inducible transmembrane protein IFITM3. I have chosen IFITM3 as 
chromosomal IFNα-response reporter gene in a model system consisting of the two 
human melanoma cell lines ME15 and D10. In the IFNα-sensitive ME15 cells IFITM3 
expression is strictly IFNα dependent whilst it is constitutively expressed in the IFNα-
resistant D10 cells. Since IFNα resistance is known to involve epigenetic 
mechanisms and since the IFNα pathway is functional in D10 cells, I decided to 
investigate DNA methylation of the core promoter of IFITM3 along with the potential 
modulatory effect of S100A2.  
 
 
 
 
 
 
 
 
 
 
 
Figure 8 
Figure 8. Key players of my thesis. The antiproliferative IFITM3 protein is IFNα-inducible and 
has been used as a marker for IFNα-resistance (Brem, Oraszlan-Szovik et al. 2003). The TGFβ-
inducible S100A2 is a small calcium binding protein and it was seen in previously published work that 
S100A2 is sufficient to restore IFNα-sensitivity in D10 cells (Foser, Redwanz et al. 2006). 
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2. MATERIAL AND METHODS 
 
2.1. Cell Lines 
ME15, D10, ME15S100A2 and D10S100A2 have been described elsewhere 
(Luscher, Filgueira et al. 1994; Pansky, Hildebrand et al. 2000; Brem, Oraszlan-
Szovik et al. 2003; Foser, Redwanz et al. 2006). Puromycin and blasticidin resistant 
cell lines ME15fPuro, ME15fBla, D10fPuro and D10fBla were generated in the 
course of this work and are described below along with the pluriploid cell line MDbla. 
 
2.2. Cell Culture 
All cell lines were cultured at 37°C in a 5% CO 2 atmosphere in RPMI 1640 
medium (GIBCO Life Sciences, Paisley, U.K.) supplemented with 10% fetal bovine 
serum (FBS), L-glutamine (2 mM), sodium pyruvate (1 mM), nonessential amino 
acids, antibiotics, and 10 mM HEPES buffer (Certa, Wilhelm-Seiler et al. 2003). 
 
2.3. Antibodies, Cytokines and Reagents 
Antibody against IFITM3 (1-8U) has been described previously (Brem, 
Oraszlan-Szovik et al. 2003). Anti-IFITM3 was diluted 1:2000 for western blotting. 
Anti-S100A2 was kindly provided by Prof. Dr. Claus W. Heizmann and diluted 1:1000 
and 1:500 for western blotting and immunofluorescence, respectively. Anti-p21 Waf1/ 
Cip1 was purchased from Bioconcept (Allschwil, Switzerland) and used at a dilution 
of approximately 1:200 (Cell Signaling Technology®, catalog number 2946). Goat 
anti-rabbit and goat anti-mouse IgG (H+L) horseradish peroxidase (HRP) conjugate 
were obtained from BioRad (Basel, Switzerland) and used at a dilution of 1:5000. 
Alexa Fluor 555 goat anti-rabbit IgG (H+L) was purchased from Invitrogen (Basel, 
Switzerland) and diluted 1:100. IFNα (IFNα2a, Roferon®-A) and its monopegylated 
isomer K134 (IFNαK134 (Foser, Schacher et al. 2003; Foser, Weyer et al. 2003; Foser, 
Redwanz et al. 2006)) was provided by F. Hoffmann-La Roche Ltd. (Basel, 
Switzerland). TGFβ has been purchased from Calobiochem (Germany). 
Concentrations used were 1000 U/ml IFNα and 2 ng/ml TGFβ unless indicated 
otherwise. 5-aza-2’-deoxycytidine (DAC) from Sigma (Basel, Switzerland) was used 
at a concentration of 2 ug/ml. Puromycin (a kind gift from Prof. Dr. Christoph Moroni, 
University of Basel, Switzerland) was used at a concentration of 0.5 mg/ml and 1 
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mg/ml and blasticidin (Alexis Biochemicals, Lausen, Switzerland) a concentration of 
3.75 mg/ml and 7.5 mg/ml for the ME15 and D10 cell line, respectively. Propidium 
Iodide was purchased from Sigma (Basel, Switzerland) and RNase was provided by 
F. Hoffmann-La Roche Ltd. (Basel, Switzerland). 
 
2.4. Cell Treatments 
Proliferation assays as well as protein detection assays were performed using 
the standard IFNα treatment of 1000 U/ml (figures 10 and 11A). For oligonucleotide 
array analysis ME15, ME15S100A2, D10 and D10S100A2 melanoma cell lines were 
grown in triplicate cultures for 2 days with either IFNαK134 (1000 U/ml), TGFβ (2 ng/ml) 
or a combination of both cytokines (figure 11B). For cell fractionation either ME15 as 
well as ME15S100A2 cells were treated with IFNα (1000 U/ml), TGFβ (2 ng/ml) or a 
combination of both cytokines for 2 days or ME15 cells were transfected with SNAP-
S100A2-Bam and SNAP-S100A2-Eco vectors for 6 and 20 hours (figure 12). In the 
S100A2 immunofluorescence localization assay cells were incubated with both IFNα 
(1000 U/ml) and TGFβ (2 ng/ml) or either the SNAP-S100A2-Bam or the SNAP-
S100A2-Eco recombinant vector for two days (figure 12). To promote genome wide 
demethylation the cell lines were treated with 5- aza-2’-deoxycytidine (DAC) (2 µg/ml) 
or a control along with IFNα (1000 U/ml, 100 U/ml or 10 U/ml), TGFβ (1µg/ml) or a 
combination of both cytokines with incubation times depicted in figures 13 and 23 
and the concentration of SAM supplementation was 160 mM (figure 14). Luciferase 
assays were performed using 1 µg of plasmid (figures 15 and 22) The standard IFNα 
concentration of 1000 U/ml were used in figures 15, 16, 18 and 19. For the IFITM3 
promoter methylation analysis ME15, ME15S100A2, D10 and D10S100A2 cells were 
stimulated with IFNα (1000 U/ml) according to figure 20 and to induce S100A2 
expression ME15 and D10 cells were incubated with TGFβ (2 ng/ml) for 2 days. The 
p53 luciferase reporter assays were performed using 5-fluoruracil (5-FU, 10 µg/ml, in 
DMSO dilution), lipopolysaccharide (LPS, 100 µg/ml, in DMSO dilution), 0.1% DMSO 
alone or DAC (2 µg/ml) treatment for 24h in ME15 and D10 cells previously 
transfected with the outlined luciferase reporter plasmids figure 22. 
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2.5. Proliferation Assays 
In order characterize growth respond to IFNα of ME15 and D10 standard 
proliferation assays have been performed previously using CellTiter Aequeous One 
Solution Cell Proliferation Assay (Promega, Madison, USA) (Foser, Redwanz et al. 
2006). Here, proliferation rates have been assessed using the RT-CES® System 
from ACEA Biosciences. ME15 and D10 cells were seeded in a gold coated 96-well 
plate at concentrations 5000, 2500, 1250 and 650 cells per well. After an incubation 
time of 8 hours cells were treated with the standard concentration of 1000 U/ml IFNα. 
Impedance was measured every three minutes over the course of a week monitoring 
cell growth in real time. 
 
2.6. Oligonucleotide Array Analysis 
Oligonucleotide array analysis has been described in detail previously (Foser, 
Redwanz et al. 2006). In this study RNA levels were measured 2 days after cytokine 
treatment. Genes considered had to exhibit a maximum mean of 50 and a 
changefactor (CHF) threshold of +/- 2. These experiments have been performed by 
the group of Stefan Foser ante inceptum operam meam. 
 
2.7. Transfections and Plasmids 
All transfections were performed using either FuGENE® from F. Hoffmann-La 
Roche Ltd. (Basel, Switzerland), Optifect or LipofectAMINE 2000 reagents from 
Invitrogen (Basel, Switzerland) according to the manufacturer’s protocol.  
PcDNA3 -S100A2 and PGL3-PA2 (S100A2 luciferase reporter plasmid) were 
kindly provided by Prof. Dr. Claus W. Heizmann (University of Zürich). The IFITM3 
Neo/N686 (IFITM3 luciferase reporter plasmid) and the 6-16 Neo/N686 (6-16 
luciferase reporter plasmid) have been described previously (Brem, Oraszlan-Szovik 
et al. 2003). PSirBGLoBla and pSirBGLoPuro carrying a blasticidin or a puromycin 
resistance, respectively, were kindly provided by Prof. Dr. Giulio Moroni (University of 
Basel). The firefly, pGL3-tk-luc, and the renilla, phRL tkluc, luciferase plasmids were 
purchased from Promega (Dübendorf, Switzerland). The p53 reporter plasmid was 
constructed by insertion of two p53 consensus sequences of GADD45 
'tggtacaGAACATGTCTAAGCATGCTGgggactg' between the NotI / SacI and the NheI 
/ Xho restriction sites of the pGL3 vector (Promega, Madison, USA) multiple cloning 
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site, resulting in a 5'-gagctcttacgcgtgctagc-3' spacer sequence in front of the herpes 
simplex virus (HSV) thymidine kinase (tk) promoter sequence and was a kind gift 
from Karen Schad from the laboratory of Dr. Adrian Roth (F. Hoffmann-La Roche Ltd., 
Basel, Switzerland). 
 
2.8. Cloning of SNAP-tagged S100A2 
For subcloning S100A2 from pcDNA3 into the pSEMS-26m vector from 
Covalys (Witterswil, Switzerland), S100A2 was amplified by PCR using primers with 
internal EcoRI and BamHI restriction sites to obtain a C-terminal SNAP-tag construct 
and a N-terminal SNAP-tag construct, respectively. Primers used for the C-terminal 
construct were (forward) 5’- CCT GGT CTG CCA CGA ATT CAT GAT GTG CAG 
TTCT and (reverse) 3’- GTT CTG AAT TCG GGT CGG TCT GGG CAG CCC. For 
the N-terminal construct following primers were used: (forward) 5’- CCT GGT CTG 
CCA CGG ATC CAT GAT GTG CAG TTCT and (reverse) 3’- AAG TGG ATC CTC 
AGG GTC GGT CTG GGC AGCC (Microsynth, Balgach, Switzerland). All sequences 
were verified by standard automated sequencing. 
 
2.9. Cell Fractionation 
ME15, D10, ME15S100A2 and D10S100A2 cells were lysed and fractionated using 
a commercial kit according to the instructions supplied (Qiagen Qproteome Cell 
Compartment Kit, Qiagen, Hombrechtikon, Switzerland). 
 
2.10. Immunoblotting 
Immunoblots were performed with total protein extracts or cell fractions. 
Protein amounts were normalized by standard BCA assays. SDS PAGE was 
performed with 4-12% Bis-Tris gels and nitrocellulose membranes using the XCell 
SureLockTM system from Invitrogen (Basel, Switzerland). Proteins were detected 
using 1° antibodies against IFITM3 or S100A2, HRP-c onjugated 2° antibody and a 
chemiluminescent substrate (SuperSignal West Pico Chemiluminescent; Pierce 
Chemical Co., Thermo Fisher Scientific Inc., Rockford, IL, USA). 
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2.11. Immunofluorescence 
Approximately 2000 ME15 cells and 4000 cells of each ME15S100A2, D10 and 
D10S100A2 were seeded on 4-well Lab-Tek® II Chamber Slides™ (LabTek, Nunc Inc., 
Langenselbold, Germany). The following day, cells were treated with a combination 
of IFNα (1000 U/ml) and TGFβ (2 ng/ml) or a control, followed by an incubation time 
of 2 days. All subsequent cell manipulations were performed on ice. Cells were 
washed twice with ice-cold OptiMEM from Invitrogen (Basel, Switzerland) and fixed 
for 2 minutes using 70% acetone kept at -20º C. After two additional washes with ice-
cold PBS the samples were treated with Image-iT® FX signal enhancer from 
Invitrogen (Basel, Switzerland) for 30 minutes and blocked for 1.5 hours in PBS 
containing 1% Bovine Serum Albumin (BSA) (Sigma, Basel, Switzerland), 1% Normal 
Goat Serum (NSG) (Sigma, Basel, Switzerland) and 1‰ Ova Albumin (OVA) (Fluka, 
Basel, Switzerland). Cells were incubated for 1 hour with anti-S100A2 serum at a 
dilution of 1:500 in blocking solution. After washing twice with PBS containing 1% 
BSA for 5 minutes, cells were stained with Alexa Fluor 555 diluted 1:100 in PBS 
containing 1% BSA for 1 hour. Cells were washed twice for 5 minutes with PBS. 
Images were recorded with a Zeiss Axiovert 135 microscope using Axiocam software 
(Zeiss, Feldbach, Switzerland). 
 
2.12. DNA Wide Demethylation by 5-Aza-2’-deoxycytidine 
Treatment 
Approximately 10’000 ME15 cells and 20’000 ME15S100A2, D10 and D10S100A2 
cells were seeded in 6-well plates. Cells were grown for three days following 
stimulation with TGFβ (1 µg/ml), IFNα (1000 U/ml) or a combination of both cytokines, 
in the presence or absence of 5-Aza-2’-deoxycytidine (DAC) (2 µg/ml). After 6, 12, 24 
and 51 hours cells were washed twice with PBS, resuspended in standard lysis 
buffer and the whole protein extract was thereafter used for immunoblot analysis. 
The same procedure was applied for the IFNα sensitivity experiment with 100 U/ml or 
10 U/ml IFNα treatment in the presence or absence of DAC (2 µg/ml). 
 
2.13. IFITM3 Protein Expression Upon S-Adenosyl-methionine 
Supplementation 
ME15 and D10 cells were grown in 6 well plates for two days. Cells were then 
stimulated with TGFβ (1 µg/ml), IFNα (1000 U/ml) or a combination of both cytokines 
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in the presence or absence of S-adenosyl methionine (SAM; 160 mM). After 6, 25 
and 50 hours cells were washed twice with PBS, resuspended in standard lysis 
buffer and the whole protein extract was thereafter used for immunoblot analysis. 
 
2.14. CpG Methyltransferase Mediated In Vitro Methylation 
PGL3-PA2 (S100A2 luciferase reporter plasmid), IFITM3 Neo/N686 (IFITM3 
luciferase reporter plasmid) and the 6-16 Neo/N686 were incubated with the CpG 
methyltransferase M. SssI (New England BioLabs Inc., Ipswich, USA) supplemented 
with methylgroup donor S-adenosyl methionine (SAM; New England BioLabs Inc., 
Ipswich, USA) according to the manufacturers protocol for 1 hour at 37°C. To control 
for successful methylation plasmids were digested for 1 hour at 37°C using the 
methyl-sensitive restriction enzyme AVA I (New England BioLabs Inc., Ipswich, USA), 
DNA was purified by precipitation and analyzed using gel electrophoresis.  
 
2.15. Luciferase Reporter Assays with the In Vitro Methylated 
Promoters IFI6, IFITM3 and S100A2 
ME15 and D10 cells were seeded into 24-well plates at a 70% confluence. 
One day later cells were transfected with either methylated or unmethylated PGL3-
PA2, IFITM3 Neo/N686 or 6-16 Neo/N686 using 1 µg of plasmid DNA according to 
standard transfection procedures and serum was added after 7 hours. Another day 
later cells were incubated with the standard concentration of 1000 U/ml IFNα and 
luciferase activity was measured 6 hours later using the Berthold Lumat (Berthold 
Technologies, Regensdorf, Switzerland). 
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2.16. Generation of the ME15-D10 Hybrid Cell Line MDbla 
 
2.16.1. Generation of Stable Cell Lines 
After optimal antibiotic concentrations were determined, ME15 and D10 cells 
were transfected with 4 µg of either PSirBGLoBla or pSirBGLoPuro plasmid DNA 
(kindly provided by Prof. Dr. Christoph Moroni, University of Basel) according to 
standard transfecion procedures. Cells were then grown under according antibiotic 
pressure to yield the puromycin and blasticidin resistant cell lines ME15fPuro, 
ME15fBla, D10fPuro and D10fBla. 
 
2.16.2. Fusion of Cell Lines 
The newly generated cell lines ME15fPuro and D10fBla as well as ME15fBla 
and D10fPuro were mixed 1:1 and washed twice in RPMI. The cell pellet was 
collected in a cuvette and given a pulse of 220 V and 900 µF. The cell pellet was 
incubated at 37°C for 30 minutes and thereafter res uspended in a standard culture 
flask. Fusioned cells were incubated for one day and then grown in selection media 
containing the adequate concentrations of antibiotics. Unfortunately only one clone 
survived, namely the MDbla which is the fusion cell line from the combined 
ME15fPuro and the D10fBla cell line. 
 
2.16.3. Evaluation by FACS 
ME15, D10 and MDbla cells were first fixed in 70% ethanol and thereafter 
labeled with propidium iodide purchased at Sigma (Basel, Switzerland) (0.05 mg/ml 
in PBS containing 0.1 mg/ml RNase provided by F. Hoffmann-La Roche Ltd. (Basel, 
Switzerland)) for one hour under standard cell culture conditions. Cells were kept on 
ice until cellcount was measured using a standard FACS analyzer. 
 
2.16.4. Evaluation by Karyotyping 
The karyotyping of the ME15, D10 and MDbla cell lines was kindly performed 
in the laboratory of Prof. Dr. Peter Miny at the UKBB (Universitäts-Kinderspital Beider 
Basel), Switzerland. 
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2.17. Isolation of Genomic DNA  
Cells were harvested using trypsin and genomic DNA was either isolated 
using the PureLink™ Genomic DNA Mini Kit from Invitrogen (Basel, Switzerland) or 
the MagNA Pure DNA Isolation Kit from Roche Applied Science (F. Hoffmann-La 
Roche Ltd., Basel, Switzerland) following manufacturers isolation protocol. 
 
2.18. DNA Wide Methylation Analysis Using the Illumina 
Infinium Methylation Assay 
ME15 cells were grown in T75 culture plates. After one hour of stimulation with 
IFNα (1000 U/ml), cells were harvested and genomic DNA was isolated. Bisulfite 
treatment for this assay was kindly performed by Dr. Patrick Urfer using the Zymo EZ 
DNA Methylation™ Kit (Orange, CA, USA) according to the manufactures protocol 
with 2µg of genomic DNA input. Bisulphited genomic DNA was processed further 
according to the instructions of the Infinium® Methylation Assay protocol (Illumina, 
San Diego, USA) and hybridization to the Illumina BeadChip. Scanning was 
performed using the Illumina BeadArray™ ReaderScanner. Data was imported into 
Illumina’s own methylation analysis software, Beadstudio, undergoing a preanalysis 
where the methylation ratios are internally calculated and displayed as beta values. 
 
2.19. Promoter Methylation Analysis by Bisulfite Sequencing 
ME15, ME15S100A2, D10 and D10S100A2 melanoma cell lines were treated with 
IFNα (1000 U/ml) for 1, 6 and 24 hours. In order to promote S100A2 expression in 
ME15 cells they were pretreated with TGFβ (2 ng/ml) for 2 days. Isolated genomic 
DNA was bisulfite treated using the Zymo EZ DNA Methylation™ Kit (Orange, CA, 
USA) according to the manufactures protocol with 2µg of DNA input. The bottom 
strand of the IFITM3 promoter was amplified to yield an 820 bp fragment using 
bisulfite adjusted primers designed to cover 19 CpG sites adjacent to the translation 
initiation site (ATG) (forward primer (Chromosome 11: 311612) 5’-ATA ATC CAA 
CTA CCT AAA CAC CATA and backward primer (Chromosome 11: 310793) 5’–GGT 
TTG GAT AGT GTG ATT TAT GG TGT TTA–3’ (Even though this primer encloses a 
mismatch this does not influence specific binding to the target sequence in silico.) 
The PCR program consists of following parameters: initial incubation time of 10 
minutes at 95°C, 40 cycles with 1 minute at 94°C, 1  minute at 58°C and 1 minute at 
72°C and an additional 10 minutes at 72°C for final  elongation. Amplified fragments 
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were cloned into the pCR®2.1-TOPO® vector (Invitrogen, Basel, Switzerland) and 
transformed into XL1-blue (Stratagene, La Jolla, CA, USA) or TOP10 (Invitrogen, 
Basel, Switzerland) competent cells and plated on IPTG/ X-gal containing agar plates. 
Plasmids from white colonies were isolated and sequenced using an ABI 3730xl DNA 
analyzer instrument and generic vector based primers using standard procedures. 
Following computer assisted alignment with the clustalw GCG-program the 
methylation state of CpG sites was determined. 
Bisulfite treated genomic DNA from healthy mucosa and colon cancer tissue 
samples of patients were a gift from Prof. P. Schär (University of Basel). 
 
2.20. P53 Luciferase Reporter Assay 
ME15 and D10 cells were transfected with a mix of a p53 negative firefly and a 
control renilla luciferase plasmid or the p53 reporter plasmid firefly mix ('2 x p53 in 
pGl3-tk-luc' and phRL tkluc') at a confluency of approximately 50% in 24 wells. To 
ensure efficient transfection reaction cells were incubated for 6 hours whereupon 
medium was replaced with culture medium containing either LPS (100 ug/mL, in 
DMSO dilution), 0.1% DMSO alone or DAC at the standard concentration. Cells were 
further incubated for 48 hours before luciferase activity was measured by Dual 
Luciferase Reporter Assay System (Promega, Dübendorf, Switzerland). Transfection 
and measurements were performed by Karen Schad (F. Hoffmann-La Roche Ltd., 
Basel, Switzerland) and Fredy Siegrist (F. Hoffmann-La Roche Ltd., Basel, 
Switzerland) analyzed data using the statistical program R. 
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3. RESULTS 
 
3.1. ME15 Cells Respond to Interferon by Decrease in 
Proliferation Rate Whereas D10 Cells Exhibit Resistance 
Previous research has established a model system to investigate IFNα-
resistance using two different melanoma cell lines. The ME15 cell line, considered 
sensitive to IFNα, markedly decreases its proliferation rate when exposed to IFNα. 
The other melanoma cell line, D10 is known to exhibit resistance to IFNα in that 
proliferation is not affected by cytokine treatment (Foser, Redwanz et al. 2006). In 
order to verify sensitivity of ME15 cells and resistance of D10 cells to IFNα we 
decided to verify the expected proliferation behaviour. 
There are three standard methods for assessing proliferation rate: either by 
cell-count, by detection of DNA synthesis or measurement of metabolic activity 
(Cunningham 2001). Each method reflects a different property of the cell line and it is 
advisable to investigate cell proliferation using different techniques. Certa et al. have 
used the thymidine incorporation to investigate DNA content in ME15 and D10 cells 
(Certa, Wilhelm-Seiler et al. 2003) and Foser et al. addressed cell proliferation by 
applying the CellTiter™ Assay (Promega) to measure metabolites in ME15, D10, 
ME15S100A2 and D10S100A2 cells (Foser, Redwanz et al. 2006). One main limitation of 
these methods is that cells must be harvested necessitating large amounts of starting 
material in order to investigate several time points. This issue can be circumvented 
by impedance measurement where proliferation is monitored in real time. The 
technique uses gold-coated wells that are attached to a low electrical circuit. Once a 
cell attaches to that surface, the resistance of the alternating current (e.g. the 
impedance) is measured and a Cell Index is calculated 
CI = (Zi-Z0)/ 15 Ω  Z = impedance, i = measured time point, 0 = time point 
zero, Ω = resistance 
reflecting both individual cell growth and population proliferation (xCELLigence, 
Roche Applied Science and ACEA Biosciences, figure 9).  
We seeded different ME15 and D10 cell concentrations into xCELLigence’s 
gold-coated 96 well plates and stimulated with IFNα after an incubation of eight hours. 
Impedance measurements were acquired every three minutes over the time-course 
of seven days (174 hours).  
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          Figure 9 
Figure 9. Principle of the xCELLigence System. Gold coated 96 well plates are connected to 
an electrical circuit and upon attachment of cells, impedance increases therefore measuring cell 
growth and proliferation (xCELLigence, Roche Applied Science and ACEA Biosciences, 2010 
(Sciences 2010)). 
 
Interestingly, ME15 cells seemed to exhibit a marked sensitivity to the seeding 
concentration. Only a concentration of 1250 cells per well allowed exponential growth 
(figure 10A); neither the higher nor the lower cell densities showed detectable 
proliferation with this method. ME15 cells exhibit a considerable downshift in the 
proliferation curve when exposed to IFNα indicating slower growth (figure 10A). 
Proliferation of untreated cells peaked at around 100 hours and then decreased, 
most likely due to detachment of the cells. For the IFNα-treated cells, peak levels are 
reached 45 hours later than in untreated cells and the cell index does not reach 
comparable levels. D10 cells, however, grow proportionally to their seeding 
concentration (figure 10B). Furthermore, it is clearly demonstrated that D10 does not 
exhibit sensitivity to IFNα.  
These findings are consistent with our previously published results (Certa, 
Wilhelm-Seiler et al. 2003; Foser, Redwanz et al. 2006) and we additionally conclude 
that cell density is a critical factor in determining proliferation rates of ME15 but not 
D10 cells. 
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Figure 10 
Figure 10. Proliferation is inhibited by IFNα in ME15 but not in the IFNα-resistant cell line D10. 
ME15 and D10 cells were seeded in gold-coated 96 well plates at the indicated concentrations. Cell 
density refers to number of cells seeded per well in 100µl media. Eight hours after seeding cells were 
stimulated with IFNα (1000 U/ml). Real-time proliferation was monitored by measurement of 
impedance every three minutes over a time range of 174 hours. Cells were normalized (NCIτi = CIτi/ 
CInrm-time) at time-point 8 hours post seeding using the ACEA Biosciences’ internal software. A. ME15 
cells grow best at an initial seeding density of 1250 cells per well and exhibit a marked decrease in 
proliferation upon IFNα stimulation. B. In contrast, D10 cells exhibit insensitivity to IFNα treatment and 
the proliferation rate is proportional to the initial cell density. 
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3.2. Restricted Enhancement of Interferon-alpha Response 
Gene Induction by S100A2 
We have shown previously that the TGFβ-inducible calcium binding protein 
S100A2 inhibits growth of stably transfected human melanoma cell lines (Foser, 
Redwanz et al. 2006). The antiproliferative activity however is potentiated by co-
stimulation with IFNα, which induces calcium release required for the activation of all 
calcium binding proteins. Since co-stimulation of cell lines with IFNα and TGFβ 
further reduces cell growth, we tested whether constitutive expression of S100A2 
modulates the induction of IFNα-inducible genes. Thus, we first measured the levels 
of IFITM3 protein in transgenic lines under conditions of single or combined 
treatment with TGFβ and IFNα. We observed a significant IFNα-dependent 
upregulation of IFITM3 protein in the S100A2 transfectants as compared to the 
precursor cells (figure 11A), which points to transcriptional enhancement. 
Interestingly, IFITM3 has marked antiproliferative activity and further upregulation 
could explain the synergistic activity of IFNα and TGFβ on cell growth in non-
transfected cells.  
We next asked whether constitutive S100A2 expression enhances the 
transcriptional IFNα response in general and we performed an mRNA expression 
microarray analysis of S100A2-transfected human ME15 melanoma cells, with 
untransfected cells as control (figure 11B). Apart from IFNα stimulation, we included 
TGFβ and the combination of both cytokines in order to detect possible interactions 
of S100A2 with the TGFβ signaling pathway. In ME15S100A2 cells, two clusters of 
genes are significantly upregulated by over-expression of S100A2 (figure 11B, 
clusters 1 and 3, table 2). Genes in cluster one do not respond to IFNα in 
untransfected cells and S100A2 over-expression renders them sensitive. 
Interestingly, this cluster contains two probes for S100A2 which suggests 
autoregulation and perhaps an autocrine amplification loop under natural conditions. 
Apart from apolipoprotein E, β-actin and a dehydrogenase this particular cluster 
includes mitogen-activated protein kinase kinase 5 (MAP2K5) which is known to 
stimulate cell cycle progression and its induction is probably required to antagonize 
complete cycle arrest and apoptosis. The second group of genes (figure 11B, cluster 
3) contains IFITM3 and other known IFNα inducible genes like p27, 9-27 or 2-5 
oligoadenylate cyclase, as expected. Others, such as ISG15, STAT1 or MHC class 1, 
are part of a third cluster and insensitive to S100A2 over-expression (figure 11B, 
cluster 2, and table 2). In contrast to the second cluster (figure 11B, cluster 3), none 
of these genes has documented antiproliferative activity. In conclusion, S100A2 
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exhibits a specific modulatory effect on particular gene expression in ME15 cells 
provided administration of IFNα is given. 
We also included the IFNα unresponsive cell line D10 in our analysis in order 
to detect possible correlations with drug resistance (figure 11B). In these cells, IFNα 
responses are not impaired but are in general delayed (Certa, Wilhelm-Seiler et al. 
2003) which might explain the obvious lack of significant S100A2 mediated 
enhancement of gene expression. Thus, S100A2 alone does not restore 
responsiveness to IFNα but requires TGFβ-inducible proteins (Foser, Redwanz et al. 
2006).  
TGFβ or combined IFNα/ TGFβ responses are in general not modified by 
recombinant S100A2 expression in ME15 or D10 cells, although certain genes 
appear moderately downregulated. In summary, this analysis shows interactions of 
S100A2 with the induction of subsets of IFNα inducible genes in ME15. In addition, 
the chromosomal copy of S100A2 becomes IFNα responsive in the transgenic ME15 
line and S100A2 hence has properties of a cis-acting transcriptional enhancer. 
 
 
 
 
 
 
Figure 11. S100A2 modulates transcriptional responses to IFNα and TGFβ. A. Immunoblot 
detection of IFITM3 in whole cell extracts of ME15 and ME15S100A2 (stably over-expressing S100A2) 
cells stimulated with IFNα (1000 U/ml) for 8 hours. B. Primary cell lines (ME15 and D10) indicated as 
P and transgenic cell lines (ME15S100A2 and D10S100A2) indicated as TG were treated with IFNα (1000 
U/ml), TGFβ (2 ng/ml) or a combination of both cytokines. After 2 days, total RNA was extracted, 
processed and hybridized to commercial DNA microarrays. The heat map indicates change of gene 
expression in stimulated P vs. non-stimulated P cell lines as well as in stimulated TG vs. non-
stimulated TG cell lines. Blue bands indicate down-regulated genes, the red ones show up-regulated 
genes. Maximum mean was set to 50 and change-factor (CHF) cut off was +/- 2. Maximum blue and 
red intensities correspond to a range of 10 (indicated as CHF). Clustering was performed using 
hierarchical clustering including the t-test. Note the clusters of up-regulated genes in ME15S100A2 vs. 
ME15 cells stimulated with IFNα (boxed: cluster 1-3). 
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Table 2. List of genes in clusters 1 to 3 including change factors (CHGF) 
 
DESCRIPTION  SYMBOL 
CHGF 
ME15 
CHGF 
ME15S100A2 
cluster 1  
  
s100 calcium binding protein a2 S100A2 0.22 2.45 
s100 calcium binding protein a2 S100A2 0.63 1.72 
apolipoprotein e APOE 0.17 2.42 
actin, beta ACTB 0.13 3.53 
mitogen-activated protein kinase kinase 5 MAP2K5 0.1 2.9 
dehydrogenase/reductase (sdr family) member 2 DHRS2 0.64 6.22 
cluster 2  
  
beta-2-microglobulin B2M 3.3 2.94 
interferon-induced protein 35 IFI35 1.83 1.98 
beta-2-microglobulin B2M 2.93 2.51 
beta-2-microglobulin B2M 2.38 2.1 
signal transducer and activator of transcription 1, 
91kda STAT1 3.72 3.07 
signal transducer and activator of transcription 1, 
91kda STAT1 4.28 3.1 
interferon-induced protein with tetratricopeptide 
repeats 1 IFIT1 11.78 6.35 
signal transducer and activator of transcription 1, 
91kda STAT1 16.79 11.77 
interferon-induced protein with tetratricopeptide 
repeats 1 IFIT1 8.59 5.27 
ubiquitin-conjugating enzyme e2l 6 UBE2L6 7.78 4.42 
lectin, galactoside-binding, soluble, 3 binding protein LGALS3 1.4 1.71 
major histocompatibility complex, class i, f HLA-F 1.55 1.4 
major histocompatibility complex, class i, f HLA-F 2.96 2.57 
major histocompatibility complex, class i, b HLA-B 3.35 4.37 
isg15 ubiquitin-like modifier ISG15 14.84 14.17 
interferon, alpha-inducible protein 6 IFI6 9.09 13.12 
isg15 ubiquitin-like modifier ISG15 18.43 22.7 
cluster 3  
  
small proline-rich protein 2d SPRR2D 0.5 1.37 
interferon-induced protein 44-like IFI44L 5.89 8.86 
interferon induced transmembrane protein 3 (1-8u) IFITM3 1.6 6.52 
interferon induced transmembrane protein 1 (9-27) IFITM1 9.73 27.19 
proteasome (prosome, macropain) subunit, beta type, 
9  PSMB9 1.97 2.46 
interferon induced transmembrane protein 1 (9-27) IFITM1 3.62 19.79 
interferon-induced protein 35 IFI35 1.43 2.69 
interferon-stimulated transcription factor 3, gamma 
48kda IRF9 1.71 4.07 
2`,5`-oligoadenylate synthetase 1, 40/46kda OAS1 5.75 13.62 
2`-5`-oligoadenylate synthetase 2, 69/71kda OAS2 1.42 2.19 
bone marrow stromal cell antigen 2 BST2 41.07 62.6 
interferon, alpha-inducible protein 27 IFI27 65.94 111.36 
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Table 3. List of genes regulated in ME15 and ME15S100A2 cells clustered in figure 11 
 
 
dopachrome tautomerase 
heat shock protein 90kda alpha (cytosolic), class a member 1 
gtpase activating protein (sh3 domain) binding protein 2 
glycoprotein m6b 
human endogenous retrovirus herv-k22 pol and envelope orf region 
dopachrome tautomerase  
melan-a 
myelin basic protein 
chromosome 11 open reading frame 72 
tubulin, beta 4 
human endogenous retrovirus herv-k22 pol and envelope orf region 
histone cluster 1, h4c 
asparagine synthetase 
tubulin, alpha 1a 
dihydropyrimidinase-like 2 
cd59 molecule, complement regulatory protein 
discoidin domain receptor family, member 1 
ae binding protein 1 
inhibitor of dna binding 1, dominant negative helix-loop-helix protein 
immediate early response 3 
collagen, type ix, alpha 3 
collagen, type iv, alpha 2 
fibronectin 1 
fibronectin 1 
fibronectin, alt. splice 1 
Zyxin 
insulin-like growth factor binding protein 5 
plasminogen activator, tissue 
eukaryotic translation elongation factor 1 alpha 2 
plasminogen activator, urokinase receptor 
milk fat globule-egf factor 8 protein 
jun b proto-oncogene 
solute carrier family 20 (phosphate transporter), member 1 
tenascin c (hexabrachion) 
s100 calcium binding protein a1 
s100 calcium binding protein a13 
transforming growth factor, beta-induced, 68kda 
insulin-like growth factor binding protein 3 
insulin-like growth factor binding protein 3 
interleukin 1, beta 
Galanin 
tyrosine kinase, receptor axl, alt. splice 2 
calbindin 2, 29kda (calretinin) 
axl receptor tyrosine kinase 
s100 calcium binding protein a2 
s100 calcium binding protein a2 
apolipoprotein e 
actin, beta 
mitogen-activated protein kinase kinase 5 
dehydrogenase/reductase (sdr family) member 2 
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v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) 
udp-gal:betaglcnac beta 1,4- galactosyltransferase, polypeptide 1 
secreted phosphoprotein 1 (osteopontin) 
secreted phosphoprotein 1 (osteopontin) 
prion protein (p27-30) 
collagen, type iv, alpha 1 
glyceraldehyde-3-phosphate dehydrogenase 
2`,3`-cyclic nucleotide 3` phosphodiesterase 
major histocompatibility complex, class i, a 
tap binding protein (tapasin) 
tryptophanyl-trna synthetase 
interleukin 1, beta 
neuroblastoma breakpoint family, member 14 
beta-2-microglobulin 
interferon-induced protein 35 
beta-2-microglobulin 
beta-2-microglobulin 
signal transducer and activator of transcription 1, 91kda 
signal transducer and activator of transcription 1, 91kda 
interferon-induced protein with tetratricopeptide repeats 1 
signal transducer and activator of transcription 1, 91kda 
interferon-induced protein with tetratricopeptide repeats 1 
ubiquitin-conjugating enzyme e2l 6 
lectin, galactoside-binding, soluble, 3 binding protein 
major histocompatibility complex, class i, f 
major histocompatibility complex, class i, f 
major histocompatibility complex, class i, b 
isg15 ubiquitin-like modifier 
interferon, alpha-inducible protein 6 
isg15 ubiquitin-like modifier 
cyclin d1 
cyclin d1 
dehydrogenase/reductase (sdr family) member 3 
ectodermal-neural cortex (with btb-like domain) 
podocalyxin-like 
lymphoid enhancer-binding factor 1 
serpin peptidase inhibitor, clade a, member 3 
nicotinamide n-methyltransferase 
insulin-like growth factor binding protein 5 
insulin-like growth factor binding protein 5 
keratin 81 
small proline-rich protein 2d 
interferon-induced protein 44-like 
interferon induced transmembrane protein 3 (1-8u) 
interferon induced transmembrane protein 1 (9-27) 
proteasome (prosome, macropain) subunit, beta type, 9 
interferon induced transmembrane protein 1 (9-27) 
interferon-induced protein 35 
interferon-stimulated transcription factor 3, gamma 48kda 
2`,5`-oligoadenylate synthetase 1, 40/46kda 
2`-5`-oligoadenylate synthetase 2, 69/71kda 
bone marrow stromal cell antigen 2 
interferon, alpha-inducible protein 27 
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Table 4. List of genes regulated in D10 and D10S100A2 cells clustered in figure 11 
 
dopachrome tautomerase 
dopachrome tautomerase 
ectodermal-neural cortex (with btb-like domain) 
fibronectin 1 
fibronectin, alt. splice 1 
fibronectin 1 
collagen, type iv, alpha 1 
immediate early response 3 
s100 calcium binding protein a13 
serpin peptidase inhibitor, clade e, member 2 
tenascin c (hexabrachion) 
prion protein (p27-30) 
insulin-like growth factor binding protein 7 
crystallin, alpha b 
crystallin, alpha b 
s100 calcium binding protein a2 
s100 calcium binding protein a2 
proteasome (prosome, macropain) subunit, beta type, 8 
interferon induced transmembrane protein 1 (9-27) 
interferon induced transmembrane protein 3 (1-8u) 
2`-5`-oligoadenylate synthetase 2, 69/71kda 
interferon, alpha-inducible protein 6 
signal transducer and activator of transcription 1, 91kda 
signal transducer and activator of transcription 1, 91kda 
isg15 ubiquitin-like modifier 
isg15 ubiquitin-like modifier 
bone marrow stromal cell antigen 2 
interferon-stimulated transcription factor 3, gamma 48kda 
interferon, alpha-inducible protein 27 
2`,3`-cyclic nucleotide 3` phosphodiesterase 
major histocompatibility complex, class i, f 
major histocompatibility complex, class i, b 
major histocompatibility complex, class i, f 
interferon induced transmembrane protein 1 (9-27) 
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3.3. Cellular Localization of Native and Recombinant S100A2 
The S100A2 mediated enhancement of transcription suggests that the 
molecule is localized in the nucleus where it might function as transcription factor or 
enhancer. The class of S100 calcium binding proteins contains EF-hand motifs which 
are required for calcium binding and subsequent activation (reviewed in (Schafer and 
Heizmann 1996)). Like S100A2, they are quite abundant and frequently associated 
with tumorigenic disorders where they function presumably as inhibitors of 
proliferation (Salama, Malone et al. 2008). In particular, S100A2 has been detected 
in the cytoplasm and nucleus from lung, kidney and corneal epithelium (Nielsen, 
Heegaard et al. 2005) or predominantly in the nucleus of keratinocytes and breast 
cancer cells (Mueller, Bachi et al. 1999; Deshpande, Woods et al. 2000) or 
exclusively in the cytoplasm of epithelial cells (Gimona, Lando et al. 1997). We thus 
wished to determine the subcellular localization of S100A2 in human melanoma 
ME15 and D10 cells in order to elucidate a mechanism of action. We included IFNα 
and TGFβ cytokine stimulation of cells because this may trigger shuttling of the 
protein between cellular compartments. 
 
 
 
 
 
Figure 12. S100A2 is localized in the cytoplasm. A. Localization of S100A2 upon cytokine 
treatment. Upper panel: Immunoblot detection of S100A2 in cell fractions of ME15 and ME15S100A2 
(stably over-expressing S100A2) cells stimulated with TGFβ (2 ng/ml), IFNα (1000 U/ml) or a 
combination of both cytokines for 2 days. Lower panel: S100A2 detection by immunofluorescence. 
ME15, ME15S100A2, D10 and D10S100A2 cells were seeded on chamber-slides, treated with both IFNα 
(1000 U/ml) and TGFβ (2 ng/ml) one day later and fixed and stained after a further two days. B. 
Localization of over-expressed S100A2-SNAP-tag fusion protein. SNAP-tag was fused either to the N-
terminus (3’) or the C-terminus (5’) of S100A2. Upper panel: Immunoblot detection of S100A2-SNAP 
fusion proteins in fractions of ME15 cells transiently transfected with S100A2-SNAP-tag. Cell-
fractioning was performed 6 and 20 hours post transfection. Lower panel: Localization of S100A2-
SNAP fusion proteins in ME15 and D10 cells three days post transfection. Left panel: Unfixed cells 
were stained with SNAP-cell TMR-star labeling reagents and visualized 3 hours thereafter. Right panel: 
Fixed cells were stained with S100A2 antibody. 
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Figure 12 
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First, we prepared subcellular fractions of ME15 and ME15S100A2 cells by 
differential centrifugation and probed them with rabbit antibodies to S100A2 in 
immunoblots (figure 12A, top). In both lines, S100A2 is exclusively detected in the 
cytoplasm and is virtually absent in the membrane, cytoskeletal or nuclear fractions 
regardless of cytokine treatment. Even a boost of expression in the S100A2 
transgenic line by TGFβ/ IFNα co-stimulation did not induce any translocation into the 
nucleus. We confirmed this finding by immunofluorescence in IFNα-treated tumor cell 
lines ME15 and D10 that are either stably transfected with S100A2 or alternatively 
TGFβ stimulated. In general, the protein is evenly distributed in the cytoplasm. 
Although in some cells we noted weak punctate staining in the nucleus and 
enhanced peri-nuclear fluorescence. 
As the cellular localization of S100A2 is important for the interpretation of the 
transcriptional results and possible mode of action, we engineered N- or C-terminal 
fusion proteins of S100A2 with the SNAP-tag. The SNAP-tag is based on the DNA 
repair protein AGT and can be post-translationally labeled by fluorescent nucleotide 
analogs. These bind with high affinity and sensitivity (Keppler, Gendreizig et al. 2003). 
In contrast to other tags, such as green fluorescent protein, SNAP fusion proteins 
preserve the subcellular localization of the native polypeptide. Indeed, the S100A2 
fusion proteins are predominantly detected in the cytoplasmic fraction of transiently 
transfected ME15 and D10 cells, regardless of the tag attachment site. In samples 
analyzed 20 hours after transfection some fusion protein is present in the membrane 
fraction but is undetectable in nuclei (figure 12B). 
Next, we labeled the fusion protein with TMR-Star and inspected the cells 
microscopically. This resulted in bright, homogeneous fluorescence in the cytoplasm 
and somewhat reduced in the nucleus, which was in disagreement with the 
immunoblotting results above (figure 12B, bottom, left panels). We therefore detected 
the S100A2 domain in the fusion protein with antibodies and obtained virtually the 
same staining pattern as with native or recombinant S100A2 (figure 12B, bottom, 
right panels). Consistent with previous findings S100A2 in contrast to other S100 
proteins does not relocalize to different compartiments of the cell upon calcium 
elevation in the cytoplasm (Mueller, Bachi et al. 1999). We conclude that S100A2 is 
predominantly localized in the cytoplasm of human melanoma cells, which eliminates 
to a large extent the possibility that S100A2 is a component of transcriptional 
activator complexes operating in the nucleus. 
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3.4. Core Promoter Methylation Modulates Expression Levels 
of S100A2 and IFITM3 
The cytoplasmic location of S100A2 excludes a direct involvement in 
transcriptional regulation, so we addressed the question of S100A2-mediated 
transcriptional enhancement on an epigenetic level. The S100A2 promoter is known 
to be methylated (Rehman, Cross et al. 2005) and this suggests a possible link 
between S100A2 and DNA methylation. We stimulated cells with the cytokines as 
above but included incubation with the cytosine analog 5-aza-2’-deoxycytidine (DAC), 
which cannot be methylated after incorporation into chromatin, and also actively 
inhibits DNA methyltransferases (DNMTs). We observed a significant upregulation of 
S100A2 expression in DAC-treated ME15 cells as compared to cells that were 
stimulated with TGFβ alone (figure 13A). As expected, IFNα did not induce this gene 
and co-stimulation with both cytokines boosted expression in untreated cells as 
previously shown (Foser, Redwanz et al. 2006). Interestingly, the levels of S100A2 in 
stably transfected cells were not modified by either treatment, including TGFβ, 
suggesting a certain expression threshold that cannot be exceeded without cell 
damage or proliferation arrest. Consistent with previous microarray data (Foser, 
Redwanz et al. 2006), S100A2 is inducible in untreated D10 cells but here the impact 
of DAC is less pronounced. The overall levels of S100A2 in stably transfected cells 
are higher and D10 may be less sensitive to S100A2 over-expression due to an 
epigenetic malfunction of D10 cells. In conclusion, DAC treatment increases the 
response of the S100A2 gene to TGFβ stimulation in ME15 cells suggesting a 
methylation dependency, as has been described before (Lee, Tomasetto et al. 1992; 
Wicki, Franz et al. 1997).  
We next analyzed expression of the IFNα-inducible gene IFITM3 in the same 
samples, because stable over-expression of S100A2 boosts IFITM3 protein levels 
(figure 11). Interferon-inducible genes have been shown to be silenced epigenetically 
(Naka, Abe et al. 2006) and we suggested a deterioration in the methylation pattern 
of the IFITM3 promoter as an additional layer of gene expression control. In 
untransformed ME15 cells, IFITM3 protein expression is detectable after 12 hours of 
IFNα exposure and as expected TGFβ does not activate this gene (figure 13B, left 
blot). Analogous to protein expression of the TGFβ-induced S100A2, treatment with 
DAC results in a clear, time dependent upregulation of IFITM3 protein by IFNα. 
Expression levels were even more enhanced after 51 hours. In addition, protein 
expression commences at earlier time points in DAC-treated cells. We noted that 
DAC treatment alone is sufficient to trigger IFITM3 expression in the absence of IFNα 
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(figure 13B, left blot, arrowhead). Consistent with the S100A2 expression mode 
described above, DAC treatment does not alter expression levels of IFITM3. IFITM3 
is however clearly upregulated by S100A2 expression (figure 13B, second blot from 
left), when compared to induction in control ME15 cells under comparable blotting 
and exposure conditions (figure 13B, left blot). As above, the detected levels of 
IFITM3 are probably at maximal tolerated levels before complete cell cycle arrest 
occurs. At 51 hours though, IFITM3 expression levels drop in the absence of DAC, 
indicating a natural mechanism of gene silencing in the presence of endogenous 
S100A2. 
In D10 cells, IFITM3 is deregulated for unknown reasons (figure 13B, third blot 
from left) (Certa, Wilhelm-Seiler et al. 2003). As previously shown, IFNα stimulation 
further upregulates IFITM3 levels and we note here that D10 cells lack IFNα-
inducible antiproliferative activity. (Certa, Seiler et al. 2001). This IFITM3 upregulation 
is entirely DAC-insensitive which suggests a methylation-related defect in these cells. 
In D10S100A2 cells, expression is further boosted so that maximal levels are already 
achieved 6 hours after stimulation. In contrast to untransfected D10 cells, IFITM3 
expression drops back to baseline levels after 24 hours under all conditions (figure 
13B, right blot). Together, these results suggest that DAC treatment increases 
promoter sensitivity in ME15 cells resulting in an earlier onset of induction and higher 
as well as more persistent protein levels in comparison to non-treated cells. Stable 
S100A2 expression upregulates IFITM3 in both ME15 and D10 cell lines in a similar 
manner to the DAC treatment, but by a mechanism which is largely DAC insensitive. 
In order to verify our suggestion that DAC increases promoter sensitivity to 
IFNα, ME15 and ME15S100A2 cells were treated with DAC and thereafter with low 
doses of IFNα (100U and 10U instead of 1000U) (figure 13C). As expected, cells 
exhibited high sensitivity to even very low levels of IFNα in the presence of DAC. 
Note that IFITM3 is upregulated with DAC treatment even in the absence of 
administered IFNα (figure 13B, star). This finding correlates well with the constitutive 
expression of IFITM3 in D10 cells and the DAC treatment insensitivity that D10 cells 
exhibit. 
In summary, DAC-mediated demethylation of CpG sites enhances the 
responsiveness of the IFITM3 and S100A2 promoters to IFNα or TGFβ in ME15 cells, 
whilst no significant DAC-mediated modulation occurs in the IFNα-resistant cell line 
D10. This strongly suggests that CpG methylation is involved in the regulation of the 
IFITM3 core promoter, particularly in ME15 cells. 
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       Figure 13 
Figure 13. 5-Aza-2’deoxycytidine (DAC) modulates cytokine-induced changes in S100A2 (A) 
and IFITM3 (B and C) protein levels. IFNα-sensitive ME15 and ME15S100A2 (stably over-expressing 
S100A2) cells, and IFNα-resistant D10 and D10S100A2 cells were stimulated with TGFβ (2 ng/ml), IFNα 
(1000 U/ml) or a combination of both cytokines, in addition to DAC (2 µg/ml). Immunoblot detection of 
either S100A2 or IFITM3 was performed using total cell extracts from interferon stimulation time points 
6h, 12h, 24h or 51h. Note expression of IFITM3 in DAC treated ME15 cells in the absence of 
administered IFNα (star). Panel C shows IFITM3 expression upon stimulation with different IFNα 
concentrations plus/ minus DAC treatment. 
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3.5. No Restoration of Interferon-alpha Sensitivity in D10 
Cells upon S-Adenosyl-methionine Supplementation 
We have shown that the IFNα-inducible IFITM3 protein exhibits DAC 
sensitivity in the IFNα-sensitive cell line ME15. However, when the IFNα-resistant 
cell line D10 is treated with DAC no changes in IFITM3 expression or S100A2 
expression are detectable (figure 13). Since IFNα resistance is known to involve DNA 
methylation we suggested a possible malfunction in the DNA methylation mechanism 
(Kulaeva, Draghici et al. 2003; Naka, Abe et al. 2006; Reu, Bae et al. 2006). This 
might include the de novo methylase DNA methyltransferase 3 (DNMT3) or the 
maintenance methylase DNA methyl transferase 1 (DNMT1) (Ehrlich 2003). It is 
known that DNMT1 activity decreases in senescent cells leading to hypomethylation 
(Lopatina, Haskell et al. 2002) and methyltransferases are proposed to be involved in 
proliferation control (Young and Smith 2001). It was found that a decrease in DNMT1 
leads to growth arrest and even to apoptosis and knock down of DNMT1 promotes 
upregulation of growth control genes such as p21 and RASSF1A (Beaulieu, Morin et 
al. 2002; Kassis, Zhao et al. 2006). DNMTs exert their methyltransferase activity by 
using S-adenosyl-methionine (SAM) as methylgroup substrate and one possibility of 
impairement is the lack of methylgroups for appropriate DNA methylation. Critical 
levels of S-adenosyl-methionine (SAM) are crucial for functional DNA methylation 
and we decided to investigate IFITM3 as well as S100A2 expression upon SAM 
supplementation especially since SAM is furthermore known to restore sensitivity to 
IFNα in resistant HCV patients (Duong, Christen et al. 2006). 
 We incubated ME15 and D10 cells with TGFβ, IFNα and a combination of 
both in the presence or absence of SAM. S100A2 and IFITM3 protein levels were 
analysed 6, 25 and 50 hours later.  
 
 
 
 
Figure 14. S-adenosyl-methionine (SAM) is not sufficient to restore IFITM3 gene expression 
control in D10. ME15 and D10 cells were supplemented with SAM (160 mM) and treated with IFNα 
(1000 U/ml), TGFβ (2 ng/ml) or a combination of both cytokines. Immunoblot detection of either 
S100A2 (A) or IFITM3 (B) was performed using total cell extracts from interferon stimulation time 
points 6, 24 or 50h. 
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ME15 and D10 cells did not exhibit significant differences in S100A2 
expression in the absence or presence of SAM at all three time points (figure 14A). 
There was a slight indication that SAM treatment might suppress S100A2 expression 
at the earliest investigated time point (figure 14A, 6h). IFITM3 is known to reach 
maximum expression levels 6 hours after IFNα treatment but SAM supplementation 
did not visibly alter IFITM3 epression in ME15 cells (figure 14B). In D10 cells IFITM3 
is deregulated and IFNα boosts expression further. SAM treatment failed to influence 
IFITM3 expression significantly, though one could suggest some decrease of IFITM3 
expression in the presence of SAM in the control and also the TFGβ samples at the 6 
and 25 hours time points (Figure 14B). Nevertheless, SAM was not able to silence 
IFITM3 expression in control D10 cells indicating that the methylation impairement in 
D10 cells does not result from insufficient SAM levels. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14 
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3.6. Lower Response to Interferon-alpha Upon In Vitro 
Methylation 
In D10 cells the methylation machinery seems to be impaired (figure 13) and 
SAM supplementation failed to restore IFITM3 expression control (figure 14B). To 
investigate the methylation defect observed in figure 13 we decided to introduce in 
vitro methylated plasmids into D10 cells in order to find possible defects in the DNA 
methyltransferases (DNMTs). For this reason, we transfected both D10 and ME15 
cell lines with untreated IFITM3 and IFI6 (interferon inducible protein 6) plasmids 
described earlier (Brem, Oraszlan-Szovik et al. 2003) as well as SssI methylase-
treated plasmids. In order to verify the results from above (figure 14) we included 
SAM in this experiment. As expected, IFITM3 as well as IFI6 were expressed upon 
IFNα stimulation in both cell lines. In contrast to previous findings (Brem, Oraszlan-
Szovik et al. 2003) D10 cells did not exhibit any differences in expression to ME15 
cells and in consistence with the results above SAM supplementation did not alter 
protein expression. Gene expression of the in vitro methylated plasmids was 
suppressed in both ME15 and D10 cell lines to comparable levels suggesting 
functional DNMT1 activity in both cell lines. As expected IFNα induced IFITM3 and 
IFI6 luciferase activity in a proportional manner though without reaching expression 
levels of methylase-untreated plasmids. These findings rule out a direct malfunction 
of DNMT1 in D10 cells and the methylation defect found in figure 15 most likely is 
more complex than we initially thought and might also include other pathways. 
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Figure 15 
Figure 15. In vitro methylated IFITM3 luciferase reporter plasmids do not exhibit any 
difference in activity in ME15 versus D10 cells. ME15 and D10 cells were transfected with either an 
IFITM3 luciferase reporter plasmid or an IFI6 luciferase reporter plasmid. Plasmids were in vitro 
methylated before transfection and luciferase activity was compared to non-methylated plasmids with 
or without SAM supplementation in the media. To induce luciferase activity cells were treated with 
IFNα for 6 hours. 
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3.7. ME15 and D10 Cells Exhibit Chromosome Aberrations 
To approach the question of a potential methylation machinery defect in D10 
cells from another direction we decided to find out whether methylation patterns as 
well as IFITM3 expression control in D10 cells can be rescued by ME15 cells. For 
this reason we created tetraploid cells by fusion of ME15 and D10 cells. In order to 
assure tetraploidity we stably transfected both cell lines with their own antibiotic 
resistance gene and selected the tetraploid cell line MDbla (for ME15 resistant to 
puromycin and D10 resistant to blastomycin) under antibiotic pressure.  
We first investigated IFITM3 expression both in control as well as IFNα-treated 
MDbla cells and included the D10S100A2 cells as an internal standard. The MDbla cells 
exhibited deregulated IFITM3 expression indicating that the ME15 cell line was not 
able to rescue the D10 cell line regarding its IFITM3 gene expression control (figure 
16A). Note though that in this newly generated cell line IFITM3 is not visibly inducible 
by IFNα. In order to verify the tetraploid nature of MDbla we measured the DNA 
content of all three cell lines, ME15, D10 as well as MDbla by FACS. Unfortunately 
we realized that MDbla cells did not exhibit the complete tetraploid feature we 
expected (figure 16B). DNA content is markedly higher but did not double in the 
course of ME15 and D10 fusion (figure 16B, red lines indicate relative DNA content). 
In order to verify these findings we decided to investigate the chromosomal content 
of all three cell lines and performed karyotyping which revealed chromosomal 
aberrations (figure 16C). Figure 16C shows chromosomes of one individual cell per 
cell line and it is very clear that chromosomes exhibit massive aberrations. This hold 
true for all 15 individual cells that were analysed. None of them is comparable to the 
other with chromosomal distribution being absolutely arbitrary. 
In conclusion, ME15 and D10 cells exhibit massive chromosomal aberrations 
and one could suppose epigenetic malfunctions which are known to be associated 
with chromosomal instability (Ehrlich 2003). Unfortunately tetraploidity was not 
achieved in the MDbla cell lines probably due to the original DNA content of ME15 
and D10 cells. Nevertheless, DNA content was enhanced in MDbla cells and they 
furthermore exhibit complete IFNα insensitivity. 
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Figure 16 
Figure 16. ME15, D10 and the tetraploid cell line MDbla, which is a fusion of ME15 and D10 
cells, exhibit massive chromosomal aberrations. MDbla cells were stimulated with IFNα (1000 U/ml) 
for 8h and immunoblots against IFITM3 were performed from total cell extracts. D10S100A2 were 
included as a positive control (A). ME15, D10 and MDbla cells were labeled with propidium iodide and 
DNA content was measured using a standard FACS assay (B). Red lines indicate the G1 and S phase 
in ME15 and D10 cells and also the S phase in MDbla. MDbla cells are clearly not tetraploid. In order 
to verify the DNA content of MDbla cells, cells underwent karyotyping (C). Here one cell per cell line is 
depicted demonstrating massive chromosome aberration. 
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3.8. DNA Wide Methylation State 
To this point it is still unclear how the methylation machinery in D10 cells is 
impaired. The chromosomal aberrations in ME15 and D10 cells may point to 
impaired methylation in both cell lines (figure 16) as chromosomal aberrations can 
result from defects in the DNA methylation machinery; a point mutation in DNMT3b 
has been shown to be involved in ICF disease (Xu, Bestor et al. 1999), RTT 
syndrome that is known to be caused by dysfunctional MeCP2 protein exhibits 
deregulation of nuclear architecture (Matarazzo, De Bonis et al. 2009). Additionally 
genetic instability has been associated with aberrant DNA methylation in liver 
cirrhosis (Kondo, Kanai et al. 2000). This led us to wonder whether ME15 and D10 
cells exhibit genome wide DNA methylation differences. Furthermore, if D10 cells 
have a defect in the DNA methyltransferase this would also lead to genome-wide 
demethylation. We therefore investigated CpG methylation genome-wide using 
Illumina microarrays. In order to monitor a possible demethylating effect of IFNα 
ME15 cells incubated with IFNα for one hour were included in this study. 
 
Figure 17 
Figure 17. The Infinium assay for methylation. Weisenberger, D. J., D. V. D. Berg, et al. 
(2008). "Comprehensive DNA Methylation Analysis on the Illumina® Infinium® Assay 
Platform." Illumina. (Weisenberger, Berg et al. 2008) 
 
The Illumina methylation assay includes 14 495 genes with 27 578 CpG sites 
resulting in an average of two CpG sites per promoter, arrayed on the Infinium 
HumanMethylation27 BeadChip (Weisenberger, Berg et al. 2008). The technology 
used to acquire results is illustrated in figure 17. Illumina beads carry either oligos 
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specific for the methylated or demethylated CpG sites and bisulfite-treated DNA 
hybridizes. Bisulfite treatment leads to deamination of cytosines given these sites are 
not protected by a methylgroup. Upon replication of the DNA thymidine is 
incorporated at the deaminated cytosine sites. The resulting ‘point mutation’ can then 
be detected by sequencing. In the Illumina assay the probe is extended with 
fluorescence-labelled nucleotides according to the methylation of the original sample 
DNA. Once fluorescence data is collected by the Ilumina scanner a ratio is then 
calculated between the intensity of the “methylation bead” vs the “un-methylation 
bead” which is called the beta-value. This beta-value lies between zero and one, and 
a value below 0.2 indicates a demethylated site whereas values above 0.8 indicate 
complete methylation for the according CpG site. 
In our study beta-values were acquired using Illumina’s internal Beadstudio 
software. Beta-values of ME15 and D10 cells were compared with each other and no 
major differences in methylation can be observed between the two cell lines, or 
between the untreated and IFNα-stimulated ME15 cells (figure 18 and 19). This 
result excludes a direct defect of the methylation machinery such as DNMTs in D10 
cells, and ultimately supports the earlier findings in this work. If anything, the 
distribution of beta-values over all investigated CpG sites demonstrates that ME15 
cells exhibit a slightly higher percentage of demethylated CpGs (figure 18). In order 
to compare single CpG sites with each other the according beta-values established in 
ME15 and D10 cells were subtracted resulting in a beta-value-difference. Of all the 
almost 28 000 measured CpG sites only a fraction exhibits a beta-value-difference of 
at least 0.6). In tables 5 and 6 genes exhibiting the absolute beta-value-difference of 
more than 0.6 are listed. D10 cells exhibit a generally higher level of methylated 
CpGs in more genes than ME15 cells (159 in D10 cells and 32 in ME15 cells). 
Interestingly, D10 cells have 1736 CpG sites that exhibit a higher methylation level 
(beta-value-difference of at least 0.2) than the corresponding ME15 sites, whereas 
ME15 cells have only 844 CpG sites that are more highly methylated than the 
equivalent sites in D10 cells (figure 19). This general impression is consistent with 
the data shown in figure 18. As ME15 cells treated with IFNα showed no difference in 
their methylation pattern we conclude that one hour of IFNα stimulation does not alter 
methylation patterns in ME15 cells (data not shown). It remains unclear why D10 
cells exhibit a slightly higher overall CpG methylation than ME15 cells. 
For the IFITM3 gene there is one CpG site measured in this assay and the 
beta-value is at approximately 0.9 in ME15 and 0.6 in D10 cells (figure 21B). 
Therefore the beta-value-difference in this CpG site is rather minimal and it is difficult 
to postulate demethylation of the IFITM3 promoter in D10 cells from this one single 
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CpG site only. Again ME15 cells treated with IFNα contain the same methylation 
level for the IFITM3 CpG site and IFNα most likely does not modulate methylation 
levels after one hour of incubation. 
In conclusion, the hypothesis of a genome-wide difference in DNA methylation 
was not supported with this finding. However, there are DNA methylation differences 
in some CpG sites, one of which is in the IFITM3 promoter. Since only one to two 
CpG sites were investigated per promoter, e.g. gene, the possibility of major 
differences in the DNA methylation patterns is not excluded. It is therefore necessary 
to investigate DNA methylation in more detail. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18 
Figure 18. Genome-wide DNA methylation screening reveals only a slight difference in 
methylation of ME15 and D10 cells. Bisulfite-treated genomic DNA from ME15 and D10 cells was 
processed and hybridizised to the Illumina Infinium HumanMethylation27 BeadChip. Single 
methylation sites were analyzed and the internal Illumina software calculated the ratio of methylated 
versus non-methylated CpG sites to yield beta-values between 0.0 and 1.0. Beta-values between 0.0 
and 0.2 are considered demethylated whereas beta-values above 0.8 indicate complete methylation. 
Frequency of methylation occurrence is shown on the left. Genome-wide beta-values from a total of > 
27000 CpGs of ME15 (blue) and D10 (red) are plotted against each other. In general, beta-value 
distribution is comparable between the two cell lines, with ME15 showing a higher number of 
unmethylated genes than D10. ME15 vs IFNα treated ME15 are not displayed since there is no 
difference in methylation. 
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Table 5. Illumina Chip methylation status with beta-values ME15 > D10  
 
SYMBOL ME15  D10  ANNOTATION Difference 
 
PSAT1 0.957 0.045 phosphoserine aminotransferase 1 0.912 
CNIH3 0.944 0.136 cornichon homolog 3 0.808 
CAV1 0.935 0.145 caveolin 1, caveolae protein, 22kDa 0.790 
MKRN3 0.871 0.097 makorin ring finger protein 3 0.774 
SERHL 0.959 0.186 serine hydrolase-like 0.773 
CHST3 0.926 0.155 carbohydrate (chondroitin 6) sulfotransferase 3 0.770 
AQP3 0.864 0.102 aquaporin 3 0.762 
CAV1 0.875 0.120 caveolin 1, caveolae protein, 22kDa 0.755 
IGFBP7 0.916 0.172 insulin-like growth factor binding protein 7 0.744 
HIST1H1B 0.844 0.103 histone cluster 1, H1b 0.741 
MLH3 0.872 0.144 mutL homolog 3 (E. coli)  0.729 
HMG20B 0.914 0.187 
high-mobility group 20B, BRCA2-associated factor 
35 0.727 
GOLPH2 0.900 0.177 golgi membrane protein 1 0.724 
ACSS3  0.851 0.129 acyl-CoA synthetase short-chain family member 3 0.722 
RCSD1 0.820 0.098 RCSD domain containing 1 0.722 
FAM13C1 0.873 0.153 family with sequence similarity 13, member C 0.720 
ID4 0.811 0.095 
inhibitor of DNA binding 4, dominant negative helix-
loop-helix protein 0.716 
TEKT2 0.834 0.121 tektin 2 0.714 
CCDC65 0.878 0.167 coiled-coil domain containing 65   0.711 
FRZB 0.891 0.181 frizzled-related protein  0.709 
PAK3 0.874 0.165 P21 protein (Cdc42/Rac)-activated kinase 3 0.709 
CSRP1 0.774 0.069 cysteine and glycine-rich protein 1 0.705 
MLH3 0.837 0.146 mismatch repair gene MLH3 0.692 
GFOD1 0.850 0.162 
glucose-fructose oxidoreductase domain containing 
1 0.688 
CCR10 0.813 0.132 chemokine (C-C motif) receptor 10 0.681 
SULF2 0.880 0.201 sulfatase 2 0.679 
ACAA1 0.848 0.170 acetyl-Coenzyme A acyltransferase 1 0.679 
C1QTNF6 0.764 0.099 C1q and tumor necrosis factor related protein 6 0.665 
FRZB 0.842 0.186 frizzled-related protein 0.656 
PAX3 0.887 0.235 paired box 3 0.652 
PGK1 0.745 0.095 phosphoglycerate kinase 1 0.650 
THBS2 0.814 0.164 thrombospondin 2 0.650 
RBBP7 0.808 0.162 retinoblastoma binding protein 7 0.646 
C9orf142 0.911 0.266  0.645 
FXYD5 0.801 0.157 FXYD domain containing ion transport regulator 5  0.644 
CAV1 0.782 0.144 caveolin 1, caveolae protein, 22kDa 0.638 
DLG1 0.762 0.135 discs, large homolog 1 (Drosophila)  0.626 
PSAT1 0.829 0.205 phosphoserine aminotransferase 1 0.624 
DDB2 0.796 0.176 damage-specific DNA binding protein 2, 48kDa 0.619 
FAM13C1 0.752 0.133 family with sequence similarity 13, member C 0.619 
SYNPO2 0.828 0.209 synaptopodin 2 0.619 
CNDP1 0.761 0.144 
carnosine dipeptidase 1 (metallopeptidase M20 
family) 0.618 
ZAR1 0.807 0.194 zygote arrest 1 0.613 
CUZD1 0.776 0.164 CUB and zona pellucida-like domains 1 0.612 
TINAGL1 0.771 0.166 tubulointerstitial nephritis antigen-like 1 0.605 
SULF2 0.923 0.321 sulfatase 2 0.602 
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Table 6. Illumina Chip methylation status with beta-values D10 > ME15 
 
SYMBOL ME15  D10  ANNOTATION Difference 
 
CRABP1 0.231 0.831 cellular retinoic acid binding protein 1 -0.601 
SYCE1 0.337 0.938 synaptonemal complex central element protein 1 -0.601 
INA 0.275 0.875 
internexin neuronal intermediate filament protein, 
alpha -0.601 
LIN7B 0.164 0.765 lin-7 homolog B (C. elegans) -0.601 
TP53INP1 0.074 0.675 tumor protein p53 inducible nuclear protein 1 -0.601 
CTSZ 0.272 0.874 cathepsin Z -0.602 
HIST1H4F 0.171 0.774 histone cluster 1, H4f -0.602 
OXCT1 0.253 0.858 3-oxoacid CoA transferase 1 -0.605 
DPM1 0.091 0.697 
dolichyl-phosphate mannosyltransferase 
polypeptide 1, catalytic subunit -0.606 
DPM1 0.170 0.777 
dolichyl-phosphate mannosyltransferase 
polypeptide 1, catalytic subunit -0.607 
LDOC1 0.098 0.705 leucine zipper, down-regulated in cancer 1 -0.607 
RBM17 0.148 0.758 RNA binding motif protein 17 -0.610 
OXCT1 0.187 0.800 3-oxoacid CoA transferase 1 -0.613 
KIT 0.324 0.938 
v-kit Hardy-Zuckerman 4 feline sarcoma viral 
oncogene homolog -0.614 
GRIA1 0.233 0.847 glutamate receptor, ionotropic, AMPA 1 -0.614 
TMEM163 0.312 0.927 transmembrane protein 163 -0.614 
RCN3 0.141 0.756 reticulocalbin 3, EF-hand calcium binding domain -0.615 
CKAP4 0.083 0.698 cytoskeleton-associated protein 4 -0.616 
CYYR1 0.147 0.764 cysteine/tyrosine-rich 1 -0.617 
GRM6 0.098 0.716 glutamate receptor, metabotropic 6 -0.617 
LTF 0.070 0.689 Lactotransferrin -0.619 
LOXL3 0.131 0.752 lysyl oxidase homolog 3 -0.620 
ZNF198 0.189 0.809 zinc finger, MYM-type 2 -0.621 
CTSZ 0.170 0.792 cathepsin Z -0.622 
NFATC1 0.135 0.759 
nuclear factor of activated T-cells, cytoplasmic, 
calcineurin-dependent 1 -0.623 
VSX2 0.199 0.823 visual system homeobox 2 -0.623 
CRABP1 0.220 0.844 cellular retinoic acid-binding protein 1 -0.624 
COLEC12 0.221 0.846 collectin sub-family member 12 -0.624 
CLDN3 0.221 0.846 claudin 3 -0.624 
MEG3 0.284 0.910 maternally expressed 3 (non-protein coding) -0.626 
ELAVL3 0.071 0.699 
ELAV (embryonic lethal, abnormal vision, 
Drosophila)-like 3 (Hu antigen C) -0.628 
LASS6 0.087 0.716 LAG1 homolog, ceramide synthase 6  -0.628 
ESX1 0.165 0.793 ESX homeobox 1 -0.629 
ESRRB 0.131 0.761 estrogen-related receptor beta -0.630 
KLF11 0.197 0.827 TGFB inducible early growth response 2 -0.631 
ASCL2 0.184 0.819 achaete-scute complex homolog 2 (Drosophila) -0.634 
FAM150A 0.224 0.860 family with sequence similarity 150, member A -0.636 
PHOX2A 0.154 0.790 paired-like homeobox 2a -0.637 
WSB2 0.289 0.927 WD repeat and SOCS box-containing 2 -0.637 
S100A1 0.109 0.748 calcium-binding protein A1 -0.639 
RUSC2 0.194 0.833 RUN and SH3 domain containing 2 -0.639 
CD8A 0.252 0.891 CD8a molecule, Leu2 -0.639 
SLC35C1 0.213 0.854 GDP-fucose transporter 1 -0.641 
PCDHAC2 0.090 0.732 protocadherin alpha subfamily C, 2 -0.642 
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GPX3 0.130 0.772 glutathione peroxidase 3 (plasma) -0.643 
CKAP4 0.166 0.809 cytoskeleton-associated protein 4 -0.643 
CTSZ 0.268 0.912 cathepsin Z -0.644 
ALDH1A3 0.245 0.893 aldehyde dehydrogenase 1 family, member A3 -0.648 
KIAA0323 0.135 0.785  -0.651 
PSTPIP2 0.283 0.935 
proline-serine-threonine phosphatase interacting 
protein 2 -0.652 
HPDL 0.077 0.729 4-hydroxyphenylpyruvate dioxygenase-like -0.652 
PNMA6A 0.200 0.853 paraneoplastic antigen like 6A -0.653 
ABHD8 0.219 0.874 abhydrolase domain containing 8 -0.655 
CCDC59 0.073 0.728 coiled-coil domain containing 59 -0.655 
SUOX 0.194 0.850 sulfite oxidase -0.655 
DEFA5 0.156 0.812 defensin, alpha 5, Paneth cell-specific -0.656 
IMP4 0.122 0.779 
IMP4, U3 small nucleolar ribonucleoprotein, 
homolog (yeast) -0.656 
SEC31L2 0.224 0.881 SEC31-like 2 (S. cerevisiae) -0.657 
ISG20 0.076 0.734 interferon stimulated gene (20kD) -0.657 
PAQR5 0.102 0.760 progestin and adipoQ receptor family member V -0.658 
HIST1H2BI 0.145 0.805 histone cluster 1, H2bi -0.660 
FAIM 0.092 0.752 Fas apoptotic inhibitory molecule -0.661 
RIBC2 0.193 0.857 43A domain with coiled-coils 2 -0.663 
CGREF1 0.167 0.831 cell growth regulator with EF-hand domain 1 -0.664 
PHLDA3 0.100 0.764 
pleckstrin homology-like domain, family A, member 
3 -0.664 
LIPG 0.189 0.853 lipase, endothelial  -0.665 
GADD45G 0.158 0.824 growth arrest and DNA-damage-inducible, gamma -0.666 
ECE1 0.035 0.704 endothelin converting enzyme 1 -0.669 
HIST1H4L 0.173 0.842 histone cluster 1, H4l -0.669 
EFCBP2 0.169 0.839 EF-hand calcium binding protein 2 -0.670 
GDF2 0.179 0.849 growth differentiation factor 2 -0.670 
C10orf107 0.161 0.831  -0.670 
FBXO39 0.135 0.807 F-box protein 39 -0.673 
THSD3 0.096 0.771 isthmin 2 homolog (zebrafish) -0.675 
KLF14 0.146 0.822 Kruppel-like factor 14 -0.676 
SOX11 0.128 0.805 SRY (sex determining region Y)-box 11 -0.676 
PTPN20B 0.124 0.801 
protein tyrosine phosphatase, non-receptor type 
20B -0.677 
SORBS3 0.108 0.787 sorbin and SH3 domain containing 3 -0.679 
SOX8 0.201 0.882 SRY (sex determining region Y)-box 8 -0.680 
MAGI2 0.103 0.785 
membrane associated guanylate kinase, WW and 
PDZ domain containing 2 -0.682 
HIST1H4F 0.152 0.834 histone cluster 1, H4f -0.683 
SOX11 0.207 0.891 SRY (sex determining region Y)-box 11 -0.684 
SLC26A11 0.103 0.787 solute carrier family 26, member 11  -0.684 
USP51 0.091 0.777 ubiquitin specific peptidase 51 -0.686 
NPR3 0.145 0.832 natriuretic peptide receptor C/guanylate cyclase C -0.687 
LZTS1 0.169 0.857 leucine zipper, putative tumor suppressor 1 -0.688 
NTSR1 0.226 0.917 neurotensin receptor 1 (high affinity) -0.691 
PXDN 0.157 0.849 peroxidasin homolog (Drosophila) -0.691 
RAC3 0.244 0.937 rho family; small GTP binding protein Rac3 -0.692 
ABTB1 0.168 0.861 ankyrin repeat and BTB (POZ) domain containing 1 -0.693 
VILL 0.104 0.797 villin-like -0.693 
GLB1L2 0.191 0.885 galactosidase, beta 1-like 2 -0.693 
LSR 0.093 0.787 lipolysis stimulated lipoprotein receptor -0.695 
OTOP3 0.164 0.859 otopetrin 3 -0.695 
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LZTS1 0.186 0.882 leucine zipper, putative tumor suppressor 1 -0.695 
TCF12 0.193 0.890 transcription factor 12  -0.697 
STXBP6 0.137 0.834 syntaxin binding protein 6 (amisyn)  -0.697 
ADAMTS14 0.152 0.852 
ADAM metallopeptidase with thrombospondin type 
1 motif, 14 -0.700 
MGAT1 0.141 0.844 
N-glycosyl-oligosaccharide-glycoprotein N-
acetylglucosaminyltransferase -0.703 
HMGA2 0.128 0.831 high mobility group AT-hook 2  -0.703 
TLX3 0.177 0.881 T-cell leukemia homeobox 3 -0.704 
RAB33A 0.180 0.885 Small GTP-binding protein S10 -0.704 
GABRQ 0.159 0.865 GABA-A receptor theta subunit -0.707 
TFAP2E 0.183 0.891 transcription factor AP-2 epsilon -0.707 
TCERG1L 0.089 0.797 transcription elongation regulator 1-like   -0.708 
GLRA3 0.097 0.805 Glycine receptor, alpha-3 -0.708 
CYB561 0.184 0.893 cytochrome b-561 -0.709 
NINL  0.068 0.778 ninein-like  -0.710 
H1F0 0.140 0.851 H1 histone family, member 0 -0.711 
FOXF1 0.096 0.808 forkhead-related activator 1 -0.711 
PROK2 0.127 0.842 prokineticin 2   -0.716 
SNX22 0.087 0.803 sorting nexin 22 -0.716 
SYN2 0.184 0.901 synapsin II -0.717 
ADCYAP1 0.113 0.833 adenylate cyclase activating polypeptide 1 -0.721 
SLC44A3 0.142 0.863 solute carrier family; member 3;  -0.721 
PPM1M 0.147 0.869 protein phosphatase 1M (PP2C domain containing) -0.723 
SPPL2B 0.124 0.847 signal peptide peptidase-like 2B -0.724 
CRABP1 0.160 0.885 cellular retinoic acid-binding protein 1 -0.725 
ALDH1A3 0.129 0.857 aldehyde dehydrogenase 6 -0.727 
SEPT10 0.166 0.894 Septin 10 -0.728 
BTBD6 0.102 0.831 
lens BTB; glucocorticoid receptor AF-1 coactivator-
1 -0.729 
CELSR3 0.131 0.864 cadherin, EGF LAG seven-pass G-type receptor 3 -0.734 
TRHDE 0.100 0.835 thyrotropin-releasing hormone degrading enzyme -0.735 
HIST1H2AJ 0.097 0.833 histone cluster 1, H2aj -0.737 
GLUL 0.180 0.918 glutamate-ammonia ligase (glutamine synthase) -0.738 
MEG3 0.121 0.859 maternally expressed 3 (non-protein coding)  -0.738 
ELF4 0.173 0.912 E74-like factor 4 (ets domain transcription factor) -0.739 
MYOD1 0.160 0.902 myoblast determination protein 1 -0.742 
HPDL  0.077 0.820 4-hydroxyphenylpyruvate dioxygenase-like -0.743 
IRXL1 0.100 0.848 mohawk homeobox -0.749 
WNK4 0.132 0.883 protein kinase; lysine deficient 4 -0.751 
HIST1H3G 0.112 0.863 histone cluster 1, H3g  -0.751 
ZNF342 0.122 0.876 zinc finger protein 296 -0.754 
ZC3HAV1L 0.062 0.819 zinc finger CCCH-type, antiviral 1-like   -0.757 
ARHGAP4 0.155 0.914 Rho-GAP hematopoietic protein C1 -0.760 
ESX1 0.142 0.904 ESX homeobox 1  -0.762 
CLDN1 0.133 0.897 
senescence-associated epithelial membrane 
protein 1 -0.764 
SOX8 0.148 0.912 SRY (sex determining region Y)-box 8 -0.764 
AQP11 0.165 0.930 aquaporin 11 -0.765 
GSTP1 0.069 0.838 
deafness; X-linked 7; fatty acid ethyl ester synthase 
III;  -0.769 
RHBDD1 0.075 0.844 rhomboid domain containing 1 -0.769 
SLC5A7 0.119 0.889 
solute carrier family 5 (choline transporter), 
member 7 -0.770 
ADCY8 0.148 0.919 Adenylyl cyclase 8; brain -0.771 
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ERBB2IP 0.102 0.873 erbb2 interacting protein -0.771 
PRKCZ 0.130 0.907 protein kinase C, zeta -0.777 
RAB33A 0.128 0.910 RAB33A, member RAS oncogene family -0.782 
NAV1 0.104 0.898 neuron navigator 1 -0.794 
SPESP1 0.038 0.833 sperm equatorial segment protein 1 -0.794 
RPRM 0.087 0.883 
reprimo, TP53 dependent G2 arrest mediator 
candidate -0.796 
ZNF342 0.075 0.873 zinc finger protein 296 -0.798 
ISL2 0.063 0.863 Insulin gene enhancer protein ISL-2 -0.800 
DMRT1 0.072 0.880 DM domain expressed in testis 1 -0.808 
GABRE 0.094 0.903 GABA(A) receptor -0.809 
TP53INP1 0.102 0.912 p53-inducible p53DINP1 -0.809 
CTSZ 0.064 0.875 cathepsin X precursor; preprocathepsin P -0.811 
TLX3 0.120 0.934 homeo box 11-like 2 -0.814 
TSC22D1 0.091 0.918 
transforming growth factor beta-stimulated protein 
TSC-22 -0.827 
FAS 0.060 0.887 
tumor necrosis factor receptor superfamily; member 
6 -0.827 
ENAH 0.057 0.888 isoform b is encoded by transcript variant 2 -0.831 
ALDH1A3 0.066 0.905 aldehyde dehydrogenase 6 -0.839 
MAGI2 0.046 0.894 activin receptor interacting protein 1  -0.848 
MTMR15 0.035 0.959 myotubularin related protein 15 -0.924 
 
 
 
 
 
 
 
 
Figure 19 
Figure 19. Genome-wide DNA methylation screening reveals only a slight difference in 
methylation of ME15 and D10 cells. Bisulfite-treated genomic DNA from ME15 and D10 cells was 
processed and hybridizised to the Illumina Infinium HumanMethylation27 BeadChip. Single 
methylation sites were analyzed and the internal Illumina software calculated the ratio of methylated 
versus non-methylated CpG sites to yield beta-values between 0.0 and 1.0. Beta-value-differences 
were achieved by subtraction of individual beta-values of ME15 and D10 cells. Absolute beta-value-
differences [ME15-D10] below 0.2 were plotted against absolute beta-value-differences higher than 
0.2. There are 1736 CpG sites with a higher methylation level in D10 cells and 844 CpG sites with a 
higher methylation level in ME15 cells. 
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3.9. Methylation State of the IFITM3 Core Promoter in ME15 
and D10 Cells. 
We have shown above (figure 11, panel B) that recombinant expression of the 
small calcium binding protein S100A2 enhances IFNα-dependent induction of IFITM3 
and S100A2 expression. DNA methylation control of S100A2 core promoter activity 
has been described (Lee, Tomasetto et al. 1992) and we show in figure 13, panel B, 
that presence of S100A2 upregulates IFITM3 protein expression to levels 
comparable to those in DAC-treated ME15 cells. IFITM3 expression levels in D10 
cells are neither affected by DAC treatment nor S100A2 over-expression. 
Nevertheless, the dynamics of IFITM3 expression levels are altered in both ME15 
and D10 cells expressing S100A2 compared with the wild type cell lines, 
independent of DAC treatment. These findings suggest a mechanism in which 
S100A2-dependent demethylation of the IFITM3 core promoter enhances IFNα 
responsiveness in ME15 cells and if correct, the model implies that the IFITM3 
promoter in D10 is hypomethylated and therefore constitutively active and not 
responsive to DAC treatment. As genome-wide DNA methylation analysis using the 
Illumnia Infinium HumanMethylation27 BeadChip only investigates two CpG sites per 
gene, we decided to study the IFITM3 promoter region in more details, by bisulfite 
sequencing of a stretch of approximately 500 bp. 
We treated ME15 and D10 cells for 1, 6 and 24 hours with 1000 U/ml IFNα 
before detection of methylated CpG sites by bisulfite sequencing (Frommer, 
McDonald et al. 1992). To supply S100A2 we either co-stimulated the cells with 
TGFβ or we used stable S100A2 transfectants of ME15 or D10 cells. Genomic DNA 
was isolated from cell cultures, treated with sodium bisulfite and the IFITM3 core 
promoter was amplified by PCR. The amplicons from each of the 32 experimental 
conditions were subcloned into E. coli, screened by blue/white colony selection and 
sequenced using an automated capillary sequencer. We then determined the 
percentage of methylated versus unmethylated C-residues across 19 CpG sites of 
the IFITM3 core promoter (figure 20). In ME15, ME15S100A2 and D10 cells the 
methylation pattern of control cells (not treated with IFNα) is virtually identical 
regardless of TGFβ treatment or S100A2 expression (figure 20; ‘co’ panels). In 
D10S100A2 CpG sites #492, #434, #425, #366 and #360 are partially demethylated in 
the presence of TGFβ. This early demethylation pattern is consistent with the 
dynamics seen in figure 20B, right blot, but is most likely S100A2 independent and 
caused by other TGFβ inducible pathways (figure 20; lower panel). Consistent with 
our hypothesis, the overall CpG methylation is notably lower in D10 and D10S100A2 
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than in ME15 and ME15S100A2 and entirely insensitive to IFNα treatment. In particular, 
the CpG sites directly upstream of the ATG translational start in D10 cells, including 
sites around the interferon-stimulated regulatory elements (ISRE), are non- or 
hypomethylated. In summary, the methylation status of the IFITM3 core promoter in 
D10 cells is largely IFNα treatment independent, although some CpG sites near the 
5’ end (#512, #492, #434) show IFNα-dependent demethylation. 
In ME15 cells dynamic changes in the methylation pattern occur 6 hours after 
IFNα treatment (figure 20; upper panels). Consistent with our hypothesis, hypo- or 
demethylation is strictly S100A2 dependent regardless of the supply route. In TGFβ-
pretreated ME15 cells demethylation occurs across the entire array of CpG sites 6 
hours after IFNα treatment, which coincides with the onset of IFITM3 protein 
expression. In the ME15S100A2 cells a similar CpG demethylation pattern appears 6h 
after IFNα stimulation in the absence of TGFβ co-stimulation. Thus, supply of 
transgenic S100A2 protein is sufficient to catalyze hypomethylation and this result 
further shows that S100A2 is the sole response protein of the TGFβ signaling 
pathway required for IFNα-inducible IFITM3 core promoter demethylation. 24 hours 
after IFNα incubation, the methylation pattern in ME15 and ME15S100A2 cells reverts 
to untreated control levels, which coincides with the decay of IFITM3 protein 
expression (figure 20, panel B). Note that the ME15 promoter CpG sites #427 and 
#24 are demethylated under all conditions and time points although they are directly 
adjacent to the methylation modulated CpG sites #225 and #21, respectively. In 
summary, the data above show for the first time that in the presence of the 
expressed small calcium protein S100A2, IFNα induces a dynamic and reversible 
modulation of CpG methylation in the core promoter of its target gene IFITM3. 
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Figure 20. A. S100A2 modulates promoter methylation of the IFNα-inducible gene IFITM3. A 
820bp region of the IFITM3 promoter was amplified from bisulfite-treated genomic DNA. PCR 
fragments were subcloned and sequenced, and individual sequences were analyzed for CpG vs TgG 
sites. The number of sequences analyzed for each condition is indicated on the right hand side of the 
figure. Black boxes indicate 90 - 100% methylation and white boxes indicate 0 - 10% methylation at 
the specific CpG site across all sequences analyzed. CpG locations are illustrated at the top of the 
figure; numbers indicate the distance from the translation initiation site. One ISRE element stretches 
over the CpG site #77 and a sp1 site is located at CpG site #107. ME15, ME15 S100A2 (stably over-
expressing S100A2), D10 and D10S100A2 cells were treated with IFNα (1000 U/ml) for 1, 6 and 24 
hours, as well as TGFβ (2 ng/ml) for 48h, or with a combination of both cytokines. Note the 
demethylation over the whole sequence at the 6h IFNα treatment in ME15 S100A2 as well as in TGFβ 
stimulated ME15, indicated by two stars. (B) Methylation pattern in two samples from colon cancer 
patients (48 being classified as CIMP positive, and 68 as CIMP negative) versus healthy mucosa 
(‘control 48’ and ‘control 68’). 
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3.10. Methylation State of the IFITM3 Core Promoter in Human 
Colon Tumor Tissue 
We have seen that the IFITM3 core promoter exhibits differences in 
methylation in ME15 and D10 cells. To investigate clinical relevance of this 
observance we included colon tumor samples classified as either ‘CpG island 
methylator phenotype’ (CIMP) positive or CIMP negative (figure 21B; #68 = CIMP 
positive, #48 = CIMP negative). Cancerous cells are known to be hypermethylated 
and this property was assayed as a possible marker for tumors. Interestingly, colon 
cancer tissues exhibit two different phenotypes: a hyper- and a hypomethylation of 
target CpG islands which led to the CIMP description in 1999 (reviewed in 
(Teodoridis, Hardie et al. 2008)). The CIMP classification today is a helpful tool in 
defining cancer therapies for patients and a CIMP positive diagnosis counts for a 
worse prognosis. 
Overall, the IFITM3 promoter is not methylated in the CIMP positive samples 
and 50% methylated in the CIMP negative samples (figure 21B). This is seen both in 
the Illumina Infinium HumanMethylation27 BeadChip array as well as in the bisulfite 
sequencing analysis (figure 21A and B). The IFITM3 CpG site in the CIMP positive 
patient samples is completely demethylated in contrast to its control. The CIMP 
negative samples show no difference for this CpG site in the control or the tumor 
samples. 
We state that our assays both the Illumina Infinium HumanMethylation27 
BeadChip array and the bisulfite sequencing are consistent with each other. The 
Illumnia Infinium HumanMethylation27 BeadChip assay elucidates a general 
genome-wide DNA methylation overview and bisulfite sequencing yields a higher 
resolution. Therefore, when a specific promoter region is of interest, bisulfite 
sequencing produces insight into the DNA methylation pattern providing thorough 
and significant results. 
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Figure 21 
Figure 21. Illumina and bisulfite asssays are consistent. Illumina’s beta-values of the IFITM3 
were closely investigated in ME15 and D10 cells. Colon cancer CIMP positive and CIMP negative 
tumor samples were included in this comparison. CpG position #134 corresponds to the CpG site 
investigated in the Illumina chip array. ME15 control cells as well as IFNα stimulated ME15 cells 
display total methylation for the site #134 in the Illumina chip array as well as in the bisulfite 
sequencing assay. This holds true for the partly methylated position #134 in D10 and the CIMP 
negative tumor samples also. The CIMP positive tumor sample exhibits complete demethylation and 
again this is seen in both technical arrays. 
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3.11. P53 Is Non- Responsive In D10 Cells 
We have demonstrated that S100A2 indirectly (figure 12) modulates 
transcriptional response to IFNα in ME15 cells (figure 11). Even though restoration of 
IFNα sensitivity is independent of gene expression in D10 cells (figure 11B bottom 
panel) this effect still relies on S100A2 expression. We suspected an epigenetic 
mechanism being involved in IFNα signaling and thus decided to investigate the 
methylation patterns of both cell lines which lead to the finding that D10 cells exhibit 
insensitivity to the demethylating chemical DAC (figure 13), and bisulfite sequencing 
showed that the IFITM3 promoter is demethylated in D10 cells (figure 20). 
Investigations as to the degree of a possible DNMT1 failure in D10 cells revealed no 
obvious defect in its activity thus proposing an alternative pathway aberration (figures 
14 and 15). Interestingly, DNMT1 is known be under p53 control in that inactivated 
p53 binds to the DNMT1 promoter resulting in DNMT1 gene repression (Peterson, 
Bogler et al. 2003). Activated p53 binds to the S100A2 promoter provided the 
promoter is not hypermethylated to induce transcription (Tan, Heizmann et al. 1999) 
and the S100A2 protein binds p53 in a calcium dependant manner therefore 
enhancing p53 transcriptional activity (Mueller, Schafer et al. 2005). Since p53 is a 
known protein in cancer development and it is subject to methylation, we decided to 
investigate p53 signaling in ME15 and D10 cells using a p53 reporter luciferase 
assay (figure 22). 
We found that ME15 cells respond to known inducers of p53 (figure 22). 
Interestingly both IFNα and TGFβ induce p53 activity in ME15 cells, but co-treatment 
is not able to activate p53 (Fredy Siegrist; personel communication). In contrast in 
D10 cells p53 is not responsive independantly of the compound introduced. This 
result strongly suggests a defect in the p53 signaling pathway in the IFNα resistant 
D10 cells. 
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Figure 22 
Figure 22. P53 is not functional in the IFNα resistant cell line D10. Cells transfected with a 
p53 luciferase reporter plasmid were treated with DMSO, DAC, 5-FU and LPS as positive control. 
Untreated cells were included as reference. In ME15 cells all p53 activators induce significant 
upregulation of luciferase activity. D10 cells do not respond to stimulation suggesting a p53 signaling 
defect. Mean values were calculated from quadruplicates and standard deviations are indicated with 
error bars. 
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3.12. P21 Is Induced in D10 Cells upon TGF-beta Stimulation 
We showed that p53 signaling is defective in D10 cells and we decided to 
investigate p21 (CDKN1A). Etoposide-induced p53 is known to induce S100A2 as 
well as p21 (Wang, Rea et al. 1999). P21 is induced upon DNA damage, and 
translocates to DNA damage breaks where it is involved in DNA repair (Cazzalini, 
Scovassi et al. 2010). It is proposed that p21 protein levels are degraded when DNA 
damage is massive (Cazzalini, Scovassi et al. 2010). Foser et al showed that 
S100A2 is upregulated in ME15 and D10 cells by TGFβ treatment (Foser, Redwanz 
et al. 2006) and co-stimulation of cells with IFNα and TGFβ may impose apoptotic 
settings. 
We stimulated ME15 and D10 cells with IFNα, TGFβ and a combination of both 
for 24h in the presence or absence of DAC. In ME15 cells p21, which is under 
epigenetic control, is constitutively expressed. IFNα or TGFβ stimulation does not 
further upregulate p21 protein expression (figure 23) but DAC treatment seems to 
enhance p21 expression in the presence of IFNα. Co-stimulation with IFNα and 
TGFβ represses p21 completely in ME15 cells which is consistent with the p53 
inactivation observed upon co-stimulation in figure 22 (Fredy Siegrist; personel 
communication). In D10 cells p21 is not visibly expressed but interestingly enough, 
TGFβ induces p21. Consistent with previous data gene expression is DAC 
insensitive in these cells (figure 23). 
 
 
 
 
 
Figure 23 
Figure 23. P21 protein expression in ME15 and D10 cells. Cells were treated with IFNα, TGFβ 
and a combination of both for 24h in the presence or absence of DAC. P21 is not expressed in the 
IFNα resistant cell line D10 but induced upon TGFβ stimulation in a DAC insensitive manner. In ME15 
cells p21 is expressed in control cells and p21 protein levels are not visibly altered by TGFβ 
stimulation. P21 is slightly downregulated in IFNα stimulated cells and markedly enhanced by DAC 
treatment in the presence of IFNα or IFNα and TGFβ co-stimulation. Co-treatment in the absence of 
DAC downregulates p21 protein expression completely. 
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4. DISCUSSION  
We have shown above that cytoplasmic expression of S100A2 enhances the 
expression of a subset of genes in ME15 cells upon IFNα stimulation. Using the 
IFNα-inducible gene IFITM3 as a model we demonstrate by bilsufite sequencing 
dynamic changes in the CpG methylation status of the IFITM3 core promoter in 
ME15 cells, whilst key residues of this promoter in the IFNα resistant cell line D10 
were hypomethylated regardless of IFNα treatment and S100A2 expression.  
The catalytic function of S100A2 and the majority of calcium binding protein 
family members is unknown (Eckert et al., 2004) and to our knowledge this is the first 
report that links S100A2 and cytokine-inducible epigenetic modulation of CpG sites in 
the core promoter of an IFNα target gene. In figure 11B we show that only a subset 
of IFNα-inducible genes is affected by S100A2 over-expression (figure 11B). Known 
IFNα response genes like IFI44L, IFITM3, IFITM5 or OAS are further upregulated in 
ME15S100A2 cells compared to their upregulation in ME15 cells (figure 11B, cluster 3 
and table 2). Such a response could be required to control acute viral infections in 
vivo. On the contrary expression of other classical IFNα response genes such as 
STATs (signal transducers and activators of transcription) or the major 
histocompatibilty complex I are not affected in ME15S100A2 by IFNα treatment (figure 
11B, cluster 2 and table 2) showing specificity of the mechanism mediated by 
S100A2 in ME15 cells.  
We have identified five genes that are unexpectedly rendered IFNα inducible 
in ME15S100A2 cells (figure 11B, cluster 1). Apart from S100A2 itself, the four genes 
apolipoprotein E, β-actin, the reductase/ dehydrogenase DHR2 and the mitogen 
activated kinase kinase 5 (MAP2K5) are clustered together (figure 11B, cluster 1) 
showing that this activating mechanism is not restricted to S100A2. Expression data 
from untreated ME15S100A2 cells were used to calculate the change factors of IFNα-
treated cells, and upregulation relates therefore to activation of the genomic copy 
(chromosome 1q21) of S100A2. It is known that the S100A2 promoter is methylated 
in many cell types (Lee, Tomasetto et al. 1992; Wicki, Franz et al. 1997; Feng, Xu et 
al. 2001; Lindsey, Lusher et al. 2007) and this includes ME15 cells, since we show 
that DAC treatment elevates the TGFβ-inducible expression of S100A2 (figure 13A). 
Upregulation of S100A2 transcription by IFNα requires only intracellular S100A2 
protein and an indirect mechanism is potentially responsible for mediating IFNα 
responsiveness. It has been described that Ca2+ is required for phosphorylation and 
activation of the methyl binding protein MeCP2, which in turn dissociates from the 
methylated BDNF promoter, whereupon transcription is induced (Chen, Chang et al. 
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2003). Also, in neuronal cells, GADD45β-promoted demethylation of specific genes 
such as BDNF and FGF is calcium sensitive (Ma, Jang et al. 2009). These findings 
strongly link calcium signaling with epigenetic regulation. We have applied three 
independent protein localization techniques for subcellular detection of S100A2. 
Based on its modulation activity we expected nuclear localization, however, all 
methods clearly suggested a cytoplasmic localization which rules out a direct nuclear 
function as a DNA methylation modifying enzyme (figure 12, panel A and B). It has 
been shown that S100 type calcium binding proteins are able to shuttle between the 
cytoplasm and the nucleus following cell stimulation (Schafer and Heizmann 1996; 
Mandinova, Atar et al. 1998). Upon calcium stimulation in human keratinocytes the 
S100C/A11 protein is phosphorylated, binds to nucleolin, transfers to the nucleus and 
liberates the Sp1 transcription factor which then transcriptionally activates p21 to 
inhibit DNA synthesis (Miyazaki, Sakaguchi et al. 2004). To rule out such a transient 
translocation we analyzed cells transfected with a tagged S100A2 expression 
construct at 6h and 20h post transfection using cell fractionation by differential 
centrifugation, and found consistent cytoplasmic localization with traces present in 
the membrane fraction (figure 12B). So far, the results obtained indicate that a direct 
participation of S100A2 in the transcription or DNA methylation is unlikely. Thus, the 
modulatory effect of S100A2 on gene expression and DNA methylation in ME15 cells 
is indirect. 
DAC treatment revealed that S100A2 expression is sensitive to methylation in 
ME15 cells, confirming previous findings (Lee, Tomasetto et al. 1992; Wicki, Franz et 
al. 1997; Feng, Xu et al. 2001). Interestingly, over-expressing S100A2 in cells 
showed a reduced impact of DAC on protein expression, suggesting that S100A2 
regulates its own expression in a similar manner to DAC. Furthermore, S100A2 
protein levels remained unchanged after TGFβ induction regardless of DAC 
treatment in ME15S100A2 and D10S100A2 cells. A feasible explanation is the 
antiproliferative activity of S100A2, which upon further increase by TGFβ treatment 
possibly results in a growth arrest (figure 13A; panel second from the left). This 
conclusion is supported by the fact that the apparent levels of S100A2 do not 
increase any more at the 51h time point in the recombinant cell line. 
On the other hand, S100A2 protein levels are not altered in the IFNα-resistant 
D10 cells (figure 10) upon DAC treatment (figure 13A, panel second from the right). 
This also holds true for the IFITM3 protein (figure 13B) which leads to the notion that 
the IFITM3 promoter is hypo- or demethylated in D10 cells. We confirmed this 
hypothesis by bisulfite sequencing (figure 20). The IFITM3 gene is constitutively 
expressed in D10 cells and stimulation with IFNα further up-regulates the protein and 
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mRNA levels (Figure 13; (Brem, Oraszlan-Szovik et al. 2003). Functional response to 
IFNα treatment regarding its gene expression was postulated previously, as the D10 
cell line was shown to exhibit a delayed rather than defective signaling (Certa, 
Wilhelm-Seiler et al. 2003). These results were confirmed because D10 cells 
expressed IFNα-inducible genes upon IFNα stimulus; but in contrast to the ME15 
cells, IFNα-responsive gene expression in D10 cells is not modulated by S100A2 
(figure 11B, bottom panel). Since spontaneous IFNα production or mutations in the 
core promoter of the IFITM3 allele have been ruled out as possible causes of 
deregulation of IFITM3 expression in D10 cells (Certa, Seiler et al. 2001), it was 
postulated previously that epigenetic aberrations might be involved in the IFNα-
resistance of the D10 cell line (Brem, Oraszlan-Szovik et al. 2003), and our results 
strongly support the concept of a defect in the methylation machinery. 
It has been shown that the chromatin-remodeling activity of the ubiquitous 
BAF complex in human HeLa cells enables binding of the Sp1 transcription factor to 
its cognate site, resulting in gene expression. Liu et al. found that the IFITM3 
promoter region contains an Sp1 binding site (figure 20, 5’ CpG position #107) which 
upon removal by mutagenesis led to diminished IFITM3 expression, by up to 
approximately 50% (Liu, Kang et al. 2002). The hypomethylation of the entire region 
in D10 cells probably enhances the accessibility for transcription factors, which 
results in constitutive production of IFITM3. Following IFNα stimulation, the 
transcriptional activator complex IFR9 is formed and transcription of the IFITM3 gene 
is then driven by these two transcription factors, generating maximal levels of IFITM3 
in D10 cells (Brem et al., 2003). Included in cluster three of figure 11B is the small 
proline rich protein SPRR2D. Like S100A2, the SPRRs are located on chromosome 
1 constituting the epidermal differentiation complex (Tan, Sun et al. 2006). The 
calcium inducible SPRR2D has been shown to have a POU domain of the OCT11 
binding element as well as a Sp1 transcription factor binding site and an ISRE 
binding element (Tesfaigzi and Carlson, 1999) therefore supporting the concept of a 
combinatory Sp1 and interferon signaling. 
In contrast to ME15 cells the IFITM3 promoter is hypomethylated in D10 cells. 
This leads to the question which epigenetic aberrations might be involved in the low 
promoter methylation in these cells. Additionally the low promoter methylation might 
deliver an explanation why D10 cells exhibit IFNα resistance. Defects in DNA 
methyltransferase are associated with growth arrest (Kassis, Zhao et al. 2006) and 
the methyltransferase substrate SAM leads to restored sensitivity to IFNα in HCV 
patients (Duong, Christen et al. 2006). SAM supplementation was not able to restore 
IFITM3 expression to basal levels in D10 cells (figure 14) and the transient IFITM3 
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promoter does not exhibit significant differences in IFNα-induced activity (figure 15) 
demonstrating functionality of the maintenance DNA methyltransferase (DNMT1) in 
both ME15 as well as D10 cells. This excludes a direct defect in DNMT1 because the 
in vitro methylated IFITM3 promoters were equally well suppressed in the transfected 
ME15 and D10 cells (figure 15). Methylation defects often occur after DNA replication 
where only one DNA strand is methylated therefore discriminating mother from 
daughter strands and serving as a template for DNMT1 (Holliday and Pugh 1975). 
Since in our experimental set-up the cells completed only one round of DNA 
replication it is possible that the methylation defect remains undetected and therefore 
it would be necessary to investigate the IFITM3 promoter sensitivity to IFNα over a 
longer timecourse. Genome-wide DNA methylation is slightly higher in D10 cells 
(figure 19) and there are an overall higher number of CpG sites with low methylation 
in ME15 than in D10 cells (figure 18), again arguing against dysfunctional DNMT1 in 
D10 cells. Interestingly, it was found that over-expression of the DNMT1 protein 
leads to tumor-specific hypermethylation, which has been associated with the 
positive CpG island methylator phenotype (CIMP) (Ting, Jair et al. 2004; Teodoridis, 
Hardie et al. 2008). According to our investigations, the specific hypomethylation 
observed in the IFITM3 promoter does not involve a defect in the DNMT1 protein 
expression and the DNA methylation abberration is likely to be related to an alternate 
malfunction of the methylation machinery. 
Microarrays have shown that DNMT1 mRNA is expressed at the same level 
both in ME15 and D10 cells (Siegrist et al., unpublished data) but protein levels and 
activities have not been investigated. Interestingly, inactivated p53 represses the 
DNMT1 promoter and DNMT1 transcription levels increase upon stress-induced p53 
activation, to meet immediate DNA repair requirements (Peterson, Bogler et al. 2003). 
Additionally, the p53-inducible p21 protein inhibits DNMT1 expression in MCF7 cells, 
closely relating DNMT1 repression to cell cycle arrest (Tan and Porter 2009). DNMT1 
expression is upregulated significantly during G1 phase (Robertson, Keyomarsi et al. 
2000) and it is possible that this upregulation is not detected in standard microarray 
studies since cells are not synchronized. It has been suggested that aberrations in 
cell-cycle regulated expression of DNMT1 lead to subsequent demethylation of DNA 
after several cell cycles (Robertson, Keyomarsi et al. 2000). P53 is not functional in 
D10 cells (figure 22) and might therefore constitutively bind to the DNMT1 promoter, 
hence inhibiting cell-cycle dependant upregulation of DNMT1. This could explain the 
hypomethylation of the IFITM3 promoter in D10 cells. Fusion of ME15 and D10 cells 
revealed clearly that the ME15 cell line was not able to rescue the D10 cell line in 
terms of silencing the otherwise constitutively expressed IFITM3 (figure 16A). 
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Interestingly, in these MDbla cells IFITM3 expression is not inducible by IFNα and 
showed maximal levels. It is therefore possible that the MDbla cells are under 
constant stress due to their chromosome content, which results in the activation of 
functional p53 provided by the ME15 cell line to reach maximal levels of IFITM3 in 
the absence of IFNα treatment. It is important to realize that functional DNMT1 would 
not actually be able to “re”-methylate the IFITM3 promoter of the D10 cell line 
because DNMT1 requires hemimethylated DNA strands (Holliday and Pugh 1975; 
Ting, Jair et al. 2004). Whichever methylation machinery defect is involved in the 
aberrant DNA methylation of the IFITM3 promoter is not related to a direct defect in 
the DNA maintenance methyltransferase DNMT1. 
FACS showed that the MDbla cell line does not contain four sets of 
chromosomes, as also seen by karyotyping (figure 16B and C). Karyotyping 
additionally revealed that the chromosomes both in ME15 and D10 cells exhibited 
massive aberrations. These findings support the notion that there is a DNA 
methylation defect in D10 cells since chromosome aberrations are known to result 
from the loss of functional MeCP2 as observed in the RTT syndrome (Matarazzo, De 
Bonis et al. 2009) or malfunctions of DNMT3b as seen in ICF (Xu, Bestor et al. 1999). 
Interestingly, ME15 cells are equally affected by this phenotype and it is likely that 
the chromosomal aberrations are due to the fact that both cells are cancer cell lines. 
In cancer the absence of telomerase during continuous proliferation leads to the 
shortening of the telomers which can result in subsequent chromosomal aberrations 
(Raynaud, Sabatier et al. 2008). Also, in some cancers the integration of viruses 
such as HBV into the genome promotes chromosomal instability (Neuveut, Wei et al.). 
The mechanisms involved in chromosomal aberrations of ME15 and D10 cells 
remain elusive. 
The enhanced IFNα-induced IFITM3 and TGFβ-induced S100A2 expression 
in ME15 cells following DAC treatment indicate an involvement of DNA methylation in 
the gene expression control. However, In D10 cells IFITM3 and S100A2 expression 
exhibit insensitivity to DAC treatment. These findings prompted us to analyze 
whether any dynamic changes in the DNA methylation of the IFITM3 core promoter 
are responsible for upregulation in ME15 cells. Furthermore, we wondered whether 
there are differences in DNA methylation of the IFITM3 core promoter in D10 cells 
compared to ME15 cells. 
Genome-wide DNA methylation analysis did not reveal major differences in 
the methylation pattern of known CpG islands which is consistent with the 
observation of chromosomal aberrations in both cell lines (figures 16, 18 and 19); 
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plus the methylation of the IFITM3 promoter region investigated by the Illumina 
Infinium HumanMethylation27 BeadChip array was restricted to one CpG site only. 
The IFITM3 promoter lacks classical CpG islands but we found 19 potential CpG 
methylation target sites in a 500 base stretch upstream of the transcription initiation 
site, which resembles the organization of the S100A2 promoter that is known to be 
regulated by DNA methylation (Wicki, Franz et al. 1997; Rehman, Cross et al. 2005). 
In figure 13A, we show the basic methylation pattern of the IFITM3 core promoter in 
ME15 cells, which is not altered upon induction of gene expression with IFNα. In the 
presence of S100A2, supplied either by TGFβ treatment or recombinant expression, 
partial hypomethylation of selected sites occurs 6 hours after IFNα stimulation, 
leading to elevated IFITM3 gene expression as shown in figure 11B. A complete and 
precise reset of promoter methylation to the naive status occurs 24 hours after 
stimulation. 
In D10 cells, IFITM3 is constitutively expressed and we showed that the 
IFITM3 promoter is hypomethylated in the absence of any treatment or stimulus 
(figure 20). It is known that the transcription factor Sp1 binds to promoter regions, 
given that their binding sites are demethylated, and as described above IFITM3 has 
also been shown to bind Sp1 (Liu, Kang et al. 2002). The insulin growth factor 
binding protein 3 (IGFBP3), which exhibits antiproliferative activity, binds MeCP2 in 
its methylated promoter region, therefore interfering with the Sp1 transcription 
binding site and leading to silencing of gene expression (Kudo 1998; Chang, Wang et 
al. 2004). Additionally, Sp1 is deacetylated in a hepatic cell line by the hepatitis B 
virus X protein through the recruitment of histone deacetylaese (HDACs) in a p53-
independent manner (Shon, Shon et al. 2009). In normal cells Sp1 acetylation is 
increased in response to stress, therefore DNA-binding of Sp1 is enhanced and 
transcription of stress response genes is amplified (Shon, Shon et al. 2009). IGFBP3 
is known to be an upstream effector of p21 and induction of IGFBP3 through DNA 
demethylation along with stress-induced activated Sp1 binding might lead to p21 
activation and inhibit proliferation (Peng, Wang et al. 2008). IGFBP3 restores IFNα 
sensitivity in D10 cells in the presence of TGFβ (Foser, Redwanz et al. 2006) and a 
p53-independent action mediated by IGFBP3 through p21 is conceivable (figure 23). 
Taken together, the results show that the Sp1 transcription factor is involved in the 
mediation of antiproliferation by epigenetic means and that binding to the 
demethylated IFITM3 promoter region provides a plausible explanation for the 
constitutive IFITM3 protein expression in the D10 cell line. 
We have previously shown that TGFβ treatment is able to restore the 
antiproliferative response to IFNα in the resistant melanoma cell line D10, which 
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indicates a functional link of these signaling cascades (Foser, Redwanz et al. 2006). 
Transfection experiments have corroborated that S100A2 expression is necessary 
and sufficient for this response. Here we demonstrate that S100A2 is mandatory for 
dynamic IFNα-mediated hypomethylation of the IFITM3 core promoter in ME15 cells, 
leading to increased protein expression. 
S100A2 is proposed to modulate cellular response to oxidative stress and one 
way in which this might occur is by stabilizing p53 and protecting it from degradation 
or de-activation (Li, Gudjonsson et al. 2009). It is known that suppressors of cytokine 
signaling 1 (SOCS1) bound to DNA damage proteins bind and activate p53 to induce 
senescence (Calabrese, Mallette et al. 2009). We propose that the combined 
antiproliferative activities of IFNα and S100A2 induce stress conditions, which can 
lead to activation of the tumor suppressor gene p53 (Vousden and Prives 2009). 
Takaoka et al. have shown that IFNα/β induces expression of p53 under adverse 
growth conditions and cell cycle arrest (Takaoka, Hayakawa et al. 2003), which occur 
in ME15 cells when co-treated with TGFβ and IFNα (Foser, Redwanz et al. 2006). 
S100A2 is a well documented target gene of p53 (Tan, Heizmann et al. 1999; Mueller, 
Schafer et al. 2005; Lapi, Iovino et al. 2006) and is known to bind p53 in a calcium 
dependant manner, thereby enhancing transcriptional p53-activity (Mueller, Schafer 
et al. 2005). This indirect mechanism could explain the acquired inducibility of 
S100A2 by IFNα (figure 11B, cluster 1).  
Interestingly, Foser et al. (Foser, Redwanz et al. 2006) have identified two 
additional p53 target genes with growth inhibitory activity in ME15 and D10 cells 
stimulated with IFNα and TGFβ: insulin growth factor binding protein 3 (IGFBP3) and 
GADD45. GADD45 is a DNA repair protein which was recently identified as a marker 
for genotoxicity and apoptosis (Olaharski, Albertini et al. 2009). The same genes 
were also identified in previous studies (Foser, Redwanz et al. 2006), supporting the 
view that p53 signaling is activated in response to the antiproliferative state of the 
cells. In figure 22, we showed that the established inducers of p53 signaling like DAC 
or 5-fluorouracil are able to activate a transfected p53 reporter construct in ME15 
cells whilst D10 cells do not respond, suggesting a defect in the p53 signaling 
cascade. Additionally, p21, which is induced by p53, is not expressed in D10 cells 
(figure 23) supporting the finding of a defect in the p53 pathway. Indeed, loss of p21 
expression in cancer cells is associated with late stage tumors (Seoane 2004). 
Interestingly, TGFβ is able to induce p21 expression in D10 cells, suggesting p53-
independent induction of p21. This has been described by Sonegawa et al. who 
show calcium-activated nuclear translocation of S100C/A11 upon TGFβ stimulation 
to induce p21 expression, and that loss of this pathway leads to TGFβ resistance 
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(Sonegawa, Nukui et al. 2007; Sakaguchi, Sonegawa et al. 2008). P21 has two Sp1 
binding sites and promoter hypermethylation leads to transcriptional repression even 
upon stimulation (Zhu, Srinivasan et al. 2003). Such a hypermethylation of the Sp1 
transcription factor binding site in the p21 promoter could be associated with IFNα 
resistance in D10 cells. 
A mechanism of dynamic, inducible CpG methylation has been shown for the 
inflammatory cytokine IL2, a key regulator of T-cell responses (Murayama, Sakura et 
al. 2006). Stimulation of lymphocytes with PMA (phorbol 12-myristate 13-acetate) 
leads to an intracellular calcium release, which results in translocation of the T-cell 
transcription factor NFAT from the cytoplasm to the nucleus and binding to the IL2 
core promoter. Next, a single CpG site of the promoter is demethylated in an 
unknown way, which leads to transition of the “naive state” to the “active state” and 
facilitates transcription by OCT1 one hour after PMA stimulation. The equivalent 
“naive state” of the IFITM3 core promoter is shown in figure 20, where IFNα alone 
does not alter the methylation pattern in a 24h time course experiment. In contrast to 
IL2, the IFITM3 promoter in this methylation state is fully responsive to IFNα 
signaling in ME15 cells. However, expression of S100A2 triggers dynamic 
hypomethylation of the IFITM3 promoter at key residues, which enhances the IFNα 
response 6 hours after IFNα stimulation and sets the promoter in a “hyperactive” 
state with enhanced response and expression of IFITM3. After 24 hours the promoter 
methylation state is reset to the naive state. To our knowledge reversible and 
cytokine-inducible promoter activation through a DNA methylation based mechanism 
has not been shown before. 
The observation of S100A2-mediated, IFNα-inducible hypomethylation of the 
IFITM3 core promoter raises the question of whether this occurs through passive of 
active demethylation. Passive demethylation occurs during DNA replication, when 
daughter strand methylation is inhibited. The methylation patterns shown in figure 20 
were compiled from individual Sanger-sequencing reads of subcloned core promoter 
amplicons; complete demethylation of all CpG target sites is rare, consistent with a 
passive mechanism (figure 24, bottom left). Active demethylation has been shown in 
plants and insects and involves recruitment of glycosylases to specific chromosomal 
locations and genes followed by demethylation and transcriptional activation (Ooi and 
Bestor 2008; Gehring, Reik et al. 2009). So far, there is only circumstantial evidence 
for active demethylation in mammals (Morgan, Santos et al. 2005) and the current 
result favors a passive mechanism. It is interesting to note that evidence is emerging 
that DNA repair enzymes and glycosylases might function as active demethylating 
agents in mammals, as suggested for the GADD45 protein, which is induced in our 
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experimental system following IFNα and TGFβ stimulation (Foser, Redwanz et al. 
2006; Rai, Huggins et al. 2008; Ma, Guo et al. 2009; Schmitz, Schmitt et al. 2009). 
Regardless of the mechanism that leads to the changes in the methylation status of 
the IFITM3 promoter after stimulation, it remains entirely unclear how the activated 
status of the promoter is reset to the naive state after 24 hours. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24 
Figure 24. Individual Sanger-sequence reads of bisulfite-treated genomic DNA. ME15 and D10 
cells were stimulated with TGFβ and IFNα, genomic DNA was bisulfite-treated and sequenced and 
individual sequences are displayed. Black circles indicate a methylated site and white circles a 
demethylated site. Note the two completely demethylated sequences in the ME15 cells treated with 
both TGFβ and IFNα. 
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Our laboratory has reported previously that IFNα treatment leads to a 
significant intracellular calcium release which is required for the antiproliferative 
activity of S100A2 (Foser, Redwanz et al. 2006). In neuronal cells it has been shown 
that GADD45β promotes calcium sensitive demethylation of specific genes like 
BDNF or FGF (Ma, Jang et al. 2009). GADD45β is a p53 target gene (Kastan, Zhan 
et al. 1992) which is expressed upon growth arrest through promoter 
hypomethylation (Qiu, Zhou et al. 2004). Additionally, p21 activates GADD45 genes 
which themselves act on a signaling pathway to induce TGFβ in the stress response 
to DNA damage (Passos, Nelson et al.). Thus, it is reasonable to propose that IFNα-
induced calcium release is required to activate GADD45β in our experimental system 
after cytokine stimulation. The cytoplasmic localization of S100A2 eliminates a direct 
function of S100A2 in the nucleus and we propose that the antiproliferative state of 
the cells induced by activated S100A2 and IFNα treatment triggers demethylation of 
selected target genes, which would augment the response to IFNα. The IFITM3 core 
promoter in D10 cells showed a significantly higher degree of demethylation 
compared to the ME15 cells in the naive and active state, which presumably leads to 
the constitutive expression. Interestingly, we demonstrated a lack of p53 activity in 
D10 cells (figure 22) and this result points to a role of p53 signaling in dynamic, 
cytokine induced promoter methylation. 
In our cell-based model, expression of the IFNα-inducible antiproliferative 
IFITM3 protein is enhanced in the presence of S100A2 and the concomitant 
hypomethylation of the IFITM3 core promoter exhibits reversibility to the naive 
methylation state 24 hours after IFNα stimulus. Resistance to IFNα in renal 
carcinoma as well as melanoma cells can be overcome either by DAC treatment or 
DNA methyltransferase (DNMT1) depletion by transfection of antisense 
oligonucleotides (Reu, Bae et al. 2006). Additionally, IFNα resistant HCV replicon 
harboring cells become sensitive to IFNα upon treatment with DAC (Naka, Abe et al. 
2006). Thus, modification of IFNα target gene expression through promoter 
methylation might be a natural mechanism to adapt the responses to pathogen 
challenge. 
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5. CONCLUSION 
Using a wide range of different technologies I was able to investigate S100A2 
as well as DAC modulated IFNα signaling in the two human melanoma cell lines 
ME15 and D10. I demonstrate for the first time dynamic demethylation upon IFNα 
and TGFβ co-treatment in the IFITM3 core promoter of the IFNα sensitive cell line 
ME15. The TGFβ inducible small calcium binding protein S100A2 is sufficient to 
promote this demethylation in ME15 cells. It was shown that S100A2 induces 
sensitivity to IFNα in D10 cells in that its proliferation rate is decreased. Interestingly, 
in the IFNα resistant D10 cells the core promoter of IFITM3 is hypomethylated and 
cytokine treatmens do not influence the methylation status. Hypomethylation is 
known to be a reliable marker for a progressed tumor cell line and the p53 signaling 
defect in the D10 cells is also pointing in the direction of a more progressed tumor 
stage. The expression pattern measured by microarray are consistent with a possible 
lower methylation status in the D10 cell line versus the ME15 cell line, but 
investigation of the genome wide methylation status revealed that ME15 cells exhibit 
lower general methylation of investigated CpG sites than D10 cells. Thus per 
definition ME15 cells are in a more progressed tumor state than D10 cells concerning 
the methylation state. This means that the methylation status itself does not alone 
explain the IFNα resistance of D10 cells, especially since D10 cells exhibit sensitivity 
both to TGFβ as well as S100A2 in that their proliferation rate does decrease. The 
IFNα resistance observed in the D10 cell line apparently is specific for the IFNα 
signaling and might involve promoter demethylation of genes under explicit IFNα 
expression control. Interestingly D10 cells are defective in their p53 pathway and this 
might play a role in resistance of D10 cells to IFNα.  
In ME15 cells the partially methylated IFITM3 core promoter is inducible under 
normal growth conditions by IFNα. Stress, growth conditions or stimuli like TGFβ 
induce S100A2 expression which following IFNα treatment leads to enhancement of 
IFITM3 expression though demethylation of the IFITM3 core promoter. Such an 
additional boost of IFITM3 expression could for instance control proliferation of 
metastasizing tumor cells where normal levels are insufficient. At least in ME15 cells 
we can reproduce this model in cell culture and it is plausible to propose that 
constitutive expression of IFITM3 in D10 cells is partially due to the extensive 
hypomethylation of the core promoter.  
Anyhow, having two levels of IFNα response intensities is an economic way 
for cells in their viral and tumor defense. The basic expression level of IFNα-inducible 
genes is operating in all cells and tissues with normal responses to IFNα and is 
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based on our current understanding of FNα signaling. The enhanced intensity of the 
IFNα response is probably used under acute circumstances where improved 
defenses are required to combat for example high loads of viral invaders. This 
second level of IFNα response is entirely dependent on S100A2 and IFNα 
stimulation. We have shown that IFNα stimulation leads to a significant intracellular 
calcium release within seconds (Foser et al., 2006). It is plausible to propose that this 
transient Ca2+ release leads to reversible activation of S100A2, which is consistent 
with the dynamic changes of IFITM3 core promoter methylation occurring in ME15 
cells. 
In conclusion, dynamic promoter methylation adds an additional layer of 
complexity to the IFNα signaling pathways and tight control of IFNα key response 
genes like IFITM3 might be required for comprehensive control of the IFNα response. 
 
 
 
 
 
 
 
 
 
 
 Figure 25. Overview of protein interactions. S100A2 expression is induced by TGFβ and 
activated by IFNα-induced elevated calcium levels. This leads to enhanced stress levels which 
modulate other gene expressions. S100A2 works as a modulator of p53 protein activation. IFNα leads 
to induction of p53 under stress conditions which then might act to further upregulate TGFβ-induced 
S100A2 and other proteins such as IGFBP3 and PTGFβ. Stress conditions and p53 as well as p21 are 
known modulators of DNA damage proteins, DNA methyltransferases and glycosylases. 
Dotted arrows indicated methylation dependant activities, the other arrows indicate gene regulation. 
Black boxes indicate genes, grey circles indicate proteins. ‘CpGmethyl’ stands for methylated 
promoter region. 
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6. OUTLOOK 
My work demonstrates dynamic demethylation of the IFITM3 promoter upon 
cytokine treatment in ME15 cells. Therefore I was able to shed light on the question 
of how S100A2 modulates gene expression in these cells. Furthermore I observed 
that the IFITM3 promoter is hypomethylated in D10 cells. Since these cells are IFNα 
resistant I propose a possible defect in the methylation machinery of D10 cells. 
However, I was not able to show a direct involvement of the methylation machinery in 
IFNα resistance in D10 cells. So the following question remains elusive: why does 
S100A2 restore IFNα sensitivity in D10 cells? 
S100A2 does not function as a transcription factor, a methylation binding 
protein or a methyltransferase since it was not found to translocate to the nucleus. 
However, Miyakazy et al. observed translocation of another S100 protein 
(S100C/A11) one hour after stimulation with TGFβ (Miyazaki, Sakaguchi et al. 2004). 
I measured S100A2 translocation at 24h or 48h time points of INFα stimulus and it 
would be interesting to investigate potential S100A2 translocation after one hour. 
Nevertheless, it is likely that traces of S100A2 protein in the nucleus would have still 
been detectable after 24 hours if the protein had translocated to the nucleus. As 
explained in the discussion S100A2 might well act as a stress factor and therefore 
induce DNA repair proteins which then affect DNA methylation. The indirect 
mechanism of S100A2 does not exclude a potential involvement in dynamic promoter 
demethylation. 
It remains unclear if S100A2 and IFNα act on the methylation status of ME15 
cells in a genome wide manner, or if this action is specific. The microarray data 
indicate that S100A2 exhibits a very distinct action on the transcription levels of a 
subset of IFNα-inducible genes and therefore implies specificity. Genome wide CpG 
methylation arrays provide a useful overview of DNA demethylation even though only 
a limited number of CpGs are investigated per promoter region or CpG island. As a 
next step we would like to investigate genome-wide demethylation 6 hours post-
stimulation, to allow comparison with bisulfite sequencing experiments. In order to 
confirm that the observed demethylation is specific, it would be necessary to 
investigate a control such as OCT4, which is a developmental gene that is 
completely methylated in mature cells, by bisulfite sequencing (Athanasiadou, de 
Sousa et al.). Investigation of promoter methylation of genes in cluster 3 (figure 13B) 
will additionally shed light on the possible action of DNA methylation. Furthermore, 
others have shown that DNA methylation is strand specific and it will be interesting to 
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investigate the upper strand of the IFITM3 promoter (Kangaspeska, Stride et al. 2008; 
Metivier, Gallais et al. 2008). 
Bisufite sequencing revealed that the whole DNA fragment investigated was 
subject to demethylation and this observation suggests passive demethylation. To 
confirm whether this demethylation is passive we will measure DNA synthesis by 
BrdU incorporation upon IFNα stimulation. Another way would be to synchronize 
cells before DNA methylation investigation, a technique used by others where cells 
are starved for three days with serum-free medium (Metivier, Gallais et al. 2008). 
In contrast to Sanger sequencing, pyrosequencing provides information on the 
methylation ratio at individual CpG sites across a cell population, however this does 
not reveal CpG methylation patterns along individual DNA strands. Therefore we 
decided to investigate CpG methylation using Sanger sequencing. Once we have 
determined whether DNA demethylation is active or passive in our system we will 
investigate the CpGs of interest using pyrosequencing, a method that allows a higher 
throughput. 
The p53 signaling defect in D10 cells points towards a more progressed tumor 
stage in these cells. P53 knock-downs in ME15 cells might illuminate possible effects 
of p53 signaling in these human melanoma cells. It is possible that ME15 p53 knock-
down cells could exhibit IFNα resistance but this must be investigated experimentally. 
It will be interesting to explore the correlation of IFNα, TGFβ and p53 signaling with 
epigenetics in my cellular model (figure 25). 
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8.  ABBREVIATIONS 
 
 
5-FU 5-fluoruracil  
AAF alpha-interferon activation factor 
BDNF brain-derived neurotrophic factor 
Ca2+ calcium 
CHF changefactor  
CIMP CpG Island Methylator Phenotype 
cpm counts per minute 
D10 human melanoma cell line D10 
DAC 5-aza-2’deoxycytidine 
DMSO dimethyl sulfoxide 
DNMT1 maintenance DNA methyl transferase 
DNMT3 de novo DNA methyl transferase 
DSS1 split hand/ foot malformation (ectrodactyly) type 1 
FGF fibroblast growth factor 
Gadd45 growth arrest and DNA-damage-inducible 
GAS interferon-gamma activated site 
h hours 
H19 
imprinted maternally expressed transcript (non-protein 
coding) 
HBV Hepatitis B virus 
HCV hepatitis C virus  
HDAC histone deacetylase 
IFI6 interferon inducible protein 6 
IFITM1 (9-27) interferon inducible transmembrane protein 1 
IFITM2 (1-8D) interferon inducible transmembrane protein 2 
IFITM3 (1-8U) interferon inducible transmembrane protein 3 
IFNAR1 interferon alpha receptor 1 
IFNAR2 interferon alpha receptor 2 
IFNα interferon-alpha 
IFNαK134 pegylated form of IFNα-2A 
IFNβ interferon-beta 
IFNγ interferon-gamma 
IGFBP3 insulin growth factor binding protein 3  
IL2 Interleukin 2 
IRF1 interferon regulatory factor 1 
IRF2 interferon regulatory factor 2 
IRF9 interferon regulatory factor 9 
ISGF3 interferon stimulated gene factor 3 
ISRE interferon-stimulated response elements  
JAK janus kinase 
LPS lipopolysaccharide 
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MAP2K5 mitogen-activated protein kinase kinase 5 
MBD methyl binding domain protein 
MDbla fused cell line from ME15 and D10 
ME15 human melanoma cell line ME15 
MeCP2 methyl CpG binding protein 2 (Rett syndrome) 
NFAT Transcription factor 
OCT1 POU class 2 homeobox 1 
OCT11 POU class 2 homeobox 11 
P  primary cell line 
p21 Cdkn1a, cyclin-dependent kinase inhibitor 1A 
p48 interferon regulatory factor 9 
PIAS protein inhibitor of activated STAT 
PMA phorbol 12-myristate 13-acetate 
PTGF-β growth differentiation factor 15 
S100A2 small calcium binding protein 2 
SAM S-adenosyl-methionine 
SOCS suppressor of cytokine signaling 
Sp1 Sp1 transcription factor 
STAT1 signal transducer and activator of transcription 1 
STAT2 signal transducer and activator of transcription 2 
TG  transgenic cell line 
TGFβ transforming growth factor beta 
TP53 Tumor protein 53 
TYK tyrosine kinase 
U unit 
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Abstract 
 
In human melanoma cell lines, the calcium binding protein S100A2 augments 
the antiproliferative activity of interferon-alpha (IFNα) by an unknown mechanism. 
We show by microarray profiling that recombinant overexpression of S100A2 
upregulates the expression of a subset of IFNα response genes beyond the maximal 
cytokine inducible level including the tumor suppressor gene IFITM3. Treatment of 
ME15 melanoma cells with the demethylating agent 5’-aza-2’deoxycytidine (DAC) 
results in a significant increase of IFITM3 expression following IFNα stimulation 
suggesting a DNA methylation mediated mechanism. We demonstrate by bisulfite 
sequencing of the IFITM3 core promoter that IFNα triggers reversible 
hypomethylation of specific CpG sites in the presence of S100A2.  
 
Key words. Interferon signaling, calcium binding proteins, transcriptional 
enhancement, DNA methylation, S100A2 protein
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1. Introduction 
 
Interferon was discovered 50 years ago as a host derived interference activity 
induced by heat inactivated viral particles (Isaacs and Lindenmann 1957). The 
advent of a novel technique termed “high performance liquid chromatography” 
enabled purification of interferon from virus infected leukocytes 20 years after its 
discovery (Rubinstein and others 1978). Cloning and recombinant expression of 
IFNα paved the way for the first protein based medicine (Maeda and others 1980). 
Since then, several additional interferons were discovered that are involved either in 
antiviral responses (type I) or play a role in immune defense (type II) (Stark and 
others 1998).  
A hallmark of interferon type I cytokines is the induction of antiproliferative 
activity coupled to transcriptional induction of target genes. IFNα inducible genes are 
divided into primary and secondary response genes (PRG’s and SRG’s) according to 
their activation mode. PRG’s are induced early after cytokine stimulation and contain 
single or tandem interferon stimulated regulatory elements (ISRE’s) in the core 
promoter region whilst SRG’s lack such motifs and show delayed induction by an 
unknown mechanism. Microarray experiments have revealed, that IFNα resistance is 
associated with reduced but not defective transcriptional activity in human melanoma 
cell lines (Certa and others 2003). The exact mechanism of resistance in clinical 
settings like hepatitis C virus infections is still unclear and dependent on host and 
pathogen factors (Gale and Foy 2005; Mbow and Sarisky 2004).  
Recently, we have addressed the molecular mechanism of IFNα resistance in 
melanoma cell lines as a model. Co-stimulation of the resistant line D10 with IFNα 
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and transforming growth factor beta (TGFβ) for instance restores antiproliferative 
activity and leads to cooperative upregulation of 28 genes including the small calcium 
binding protein S100A2 (Foser and others 2006). Stable overexpression of S100A2 
together with IFNα stimulation enhances inhibition of cell proliferation in the 
responder line ME15 by an unknown mechanism.  
The S100 type calcium binding proteins belong to a class of genes with 
pleiotropic functions and properties (Eckert and others 2004). Shared feature of all 
S100 proteins is the so called EF-hand motif which binds calcium ions resulting in 
dimerization and catalytic activation (Donato 2001). Calcium signaling is involved in a 
wide range of cellular functions (Berridge and others 2000) and tissue and cell type 
specific expression of calcium binding proteins is an important mechanism to provide 
cell type specific Ca2+ signal transduction leading to stress response, epidermal 
wound repair, cell differentiation or tumorigenic disorders (Zimmer and others 2003). 
S100 proteins are distinguished by their different subcellular distribution patterns and 
can undergo translocation between cellular compartments in response to a stimulus 
(Mandinova and others 1998). In addition, certain family members interact directly 
with the transcription machinery and sense Ca2+ levels triggering intracellular release 
when necessary (Mandinova and others 1998; Schafer and Heizmann 1996).  
In melanoma and breast tumors S100A2 expression is often suppressed which 
points to a role in growth control under normal circumstances (Maelandsmo and 
others 1997; Pedrocchi and others 1994). DNA methylation studies of the S100A2 
core promoter in mammary and prostate cancer have shown significant 
hypermethylation, which apparently suppresses S100A2 expression. (Lee and others 
1992; Rehman and others 2005; Wicki and others 1997). We have shown previously 
(Foser and others 2006) that recombinant overexpression of S100A2 in the human 
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melanoma cell line ME15 leads to significant enhancement of antiproliferative activity 
induced by IFNα. 
Several studies link DNA methylation and IFNα signaling, e.g. senescence can 
be induced in the immortalized Li-Fraumeni syndrome cells by treatment with the 
DNA demethylating and DNA methyltransferase (DNMT) inhibitory agent 5’-aza-
2’deoxycytidine (DAC) and interestingly IFNα treatment induces a similar effect in 
these cells (Fridman and others 2007). In mice, suppression of endogenous IFNs 
enhances development of metastases (Reid and others 1981) and microarray studies 
with DAC treated immortalized human cells revealed deregulation of a significant 
number of IFN pathway genes (Kulaeva and others 2003). 
Here we approach the molecular mechanism of how S100A2 enhances the 
antiproliferative activity of IFNα. Using microarray based mRNA profiling we found 
that S100A2 upregulates the expression of a small number IFNα response genes 
including IFITM3, a gene with antiproliferative activity. We investigated core promoter 
DNA methylation of IFITM3 as a possible mechanism for enhancement of expression 
and show that DAC treatment enhances the response to IFNα in ME15 cells. We 
show by bisulfite sequencing of the IFITM3 core promoter in a time course 
experiment, that IFNα induces reversible hypomethylation of specific CpG residues 6 
hours after incubation only when S100A2 is expressed. Finally, we show virtually 
complete hypomethylation of the IFITM3 core promoter in the melanoma line D10, 
where IFITM3 is constitutively expressed without IFNα stimulation.  
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2. Material and Methods 
 
2.1. Cell lines 
 
The primary human melanoma cell lines ME15 and D10 were kindly supplied by Prof. 
Giulio Spagnioli (University of Basel) and have been described elsewhere (Luscher 
and others 1994; Pansky and others 2000). The ME15S100A2 cell line has been 
described by Foser et. al. (Brem and others 2003; Foser and others 2006; Luscher 
and others 1994; Pansky and others 2000).  
 
2.2. Antibodies, cytokines and reagents 
 
Antibody against IFITM3 (1-8U) has been described previously (Brem and others 
2003). Rabbit-anti-S100A2 serum was kindly provided by Prof. C.W. Heizmann 
(University of Zürich). Goat anti-rabbit IgG (H+L) horseradish peroxidase (HRP) 
conjugate was obtained from BioRad (Basel, Switzerland). Alexa Fluor 555 goat anti-
rabbit IgG (H+L) was purchased from Invitrogen (Basel, Switzerland). IFNα (IFNα2a, 
Roferon®-A) and its monopegylated isomer K134 (IFNαK134 (Foser and others 2006)) 
were provided by F. Hoffmann-La Roche Ltd. (Basel, Switzerland). TGFβ was 
purchased from Calobiochem (Germany) and 5- aza-2’-deoxycytidine (DAC) from 
Sigma (Basel, Switzerland). Lipopolysaccharide (LPS) was purchased from Sigma 
(Basel, Switzerland) and 5-fluoruracil (5-FU) at Fluka (Buchs, Switzerland). 
 
2.3. Cell culture 
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All cell lines were cultured at 37°C in a 5% CO 2 atmosphere in RPMI 1640 medium 
(GIBCO Life Sciences, Paisley, U.K.) supplemented with 10% fetal bovine serum 
(FBS), L-glutamine (2 mM), sodium pyruvate (1 mM), nonessential amino acids, 
antibiotics, and 10 mM HEPES buffer (Certa and others 2003). 
 
2.4. Cell treatments 
 
For oligonucleotide array analysis ME15 and ME15S100A2 melanoma cell lines were 
grown in triplicate cultures for 2 days with either IFNαK134 (1000 U/ml) , TGFβ (2 
ng/ml) or a combination of both cytokines (Fig. 1A). ME15 and ME15S100A2 cells were 
treated with IFNα (1000 U/ml) for 2 days in order to verify IFITM3 mRNA expression 
by quantitative real-time PCR (Fig. 1B). To investigate IFITM3 protein levels in the 
presence and absence of S100A2, ME15 and ME15S100A2 melanoma cell lines were 
stimulated with IFNα (1000 U/ml) for 8 hours (Fig. 1C). For cell fractionation ME15 as 
well as ME15S100A2 cells were treated with IFNα (1000 U/ml), TGFβ (2 ng/ml) or a 
combination of both cytokines for 2 days or ME15 cells were transfected with SNAP-
S100A2-Bam and SNAP-S100A2-Eco vectors for 6 and 20 hours (data not shown). 
In the S100A2 immunofluorescence localization assay cells were incubated with both 
IFNα (1000 U/ml) and TGFβ (2 ng/ml) or either the SNAP-S100A2-Bam or the 
SNAP-S100A2-Eco recombinant vector for two days (data not shown). To promote 
genome wide demethylation the cell lines were treated with 5- aza-2’-deoxycytidine 
(DAC) (2 µg/ml) or a control along with IFNα (1000 U/ml, 100 U/ml or 10 U/ml), TGFβ 
(1 µg/ml) or a combination of both cytokines with incubation times depicted in figure 2. 
For the IFITM3 promoter methylation analysis ME15, ME15S100A2 and D10 cells were 
stimulated with IFNα (1000 U/ml) according to figure 3.  In order to induce S100A2 
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expression ME15 cells were incubated with TGFβ (2 ng/ml) for 2 days. For the 
reporter assays ME15 and D10 cells were transfected with the according luciferase 
plasmids and incubated with 5-fluoruracil (5-FU, 10 µg/ml, in DMSO dilution), 
lipopolysaccharide (LPS, 100 µg/ml, in DMSO dilution), 0.1% DMSO alone or DAC (2 
µg/ml) (Fig. 4). 
 
2.5. Oligonucleotide array analysis 
 
Total RNA was isolated, processed and hybridized to Affymetrix U95Av2 human 
microarrays according to the manufacturer’s instructions (for details see (Foser and 
others 2006)). After intensities were recorded by laser scanning, normalized data 
was analyzed for differential expression using RACE-A software as described (Certa 
and others 2003). Genes with a standard deviation smaller than the absolute change 
in signal intensity, a signal intensity of a minimum of 50 RFUs, and an  absolute 
change factor (CHF) of at least 2 (Certa and others 2003) were considered. 
Expression data from untreated cells (ME15 and ME15S100A2) were used as baseline 
to calculate the change factor values. The raw data are available on request. 
 
2.6. Quantitative Real-time PCR 
 
Upon reverse transcription of total RNA, IFITM3 and GAPDH derived cDNA were 
detected by real-time PCR using primers and dual-labeled fluorogenic probes 
(Applied Biosystems assay reagents Hs03057129_s1 and Hs99999905_m1, 
respectively). Amplification reactions were performed using 2x TaqMan® Fast 
Universal Mastermix (Applied Biosystems) and realtime change of fluorescence 
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intensity was monitored using an ABI 7500 detection system (Applied Biosystems). 
Data was analyzed with the comparative cycle threshold method. 
 
2.7. Immunoblotting 
 
Cell fractions or total calibrated protein extracts, were separated by SDS PAGE and 
electroblotted onto nitrocellulose membranes, which were blocked in commercial 
blocking buffer (SuperBlock® Blocking Buffer; Pierce Chemical Co., Thermo Fisher 
Scientific Inc., Rockford, IL, USA). Proteins were detected using primary antibodies 
against IFITM3 at a dilution of 1:2000 or S100A2 at a dilution of 1:1000 and a horse-
radish-peroxidase (HRP)-conjugated secondary antibody diluted 1:5000 for detection 
with a chemiluminescent substrate (SuperSignal West Pico Chemiluminescent; 
Pierce Chemical Co., Thermo Fisher Scientific Inc., Rockford, IL, USA). 
 
2.8. Transfections and Plasmids 
 
All transfections were performed using either FuGENE® from F. Hoffmann-La Roche 
Ltd. (Basel, Switzerland), Optifect or LipofectAMINE 2000 reagents from Invitrogen 
(Basel, Switzerland) according to the manufacturer’s protocol. PcDNA3 -S100A2 was 
kindly provided by Prof. C.W. Heizmann (University of Zürich). The firefly, pGL3-tk-
luc, and the renilla, phRL tkluc, luciferase plasmids were purchased from Promega 
(Dübendorf, Switzerland). The p53 reporter plasmid was constructed by an insertion 
of two p53 target sequences of the GADD45 promoter region into the pGL3-tk-luc 
plasmid and was a kind gift of K. Schad (F. Hoffmann-La Roche Ltd., Basel, 
Switzerland). 
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2.9. Cell fractionation 
 
ME15, ME15S100A2 and D10 cells were harvested and fractionated using a 
commercial kit according to the instructions supplied (Qiagen Qproteome Cell 
Compartment Kit, Qiagen, Hombrechtikon, Switzerland). 
 
2.10. Cloning of SNAP-tagged S100A2 
 
The 970bp fragment containing the entire S100A2 coding region was amplified from 
pcDNA3 -S100A2 (Foser and others 2006) by PCR using primers with internal 
EcoR1 and BamH1 sites (underlined in the following primer sequences) for 
subcloning into pSEMS-26m (Covalys Witterswil, Switzerland) to generate N- or C-
terminal fusion proteins with SNAP-Tag. Following primers were used for the C-
terminal construct, pSEMS-S100A2-Eco: forward (nucleotide at position 317, 
RSN;NM_005978) 5’- CCT GGT CTG CCA CGA ATT CAT GAT GTG CAG TTCT 
and backward (nucleotide at position 611, RSN;NM_005978) 5’- CCC GAC GGG 
TCT GGC TGG GCT TAA GTC TTG. For the N-terminal construct, pSEMS-S100A2-
Bam, primers were as follows: forward (nucleotide at position 317, RSN;NM_005978) 
5’- CCT GGT CTG CCA CGG ATC CAT GAT GTG CAG TTCT and backward 
(nucleotide at position 612, RSN;NM_005978) 5’- CCGA CGG GTC TGG CTG GGA 
CTC CTA GGT GAA. All sequences were verified and screened for correct 
orientation by standard automated DNA sequencing using standard sequencing 
primers. 
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2.11. Immunofluorescence 
 
Approximately 2000 ME15 cells and 4000 cells of each ME15S100A2 and D10 were 
seeded in 4-well Lab-Tek® II Chamber Slides™ (LabTek, Nunc Inc., Langenselbold, 
Germany). The following day, cells were treated with a combination of IFNα (1000 
U/ml) and TGFβ (2 ng/ml) or a control, followed by an incubation time of 2 days. All 
subsequent cell manipulations were performed on ice. Cells were washed twice with 
ice-cold OptiMEM from Invitrogen (Basel, Switzerland) and fixed for 2 minutes using 
70% acetone kept at -20ºC. After two additional washes with ice-cold PBS the 
samples were treated with Image-iT® FX signal enhancer from Invitrogen (Basel, 
Switzerland) for 30 minutes and blocked for 1.5 hours in PBS containing 1% Bovine 
Serum Albumin (BSA) (Sigma, Basel, Switzerland), 1% Normal Goat Serum (NSG) 
(Sigma, Basel, Switzerland) and 1‰ Ova Albumin (OVA) (Fluka, Basel, Switzerland). 
Cells were incubated for 1 hour with anti-S100A2 serum at a dilution of 1:500 in 
blocking solution. After washing twice with PBS containing 1% BSA for 5 minutes, 
cells were stained with Alexa Fluor 555 diluted 1:100 in PBS containing 1% BSA for 1 
hour. Cells were washed twice for 5 minutes with PBS. Images were recorded with a 
Zeiss Axiovert 135 microscope using Axiocam software (Zeiss, Feldbach, 
Switzerland). 
 
2.12. DNA wide demethylation by 5- aza-2’-deoxycytidine (DAC) treatment 
 
Approximately 10’000 ME15 cells and 20’000 ME15S100A2 cells were seeded in 6-well 
plates. Cells were grown for three days following stimulation with TGFβ (1 µg/ml), 
IFNα (1000 U/ml) or a combination of both cytokines, in the presence or absence of 
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DAC (2 µg/ml). After 6,12, 24 and 51 hours cells were washed twice with PBS, 
resuspended in standard lysis buffer and the whole protein extract was thereafter 
used for immunoblot analysis (Fig. 3A and B). The same procedure was applied for 
the IFNα sensitivity experiment with 100 U/ml or 10 U/ml IFNα treatment in the 
presence or absence of DAC (2 µg/ml) (Fig. 3C). 
 
2.13. Promoter methylation analysis 
 
ME15, ME15S100A2 and D10 melanoma cell lines were treated with IFNα (1000 U/ml) 
for 1, 6 and 24 hours. In order to promote S100A2 expression in ME15 cells they 
were pretreated with TGFβ (2 ng/ml) for 2 days. Isolated genomic DNA was bisulfite 
treated using the Zymo EZ DNA Methylation™ Kit (Orange, CA, USA) according to 
the manufactures protocol with 2µg of DNA input. The bottom strand of the IFITM3 
promoter was amplified to yield an 820 bp fragment using bisulfite adjusted primers 
designed to cover 19 CpG sites adjacent to the translation initiation site (ATG) 
(forward primer (Chromosome 11: 311612) 5’-ATA ATC CAA CTA CCT AAA CAC 
CATA and backward primer (Chromosome 11: 310793) 5’- GGT TTG GAT AGT GTG 
ATT TAT GGT GTT TA) with the PCR program consisting of following parameters: 
initial incubation time of 10 minutes at 95°C, 40 c ycles with 1 minute at 94°C, 1 
minute at 58°C and 1 minute at 72°C and an addition al 10 minutes at 72°C for final 
elongation. Amplified fragments were cloned into the pCR®2.1-TOPO® vector 
(Invitrogen, Basel, Switzerland) and transformed into XL1-blue (Stratagene, La Jolla, 
CA, USA) or TOP10 (Invitrogen, Basel, Switzerland) competent cells and plated on 
IPTG/ X-gal containing agar plates. Plasmids from white colonies were isolated and 
sequenced using an ABI 3730xl DNA analyzer instrument and generic vector based 
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primers using standard procedures. Following computer assisted alignment with the 
clustalw GCG-program the methylation state of CpG sites was determined and a 
Wilson’s test showed significances of methylation changes for each treatment 
condition (Wilson 1927). 
 
2.14. P53 luciferase reporter assay 
 
ME15 and D10 cells were transfected with a combination of the p53 negative firefly 
and the control renilla luciferase plasmid or with the p53 reporter plasmid firefly along 
with the renilla luciferase control plasmid ('2 x p53 in pGl3-tk-luc' and phRL tkluc') in 
quadruplicates at a confluency of approximately 50% in 24 wells. To ensure efficient 
transfection reaction cells were incubated for 6 hours whereupon medium was 
replaced with culture medium containing either 5-fluoruracil (5-FU), 
lipopolysaccharide (LPS, 100 ug/mL, in DMSO dilution), 0.1% DMSO alone or DAC 
at the standard concentration. Cells were further incubated for 48 hours before 
luciferase activity was measured by Dual Luciferase Reporter Assay System 
(Promega, Dübendorf, Switzerland). 
___________________________________________________________________ 
 
 
 
108 
3. Results 
 
3.1. Transcriptional responses to IFNα in the presence of S100A2 
 
We have shown previously that the TGFβ-inducible calcium binding protein S100A2 
inhibits growth of stably transfected human melanoma cell lines (Foser and others 
2006). The antiproliferative activity however, requires co-stimulation with IFNα, which 
induces calcium release required for the activation of all calcium binding proteins. In 
order to test whether constitutive expression of S100A2 modulates the induction of 
IFNα-inducible genes, we first performed an mRNA expression microarray analysis 
of S100A2-transfected human ME15 melanoma cells with untransfected cells as 
control (Fig. 1A). In addition to IFNα, we treated cell cultures with TGFβ and the 
combination of both cytokines in order to detect possible interactions of S100A2 with 
the TGFβ signaling pathway. In ME15S100A2 cells, one cluster of genes is significantly 
upregulated by overexpression of S100A2 as compared with the parent line ME15 
(Fig. 1A, cluster 2, Table 1). For clarity, the calculated change factors for all genes in 
clusters 1 and 2 are shown in table 1.  
Gene cluster two in figure 1A contains IFITM3 and other known IFNα-inducible genes 
like p27, 9-27 or 2-5 oligoadenylate cyclase and this gene cluster is upregulated in 
the presence of S100A2 beyond maximal IFNα inducible levels. Another regulated 
gene in cluster two is the small proline-rich protein 2d (SPRR2D) which along with 
the S100 proteins is located on chromosome 1q21, forming the proposed epidermal 
differentiation complex (Mischke and others 1996). Other regulated genes like ISG15, 
STAT1 or MHC class 1 are part of cluster one and are insensitive to S100A2 
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overexpression (Fig. 1A, cluster 1, Table 1). In contrast to the genes in cluster two 
(Fig. 1A, cluster 2, Table 1), none of these genes has documented antiproliferative 
activity. TGFβ or combined IFNα/ TGFβ responses are in general not affected by 
S100A2 expression in ME15 or ME15S100A2 cells, although certain genes appear 
moderately downregulated (Fig. 1A). 
Within the group of IFNα inducible genes that is further upregulated by S100A2, 
IFITM3 is the only gene with documented antiproliferative activity (Brem and others 
2003) and elevated levels would explain augmented inhibition of cell growth and 
proliferation. IFITM3 expression enhancement in the presence of S100A2 was 
verified using real time PCR (Fig. 1B) To support this finding, we determined the 
protein levels in ME15S100A2 cells treated with IFNα. After treatment of ME15 and 
ME15S100A2 cells with 1000 U/ml of IFNα for 8 hours, protein extracts were analyzed 
by immunoblotting using rabbit serum against IFITM3 (Brem and others 2003). 
Consistent with mRNA expression, we found elevated levels of IFITM3 in ME15S100A2 
relative to untransfected ME15 cells (Fig. 1C). Thus, S100A2-mediated upregulation 
of IFITM3 provides a plausible explanation for increased antiproliferative activity of 
IFNα in this cell line. 
 
3.2. Core promoter methylation modulates expression levels of S100A2 and IFITM3 
 
Treatment of ME15 cells with 1000 U/ml IFNα induces maximal antiproliferation and 
expression of IFITM3 approximately 6 hours after stimulation (data not shown). 
Therefore, an IFNα independent mechanism must account for elevated expression. 
By immunofluorescence, protein tagging and cell fractionation, we have shown 
cytoplasmic localization of S100A2 which rules out the obvious possibility that 
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S100A2 operates in the nucleus as transcriptional enhancer or co-factor (data not 
shown). Microarray studies with 5-aza-2’-deoxycytidine (DAC) treated cells show 
enhanced expression of several IFNα target genes suggesting that promoter 
methylation modulates the activity and response to IFNα (Kulaeva and others 2003) .  
To assess this possibility, we stimulated ME15 cells with cytokines and 
compared the expression levels of S100A2 and IFITM3 in the presence or absence 
of the cytosine analog DAC as a general methylation inhibitor. S100A2 was included 
as positive control, because this promoter is known to be methylated (Lee and others 
1992; Wicki and others 1997) and expression in ME15 cells is TGFβ inducible. As 
expected, DAC treatment results in significant upregulation of S100A2 expression in 
TGFβ treated cells suggesting S100A2 promoter methylation in ME15 cells (Fig. 2A, 
left panel). Co-stimulation with TGFβ and IFNα leads to elevated S100A2 expression 
even without DAC treatment which suggests the possibility that IFNα modulates the 
methylation status of the S100A2 core promoter (Fig. 2A, left panel). Interestingly, 
the levels of S100A2 in stably transfected cells were not modified by either treatment, 
including TGFβ, suggesting that a certain expression threshold that cannot be 
exceeded through activation of the chromosomal copy of S100A2 probably due cell 
damage or proliferation arrest. The results above confirm the literature for ME15 cells 
and validate the conditions for DAC treatment.  
We next analyzed expression of the IFNα inducible gene IFITM3 in the same 
samples by immunoblotting (Fig. 2B). As expected, IFITM3 is inducible by IFNα but 
not by TGFβ and co-incubation with both cytokines has no obvious impact on 
expression. However, when cells are treated with DAC the duration of IFITM3 
expression is extended to 51 hours after treatment compared to untreated cells (Fig. 
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2B, left panel) suggesting a methylation dependent modification of the core promoter. 
We noted, that DAC treatment alone is sufficient to turn on expression of IFITM3 in 
the absence of IFNα treatment (Fig. 1B, left panel; 51 h time point) suggesting 
activation by generic transcription factors.  
The experiments so far suggest that S100A2 is necessary and sufficient to 
induce IFNα dependent changes in core promoter methylation. When S100A2 is 
supplied by transgenic expression (ME15S100A2), the apparent levels of IFITM3 
proteins are insensitive to DAC treatment (Fig. 2B, right panel) although expression 
of IFITM3 seems to decline more rapidly without DAC treatment perhaps due to re-
methylation (Fig. 2B, right panel; 51 h time point).  
To test whether DAC increases IFITM3 promoter sensitivity in ME15 and 
ME15S100A2 cells we used 10U or 100U IFNα for induction. In untreated cells low 
levels of IFITM3 are detectable 12 hours after induction followed by rapid decline (Fig. 
2C). In contrast, in DAC treated cells IFITM3 is detectable 48 hours after induction at 
both IFNα doses (10U or 100U). As shown in figure 2B, detectable IFNα independent 
expression occurs in DAC treated cells after 51 hours.  
In summary, DAC treatment enhances the sensitivity and response of the 
S100A2 and IFITM3 core promoters after stimulation with TGFβ. and IFNα, 
respectively.   
 
3.3. Methylation state of the IFITM3 core promoter in ME15 cells 
 
In order to demonstrate IFITM3 core promoter methylation in ME15 cells in vivo 
we used conventional bisulfite sequencing to examine the methylation status of 
individual CpG sites in the IFITM3 promoter (Frommer and others 1992). Since 
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IFITM3 induction is time dependent we included a time course and DNA was 
extracted 1, 6 and 24 hours after IFNα (1000 U/ml) stimulation followed by bisulfite 
treatment, PCR amplification of the IFITM3 core promoter fragment and sequencing. 
We then determined the percentage of methylated versus unmethylated C-residues 
across 19 CpG sites of the IFITM3 core promoter (Fig. 3). Note that the CpG site at 
422 is a known SNP which is altered in our cell line (C T), therefore eliminating one 
methylation site from our investigation to give 18 CpG sites. Under these 
experimental conditions, we did not observe any significant changes of the baseline 
CpG methylation pattern over all time points indicating that regular induction of 
IFITM3 expression does not require any modifications of the methylation status of 
CpG sites in the core promoter (Fig. 3A).  
Next we repeated the experiment in the presence of S100A2 supplied either by 
TGFβ treatment of ME15 cells or by transgenic expression (ME15S100A2). Under both 
conditions, we observed significant hypomethylation across the entire panel of CpG 
sites 6 hours after IFNα treatment (Fig. 3 panel B and C). 24 hours after IFNα 
treatment the methylation status reverts to the pattern of untreated control cells which 
coincides with the decay of IFITM3 protein expression (Fig. 2, panel B). Note also, 
that CpG sites 427 and 24 remain demethylated under all conditions although they 
are directly adjacent to sites that are targets of dynamic modification.  
IFITM3 expression in the human melanoma cell line D10 is constitutive and 
does not require IFNα stimulation (Brem and others 2003). Based on the studies 
above, we expected significant, S100A2 independent hypomethylation of the core 
promoter resulting in IFNα independent expression. We thus treated D10 cells with 
IFNα as above and determined the methylation status of the core promoter by 
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bisulfite sequencing (Fig. 3, panel D). In contrast to ME15, the CpG sites around the 
ISRE site show almost complete demethylation independent of IFNα treatment.  
In summary, demethylation of CpG sites of the IFITM3 core promoter is 
associated with improved expression and response. IFNα dependent changes in 
methylation status require expression of the small calcium protein S100A2.
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4. Discussion 
 
We have shown that expression of the calcium binding protein S100A2 
modifies the transcription efficiency of a small number of IFNα target genes. Maximal 
IFNα-inducible IFITM3 levels are associated with dynamic and reversible changes of 
the methylation state of the core promoter; these methylations are INFα dependent 
and require the presence of S100A2. Elevated expression of IFITM3 provides a 
plausible explanation for the strong antiproliferative activity induced by co-stimulation 
of ME15 cells with IFNα and TGFβ.  
To our knowledge this is the first report that links S100A2 and cytokine-
inducible epigenetic modulation of CpG sites in the core promoter of an IFNα target 
gene. The catalytic function of S100A2 and of the majority of calcium binding protein 
family members is unknown (Eckert and others 2004). In the microarray experiment 
shown in figure 1, bona fide IFNα response genes like IFI44L, IFITM3, IFITM5 or 
OAS are further upregulated in ME15S100A2, cells and bisulfite sequencing of these 
promoters is the subject of current studies in our laboratory. Expression of other 
classical IFNα response genes such as STATs (signal transducers and activators of 
transcription) (Fig. 1A, cluster 2) is not affected in ME15S100A2 which shows specificity 
of the mechanism supported by S100A2. 
It is known that the promoter methylation status regulates expression of 
S100A2 in many cell types and tumor cell lines (Lee and others 1992) and this is also 
the case for ME15 as DAC treatment elevates the TGFβ-inducible expression level of 
S100A2 (Fig. 2A). It has been described that Ca2+ is required for phosphorylation and 
activation of the methyl binding protein MeCP2 which then releases the methylated 
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BDNF promoter, whereupon transcription is induced (Chen and others 2003). Also, in 
neuronal cells, GADD45β-promoted demethylation of specific genes such as BDNF 
or FGF is calcium sensitive (Ma and others 2009b). These findings strongly link 
calcium signaling with epigenetic regulation. 
The enhanced expression of IFITM3 in response to IFNα following DAC 
treatment prompted us to analyze whether alterations in DNA methylation of the core 
promoter are responsible for upregulation. The IFITM3 promoter lacks classical CpG 
islands but we found 19 potential CpG methylation target sites 500 bases upstream 
of the transcription initiation site, 18 of which are present in ME15 cells. In figure 3A, 
we show the basic methylation pattern of the IFITM3 core promoter in ME15 cells, 
which is not altered upon induction of gene expression with IFNα. In the presence of 
S100A2 supplied either by TGFβ treatment or recombinant expression, partial 
hypomethylation of selected sites occurs 6 hours after IFNα stimulation, leading to 
elevated IFITM3 gene expression, as shown in figure 1B. A complete and precise 
reset of promoter methylation to the naive status occurs 24 hours after stimulation. 
In D10 cells, IFITM3 is constitutively expressed and we show that the IFITM3 
promoter is hypomethylated in the absence of any treatment or stimulus (Fig. 3D). 
Liu et al. showed that the IFITM3 promoter region contains an Sp1 binding site (Fig. 
3, 5’ CpG position # 107) that upon removal by mutagenesis leads to a reduction of 
IFITM3 expression to about 50% (Liu and others 2002), providing a plausible 
explanation for the constitutive IFITM3 protein expression in the D10 cell line. 
We have previously shown that TGFβ treatment is able to restore the 
antiproliferative response to IFNα in resistant melanoma D10, which indicates a 
functional link of these signaling cascades (Foser and others 2006). Transfection 
experiments have confirmed that S100A2 expression is necessary and sufficient for 
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this response(Foser and others 2006). Here we demonstrate that S100A2 is 
mandatory for cyclical IFNα-mediated hypomethylation of the IFITM3 core promoter 
in ME15 cells, leading to increased protein expression. The cytosolic localization of 
S100A2 rules out a direct function of this protein in the nucleus (data not shown). We 
propose that the antiproliferative activity of IFNα and the growth inhibitory activity of 
S100A2 induce apoptotic conditions, which can lead to activation of the tumor 
suppressor gene p53. Takaoka et al. have shown that IFNα/β induces expression of 
p53 under adverse growth conditions and cell cycle arrest (Takaoka and others 
2003), which occurs in ME15 cells after treatment with TGFβ and IFNα (Foser and 
others 2006). S100A2 is a well documented target gene of p53 (Lapi and others 2006; 
Mueller and others 2005; Tan and others 1999).  
In figure 4 we show that established inducers of p53 signaling like DAC or 5-
fluorouracil are able to activate a transfected p53 reporter construct in ME15 cells, 
whilst D10 cells do not respond, suggesting a defect in the p53 signaling cascade. 
Thus, the enhanced antiproliferative activity induced by co-stimulation with IFNα and 
TGFβ may trigger further upregulation of growth control genes, perhaps by modifying 
the methylation status of key residues in the target gene promoters as shown here 
for IFITM3. 
Mechanisms of dynamic, inducible CpG methylation have been shown 
previously. The trefoil factor 1 (TFF1) is a protein that is known to be under estrogen 
control and its promoter undergoes cyclical demethylation upon estrogen stimulation 
by recruitment of the de novo DNA methyltransferase 3a and 3b (DNMT3a and 
DNMT3b), thymine DNA glycosylase (TDG) and base excision repair (BER) proteins 
in a cell cycle independant manner (Metivier and others 2008) (Kangaspeska and 
others 2008). The promoter of the inflammatory cytokine IL2 undergoes 
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demethylation upon  stimulation with PMA (phorbol 12-myristate 13-acetate) 
(Murayama and others 2006). The mechanism in this case involves intracellular 
calcium release, which results in translocation of the T-cell transcription factor NFAT 
from the cytoplasm to the nucleus and binding to the IL2 core promoter where a 
single CpG site of the promoter is hypomethylated. This  leads to transition of the 
“naive state” to the “active state” and facilitates transcription by OCT1 1 hour after 
PMA stimulation. The similar “naive state” of the IFITM3 core promoter is shown in 
figure 3A. In contrast to IL2, the IFITM3 promoter in this methylation state is fully 
responsive to IFNα signaling in ME15 cells but IFNα alone does not alter the 
methylation pattern in a 24 h time course experiment. However, expression of 
S100A2 triggers time-dependant hypomethylation of the IFITM3 promoter at key 
residues, which enhances the IFNα response 6 hours after IFNα stimulation and sets 
the promoter in a “hyperactive” state with enhanced response and expression of 
IFITM3. After 24 hours the promoter methylation is reset to the naive state. To our 
knowledge reversible and cytokine inducible promoter activation through a DNA 
methylation based mechanism has not been shown before. 
The observation of S100A2-mediated, IFNα-inducible hypomethylation of the 
IFITM3 core promoter raises the question of the mechanism by which this occurs. 
Passive hypomethylation occurs during DNA replication where daughter strand 
methylation is inhibited and therefore absent or partial. The methylation patterns 
shown in figure 3 were compiled from individual Sanger-sequencing reads of 
subcloned core promoter amplicons and complete demethylation of all CpG target 
sites is rare, which is in agreement with a passive mechanism (data not shown). So 
far, only a few reports provide evidence for active demethylation in mammals and the 
results presented favour a passive mechanism (Metivier and others 2008; Morgan 
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and others 2005). It is interesting to note that evidence is arising that DNA repair 
enzymes as well as glycosylases might function as active demethylating agents in 
mammals, as suggested for the GADD45 protein, which is induced in our 
experimental system following IFNα and TGFβ stimulation (Foser and others 2006; 
Ma and others 2009a; Rai and others 2008; Schmitz and others 2009). Regardless of 
the mechanism that leads to changes in the methylation status of the IFITM3 
promoter after stimulation, it remains entirely unclear how the activated status of the 
promoter is reset to the naive state after 24 hours and how this might be related to a 
decay of IFNα signaling.  
Our laboratory has previously shown that IFNα treatment leads to a significant 
intracellular calcium release which is required for the antiproliferative activity of 
S100A2 (Foser and others 2006). In neuronal cells it has been shown that GADD45β 
promotes calcium sensitive demethylation of specific genes like BDNF or FGF (Ma 
and others 2009b). GADD45β is a p53 target gene (Kastan and others 1992) which is 
expressed upon growth arrest through promoter hypomethylation (Qiu and others 
2004). Thus, it is reasonable to propose that IFNα-induced calcium release is 
required to activate GADD45β in our experimental system after cytokine stimulation. 
The cytoplasmic localization of S100A2 eliminates a direct function of S100A2 in the 
nucleus and we propose that the antiproliferative state of the cells induced by 
activated S100A2 and IFNα treatment triggers demethylation of selected target 
genes, which would augment the response to IFNα. The IFITM3 core promoter of 
D10 cells shows a significantly higher degree of demethylation compared to ME15 
cells in the naive and active states, which leads to constitutive expression. 
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Interestingly, we failed to demonstrate p53 activity in D10 cells (Fig. 4) and this result 
points to a role of p53 signaling in dynamic, cytokine-induced promoter methylation.  
In our cell-based model, expression of the IFNα-inducible antiproliferative 
IFITM3 protein is enhanced in the presence of S100A2 and the concomitant 
hypomethylation of the IFITM3 core promoter exhibits reversibility to the naive 
methylation state 24 hours after IFNα stimulus. Resistance to IFNα in renal 
carcinoma as well as melanoma cells can be overcome either by DAC treatment or 
DNA methyltransferase (DNMT1) depletion by transfection of antisense 
oligonucleotides (Reu and others 2006) and IFNα-resistant HCV replicant-harboring 
cells become sensitive to IFNα upon treatment with DAC (Naka and others 2006). 
Thus, modification of IFNα target gene expression through promoter methylation 
might be a natural mechanism to adapt the responses to pathogen challenge. 
In conclusion, dynamic promoter methylation adds an additional layer of 
complexity to the IFNα signaling pathways and tight control of IFNα key response 
genes like IFITM3 might be required for comprehensive control of the IFNα response. 
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Figure legends 
 
FIG. 1. S100A2 modulates expression efficiency of IFNα-inducible genes.  
S100A2 modulates the transcription of selected IFNα target genes (A). ME15 and 
ME15 recombinant S100A2 (ME15S100A2) cell cultures were treated with IFNαK134, 
TGFβ or both cytokines for two days followed by RNA extraction and processing of 
the samples for microarray analysis and data processing. Downregulated genes are 
shown in blue and induced genes in red and maximum color intensity corresponds to 
a 2- fold change (CHF). IFNα-inducible genes with a common S100A2-dependent 
expression mode after IFNα induction in ME15 cells are boxed (cluster 2) and IFNα-
inducible genes with no apparent S100A2 dependency appear in cluster 1. 
Enhancement of IFITM3 expression in ME15 and ME15S100A2 cells in the presence of 
S100A2 (B and C). ME15 and ME15 recombinant S100A2 (ME15S100A2) cell cultures 
were treated with IFNα for two days followed by RNA extraction and processing of 
the samples for real time PCR analysis (B). For protein analysis, cell cultures were 
treated with IFNα for 8 hours and cell lysates were probed by immunoblotting with 
α−IFITM3 antibodies (C). 
The apparent IFITM3 mRNA and protein levels are increased in cells expressing 
recombinant S100A2 relative to the parental cell line. 
 
FIG. 2. DAC (5’-aza-2’-deoxycytidine) treatment enhances the induction efficiency of 
S100A2 and IFITM3. ME15 and ME15S100A2 cell cultures were treated with cytokines 
for 24 and 51 hours as indicated in the presence (DAC +) or absence (DAC -) of DAC. 
Detection of S100A2 protein in DAC treated ME15 and ME15S100A2 cells by 
immunoblotting (A). Cell lysates were electroblotted for each condition and probed 
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with S100A2. Note that DAC enhanced, time dependent S100A2 expression is only 
evident in parental ME15 cells, whilst no significant changes occur in ME15S100A2.  
Impact of DAC treatment on the expression of IFITM3 in ME15 and ME15S100A2 cell 
lines treated for 6, 12, 24 or 51 hours using the cytokine treatment protocol as above 
(B). DAC treatment affects the IFITM3 levels in ME15 and ME15S100A2 cells and low-
level expression occurs 51 hours after DAC treatment without IFNα stimulation in 
ME15 (highlighted by a white asterisk in the left data panel). 
DAC increases the sensitivity of the IFITM3 promoter to IFNα stimulation (C). ME15 
and ME15S100A2 cells were treated with 10U or 100U of IFNα for the times indicated. 
In both lines 10U of IFNα are sufficient for induction of IFITM3 in the presence of 
DAC for an extended period of 48 hours. Consistent with the experiments shown in 
(B), IFNα independent expression occurs 48 hours after DAC incubation in both lines.  
 
FIG. 3. S100A2 expression is sufficient to modulate IFNα induced dynamic and 
reversible methylation of the IFITM3 core promoter. ME15 cells were cultured in the 
absence (A) or presence (B) of TGFβ for S100A2 induction. TGFβ treatment was not 
necessary for ME15S100A2 cells (C) and the IFNα resistant cell line D10 was included 
in this experiment as well (D). All cell lines were analyzed 0, 1, 6 and 24 hours after 
IFNα stimulus. 
Total genomic DNA from each culture was isolated, bisulfite treated and the IFITM3 
core promoter was amplified using a bisulfite converted DNA adapted PCR protocol 
(for details see materials and methods). The amplicons were subcloned and 
sequenced from both ends using vector born primers. The number of clones 
sequenced per time point and treatment conditions is indicated on the right to the 
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methylation status of individual CpG sites displayed as boxes. White filling indicates 
bisulfite conversion of individual CpG sites in at least nine out of ten clones (0-10% 
methylation). Grey indicates conversion of single CpG sites in two to eight per ten 
sequence reads(11-89% methylation) and black indicates conversion in one out of 
ten sequence reads (90-100% methylation). The nucleotide positions of the CpG 
sites upstream of the ATG start codon are indicated and the position of the ISRE 
consensus binding site is depicted. 
 
FIG. 4. P53 is not functional in the IFNα resistant cell line D10. Cells transfected with 
a p53 luciferase reporter plasmid were treated with DMSO, DAC, 5-FU and LPS as 
positive control. Untreated cells were included as reference. In ME15 cells all p53 
activators induce significant upregulation of luciferase activity. D10 cells do not 
respond to stimulation suggesting a p53 signaling defect.  
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Table 1. Change factors of genes in clusters 1 and 2 of figure 1A 
DESCRIPTION  SYMBOL CHGF ME15 CHGF ME15S100A2 
cluster 1  
  
beta-2-microglobulin B2M 3.3 2.94 
interferon-induced protein 35 IFI35 1.83 1.98 
beta-2-microglobulin B2M 2.93 2.51 
beta-2-microglobulin B2M 2.38 2.1 
signal transducer and activator of transcription 1, 91kda STAT1 3.72 3.07 
signal transducer and activator of transcription 1, 91kda STAT1 4.28 3.1 
interferon-induced protein with tetratricopeptide repeats 1 IFIT1 11.78 6.35 
signal transducer and activator of transcription 1, 91kda STAT1 16.79 11.77 
interferon-induced protein with tetratricopeptide repeats 1 IFIT1 8.59 5.27 
ubiquitin-conjugating enzyme e2l 6 UBE2L6 7.78 4.42 
lectin, galactoside-binding, soluble, 3 binding protein LGALS3 1.4 1.71 
major histocompatibility complex, class i, f HLA-F 1.55 1.4 
major histocompatibility complex, class i, f HLA-F 2.96 2.57 
major histocompatibility complex, class i, b HLA-B 3.35 4.37 
isg15 ubiquitin-like modifier ISG15 14.84 14.17 
interferon, alpha-inducible protein 6 IFI6 9.09 13.12 
isg15 ubiquitin-like modifier ISG15 18.43 22.7 
cluster 2  
  
small proline-rich protein 2d SPRR2D 0.5 1.37 
dehydrogenase/reductase (sdr family) member 2 DHRS2 0.64 6.22 
interferon-induced protein 44-like IFI44L 5.89 8.86 
interferon induced transmembrane protein 3 (1-8u) IFITM3 1.6 6.52 
interferon induced transmembrane protein 1 (9-27) IFITM1 9.73 27.19 
proteasome (prosome, macropain) subunit, beta type, 9  PSMB9 1.97 2.46 
interferon induced transmembrane protein 1 (9-27) IFITM1 3.62 19.79 
interferon-induced protein 35 IFI35 1.43 2.69 
interferon-stimulated transcription factor 3, gamma 48kda IRF9 1.71 4.07 
2`,5`-oligoadenylate synthetase 1, 40/46kda OAS1 5.75 13.62 
2`-5`-oligoadenylate synthetase 2, 69/71kda OAS2 1.42 2.19 
bone marrow stromal cell antigen 2 BST2 41.07 62.6 
interferon, alpha-inducible protein 27 IFI27 65.94 111.36 
        
 
 
Table 1. The calculated change factors for the interferon-induced genes in clusters 1 
and 2 of figure 1A are shown together with the annotation and official gene symbol. 
Change factors (CHF) were calculated as described in material and methods (section 
2.5). ME15 refers to native cells and ME15S100A2 are cells stably transfected with 
S100A2 cDNA. 
___________________________________________________________________ 
 
 
 
130 
 
___________________________________________________________________ 
 
 
 
131 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
___________________________________________________________________ 
 
 
 
132 
 
 
 
___________________________________________________________________ 
 
 
 
133 
 
 
 
 
___________________________________________________________________ 
 
 
 
134 
___________________________________________________________________ 
 
 
 
135 
10. CURRICULUM VITAE 
 
 
Rachel Woodward Scott 
 
For details on Rachel Woodward Scott’s curriculum vitae please see hardcopies stored at the 
library of the University of Basel in Basel, Switzerland 
 
_________________________________________________________________________ 
 
Submitted Papers and Published Posters and Abstracts 
_________________________________________________________________________ 
 
 
R. Scott, F. Siegrist, S. Foser, U. Certa, Interferon-alpha promotes S100A2 dependant 
dynamic demethylation of the IFITM3 core promoter, submitted 
 
R. Scott, F. Siegrist, Y. Burki, S. Foser, U. Certa, Methylation Status’ Influence On 
Interferon-alpha Sensitivity In Human Melanoma Cells. 3rd Swiss Meeting on Genome 
Stability „DNA Dynamics and Epigenetics“, October 3-5, 2007, Uetendorf, Switzerland. 
R. Scott, H. L. Henry, M. Heim, J. E. Bishop, T. Pennimpede, G. Kampmann, W. Hunziker, P. 
Weber, A. W. Norman and I. Bendik. Comparison of intestinal gene expression of wild type 
and VDR KO-mice challenged with 1-α,25-Dihydroxy-Vitamin D3 and 24R,25-Dihydroxy-
Vitamin D3. 12th Workshop on Vitamin D, July 6-10, 2003; Maastricht, The Netherlands.  
M. Heim, T. Pennimpede, G. Kampmann, P. Fuchs, R. Scott, P. Weber, C. Riegger, W. 
Hunziker and I. Bendik. The estrogen receptor a pathway is the major route for genistein's 
bone promoting effects. 1st Joint Meeting of the International Bone and Mineral Society and 
the Japanese Society for Bone and Mineral Research, June 3-7, 2003; Osaka, Japan.  
T. Pennimpede, S. Lorenzetti, M. Heim, G. Kampmann, R. Scott, P. Fuchs, F. Branca, P. 
Weber, W. Hunziker and I. Bendik. Human osteoclast estrogen receptor expression differs 
from that of osteoblasts. 30th European Symposium on Calcified Tissues, May 8-12, 2003; 
Rome, Italy.  
S. Lorenzetti, T. Pennimpede, M. Heim, G. Kampmann, R. Scott, P. Fuchs, P. Weber, W. 
Hunziker, I. Bendik, and F. Branca. An ex-vivo human model of osteoclastogenesis to 
investigate the role of the phytoestrogen genistein. 30th European Symposium on Calcified 
Tissues, May 8-12, 2003; Rome, Italy.  
T. Pennimpede, S. Lorenzetti, G. Kampmann, M. Heim, R. Scott, P. Fuchs, F. Branca, P. 
Weber, W. Hunziker and I. Bendik. Nuclear hormone receptor profiling in human osteoclasts. 
FASEB Journal, Volume 17, No. 4-5, p. Abstract No. 442.4, 2003. FASEB Meeting April 11 - 
April 15, 2003; San Diego, CA, USA.  
S. Lorenzetti, T. Pennimpede, M. Heim, G. Kampmann, R. Scott, P. Fuchs, P. Weber, W. 
Hunziker, I. Bendik and F. Branca. The influence of the phytoestrogen genistein on 
osteoclast differentiation. FASEB Journal, Volume 17, No. 4-5, p. Abstract No. 442.3, 2003. 
FASEB Meeting April 11 - April 15, 2003; San Diego, CA, USA.  
